

Cumulative Index

Volume 45, Numbers 1-4, 2002

A

- ABCD survey, in cardiopulmonary resuscitation, 377
- Abdomen
- acute, in pregnancy, 405, 553
 - causes of, 405
 - definition of, 405
 - differential diagnosis of, 405
 - burst. *See* Wound, abdominal incision, dehiscence
 - Abdominal incision, wound breakdown, 507. *See also* Wound
 - Abdominal wall, pain from, 233
 - Aberrations of Normal Development and Involution (ANDI), classification of benign breast disease, 1129, 1140
- Abortion
- elective, in breast cancer patient, 770
 - septic, 562
 - spontaneous, smoking and, 784
- Abruptio placentae, trauma-related, 414, 553
- Abscess, pelvic, postoperative, 562
- Abuse, in pregnancy, 414, 553
- Acebutolol, adverse effects of, in breast-fed infant, 6
- Acetaminophen
- for headache, in pregnancy, 136
 - use of, in pregnancy, 89
- Acid-base equilibrium, 518
- perioperative management of, 449
 - in pregnancy, 377, 414
- Acidemia, fetal
- biophysical effects of, 975
 - prediction of, 1054
- Acidosis, 518
- in pregnancy, effect on CPR, 377
- Acitretin, teratogenicity of, 6
- Acoustic neuroma, 904
- Acquired immunodeficiency syndrome (AIDS). *See also* HIV-infected (AIDS) patients; Human immunodeficiency virus (HIV) infection
- in women, trends in, 1073
- Acrolein, and bladder cancer, 844
- Acromegaly, 904
- Actinomycin-D. *See* Dactinomycin
- Actocardiocography, 986
- Acupressure, for gastrointestinal disorders in pregnancy, 136
- Acute abdomen. *See* Abdomen, acute
- Acute lymphocytic leukemia
- clinical presentation of, 855
 - epidemiology of, 855
 - FAB classification of, 855
 - treatment of, 855
- Acute myelogenous leukemia
- clinical presentation of, 855
 - epidemiology of, 855
 - FAB classification of, 855
 - treatment of, 855
- Acute respiratory distress syndrome
- clinical presentation of, 518
 - hypoxia in, 518
 - lung injury in, 369, 518
 - management of, 369, 518
 - pathophysiology of, 518
 - perioperative, 518, 562
 - in pregnancy
 - delivery in, 369
 - etiology of, 369
 - fetal monitoring in, 369
 - lung injury in, 369
 - management of, 369
 - maternal stabilization in, 369
- Acyclovir therapy, in pregnancy, 136
- for disseminated herpes simplex infection, 393
 - for varicella pneumonia, 393
- A-delta fibers, and bladder function, 182, 205, 218
- Adenocarcinoma, of lung, 784
- Adenomas, colorectal, and colorectal cancer, 812
- Adhesions
- pelvic, 233
 - surgical, postoperative, and gastrointestinal complications, 492
- Adipose tissue, environmental toxins in, 1119
- Adnexal mass, preoperative assessment of, 439
- Adnexal torsion, in pregnancy, 405
- Adolescence
- breast cancer in, 758
 - depression in, 1181
 - smoking cessation in, 1169
 - nicotine replacement products in, 1169
- Adrenocorticotrophic hormone (corticotropin, ACTH), excess, tumors producing, 904
- Adria. *See* Doxorubicin
- Adriamycin. *See* Doxorubicin
- Adult respiratory distress syndrome. *See* Acute respiratory distress syndrome
- Advanced cardiac life support
- algorithms, for cardiopulmonary resuscitation, 377
 - modification of, for pregnant patient, 377
 - techniques for, 377

Page numbers indicate first page of relevant article.

Cumulative Index

Volume 45, Numbers 1-4, 2002

A

- ABCD survey, in cardiopulmonary resuscitation, 377
- Abdomen
- acute, in pregnancy, 405, 553
 - causes of, 405
 - definition of, 405
 - differential diagnosis of, 405
 - burst. *See* Wound, abdominal incision, dehiscence
 - Abdominal incision, wound breakdown, 507. *See also* Wound
 - Abdominal wall, pain from, 233
 - Aberrations of Normal Development and Involution (ANDI), classification of benign breast disease, 1129, 1140
- Abortion
- elective, in breast cancer patient, 770
 - septic, 562
 - spontaneous, smoking and, 784
- Abruptio placentae, trauma-related, 414, 553
- Abscess, pelvic, postoperative, 562
- Abuse, in pregnancy, 414, 553
- Acebutolol, adverse effects of, in breast-fed infant, 6
- Acetaminophen
- for headache, in pregnancy, 136
 - use of, in pregnancy, 89
- Acid-base equilibrium, 518
- perioperative management of, 449
 - in pregnancy, 377, 414
- Acidemia, fetal
- biophysical effects of, 975
 - prediction of, 1054
- Acidosis, 518
- in pregnancy, effect on CPR, 377
- Acitretin, teratogenicity of, 6
- Acoustic neuroma, 904
- Acquired immunodeficiency syndrome (AIDS). *See also* HIV-infected (AIDS) patients; Human immunodeficiency virus (HIV) infection
- in women, trends in, 1073
- Acrolein, and bladder cancer, 844
- Acromegaly, 904
- Actinomycin-D. *See* Dactinomycin
- Actocardiocography, 986
- Acupressure, for gastrointestinal disorders in pregnancy, 136
- Acute abdomen. *See* Abdomen, acute
- Acute lymphocytic leukemia
- clinical presentation of, 855
 - epidemiology of, 855
 - FAB classification of, 855
 - treatment of, 855
- Acute myelogenous leukemia
- clinical presentation of, 855
 - epidemiology of, 855
 - FAB classification of, 855
 - treatment of, 855
- Acute respiratory distress syndrome
- clinical presentation of, 518
 - hypoxia in, 518
 - lung injury in, 369, 518
 - management of, 369, 518
 - pathophysiology of, 518
 - perioperative, 518, 562
 - in pregnancy
 - delivery in, 369
 - etiology of, 369
 - fetal monitoring in, 369
 - lung injury in, 369
 - management of, 369
 - maternal stabilization in, 369
- Acyclovir therapy, in pregnancy, 136
- for disseminated herpes simplex infection, 393
 - for varicella pneumonia, 393
- A-delta fibers, and bladder function, 182, 205, 218
- Adenocarcinoma, of lung, 784
- Adenomas, colorectal, and colorectal cancer, 812
- Adhesions
- pelvic, 233
 - surgical, postoperative, and gastrointestinal complications, 492
- Adipose tissue, environmental toxins in, 1119
- Adnexal mass, preoperative assessment of, 439
- Adnexal torsion, in pregnancy, 405
- Adolescence
- breast cancer in, 758
 - depression in, 1181
 - smoking cessation in, 1169
 - nicotine replacement products in, 1169
- Adrenocorticotrophic hormone (corticotropin, ACTH), excess, tumors producing, 904
- Adria. *See* Doxorubicin
- Adriamycin. *See* Doxorubicin
- Adult respiratory distress syndrome. *See* Acute respiratory distress syndrome
- Advanced cardiac life support
- algorithms, for cardiopulmonary resuscitation, 377
 - modification of, for pregnant patient, 377
 - techniques for, 377

Page numbers indicate first page of relevant article.

- Aflatoxin B₁, and liver cancer, 939
- Age
 and abdominal wound breakdown, 507
 and alcohol abuse, 1169
 and bladder cancer, 844
 and breast cancer risk, 778, 1140
 and colorectal cancer risk, 812
 and incidence of acute leukemias, 855
 maternal, and Down syndrome, 622, 657, 661
 and multiple myeloma, 928
 and oral cancer, 952
 and prevalence of overactive bladder syndrome, 173
 and tobacco use, 1169
- Aging. *See also* Reproductive aging in women
 demographics of, 1099
 functional decline with, 1099
 and illness, 1099
 stressors of, 1099
 and vulnerability to stress, 1099
 and women's sexuality, 1089
- AIDS. *See* HIV-infected (AIDS) patients
- Air, household, contaminants in, 1119
- Airbags, and maternal/fetal outcome in trauma, 414
- Airway
 obstructed, in pregnancy, 377
 opening, in cardiopulmonary resuscitation, 377
- Albumin, in surgical patient, 537
- Albuterol, for asthma, 518
 in pregnancy, 136
- Alcohol
 abuse
 diagnosis of, 1169
 epidemiology of, 1169
 health consequences of, 73, 1169
 and smoking, concurrent, 1169
 treatment of, 1169
 without dependence, lifetime prevalence of, sex differences in, 1162
 adverse effects of, in breast-fed infant, 6
 dependence, lifetime prevalence of, sex differences in, 1162
 and pancreatic cancer, 855
 perinatal exposure to, fetal/neonatal effects of, 73, 1169
 use of
 health consequences of, 1169
 morbidity and mortality caused by, 1169
 in pregnancy, 73, 1169
 withdrawal, pharmacological management of, 1169
- Alcoholism. *See* Alcohol, abuse
- Alkalosis, 518
 respiratory, in pregnancy, 414
- Alkeran. *See* Melfalan
- Alkylating agents
 leukemia caused by, 855
 therapy with, in pregnancy, 153
- Allele, definition of, 593
- Allele dropout, and polymerase chain reaction, 640, 649
- Allele frequency, 711
- Allergy, and interstitial cystitis, 242
- All-fours maneuver, for shoulder dystocia, 345
- Alper's disease, 593
- Alpha-adrenergic agonists, central-acting
 adverse effects and side effects of, 22
 antihypertensive therapy with, in pregnancy, 22
- Alpha beta-adrenergic blockers, for hypertension, 518
- Alpha-fetoprotein, in hepatocellular carcinoma, 939
- Alprazolam, adverse effects of, in breast-fed infant, 6
- Aluminum hydroxide, use of, in pregnancy, 89
- Alveolar-arterial oxygen gradient, 518
- Alveolar oxygen tension, 518
- Alzheimer's disease, genetics of, 711
- Amantadine, 136
 adverse effects of, in breast-fed infant, 6
- Ambulatory urodynamics, 193
- American College of Obstetricians and Gynecologists, office records developed by, 1181
- American Society of Addiction Medicine (ASAM), guidelines for treatment of substance abuse, 1169
- Amethopterin. *See* Methotrexate
- Amikacin. *See also* Aminoglycosides
 cost of, 59
 dosage and administration of, 59
 for sepsis, in pregnancy, 393
- Aminoglycosides
 adverse effects and side effects of, 59
 cost of, 59
 dosage and administration of, 59
 intramuscular, 59
 intravenous, 59
 mechanism of action of, 59
 obstetric applications of, 59
 for sepsis, in pregnancy, 393
 spectrum of activity of, 59
 teratogenicity of, 6, 553
- Aminophylline, toxicity of, 518
- Aminopterin, teratogenicity of, 855
- Amiodarone, adverse effects of, in breast-fed infant, 6
- Amitriptyline
 adverse effects of, in breast-fed infant, 6
 for interstitial cystitis, 242, 259
 starting dosage for, in pregnancy, 136
- Amniocentesis
 early, 1039
 complications of, 1039
 risks of, 1039
 technique for, 1039
 historical perspective on, 1039
 in HIV-infected (AIDS) patients, 1039
 long-term follow-up of, 1039
 in multifetal pregnancy, 1039
 potential complications of, 1039
 Rh prophylaxis with, 1039
 risks of, 1039
 safety of, 1039
 technique for, 1039
- Amnionitis
 after amniocentesis, 1039
 management of, 393
- Amniotic fluid embolism, 377
- Amniotic fluid index, 1026, 1063
 in normal pregnancy, 1026
 and perinatal morbidity, correlation of, 1026
 and perinatal outcome, correlation of, 1026
- Amniotic fluid volume
 estimates of, and perinatal outcome, correlation of, 1026
 evaluation of, 1063
 color flow Doppler and, 1026

- frequency of, 1026
- maximum vertical pocket technique for, 1026
- methods for, 1026
- semiquantitative methods for, 1026
- single deepest pocket technique for, 1026
- sonographic, 1026
 - correlation with actual volume, 1026
 - subjective, 1026
 - three-dimensional ultrasound in, 1026
 - two-diameter pocket technique for, 1026
- fetal hypoxemia/acidemia and, 975
- in multiple gestation, 1026
- normal, 1026
- Amoxapine, adverse effects of, in breast-fed infant, 6
- Amoxicillin
 - adverse effects and side effects of, 59
 - obstetric applications of, 59
 - pregnancy category of, 59
 - spectrum of activity of, 59
- Amoxicillin-clavulanate
 - cost of, 59
 - obstetric applications of, 59
 - pregnancy category of, 59
 - spectrum of activity of, 59
- Amphetamines
 - abuse, health consequences of, 73
 - adverse effects of, in breast-fed infant, 6
 - contraindications to, in pregnancy, 136
 - perinatal exposure to, fetal/neonatal effects of, 73
 - toxicity in fetus and/or newborn, 6
- Ampicillin
 - adverse effects and side effects of, 59
 - cost of, 59
 - formulations of, 59
 - obstetric applications of, 59
 - pregnancy category of, 59
 - for sepsis, in pregnancy, 393
 - spectrum of activity of, 59
- Ampicillin-sulbactam
 - mechanism of action of, 59
 - obstetric applications of, 59
 - spectrum of activity of, 59
- Ampicillin-sulbactam (Unasyn), for operative site infection, 562
- Amrinone, for heart failure, perioperative management of, 518
- Analgesics, mild, over-the-counter, use of, in pregnancy, 89
- Anaphase lag, 622
- Androgen deficiency syndrome, 1089
- Androgenic hormones, teratogenicity of, 6
- Androgens, for female sexual dysfunction, 1089
- Anemia
 - causes of, diagnosis of, 449
 - classification of, by mean cell volume, 449
 - colorectal cancer and, 812
 - perioperative management of, 449
 - physiologic, in pregnancy, 414, 553
 - effect on CPR, 377
 - sickle cell. *See* Sickle cell anemia
- Anesthesia
 - complications of, pharmacologic management of, 125
 - for laparoscopy, complications of, 469
 - obstetric, complications of, 377
 - in pregnant patient, 553
 - total spinal, peripartum management of, 125
- Anesthetic cocktail, intravesical, for interstitial cystitis, 259
- Anesthetics, inhaled, for excessive uterine tone, 125
- Aneuploidy, 622, 711
 - in multiple myeloma, 928
 - screening for
 - in IVF patients, fluorescence in situ hybridization for, 640
 - by preimplantation genetic diagnosis, 640
- Angelman syndrome
 - clinical features of, 593, 622
 - genomic imprinting and, 593
 - uniparental disomy in, 593, 622
- Angina pectoris, 449
 - unstable, 518
- Angiotensin-converting enzyme inhibitors (ACEI)
 - for heart failure, perioperative management of, 518
 - for hypertension, 518
 - postpartum use of, 22
 - toxicity in fetus and/or newborn, 6, 22
- Angiotensin II receptor antagonists, teratogenicity of, 6
- Annealing, of oligonucleotide primers, for polymerase chain reaction, 605
- Anorexia nervosa, lifetime prevalence of, sex differences in, 1162
- Antacids
 - for gastroesophageal reflux disease, in pregnancy, 136
 - over-the-counter, use of, in pregnancy, 89
- Anthrax
 - immunizing agent for, 42
 - in pregnancy, 42
- Antianxiety agents, use of, in pregnancy, 136
- Antibiotic-associated colitis, 492
- Antibiotic-associated diarrhea, 492
- Antibiotics
 - chemotherapy using, in pregnancy, 153
 - in chronic obstructive pulmonary disease, 518
 - combination therapy with, obstetric applications of, 59
 - hypersensitivity to, and immunization, 42
 - in obstetrics
 - applications of, 59
 - cost-effective use of, 59
 - toxicity of, 59
 - for operative site infection, 562
 - for perioperative pneumonia, in pelvic surgery patient, 518
 - preoperative administration of, 492
 - prophylaxis with
 - in gynecologic surgery, 562
 - principles of, 562
 - for sepsis, 562
 - in pregnancy, 393
 - for suspected postoperative (operative site) infection, 562
 - teratogenicity of, 553
- Anticancer therapy, in pregnancy, 153
- Anticholinergics
 - adverse effects and side effects of, 205
 - for bladder overactivity, 205
 - contraindications to, 205
 - intravesical therapy with, 205
- Anticoagulants
 - teratogenicity of, 6
 - use of, in pregnancy, 136

- Anticoagulant therapy
 - for deep venous thrombosis, 363, 545
 - perioperative management of, 449
 - in prevention of thromboembolism, 545
 - for pulmonary embolism, 363, 545
 - for venous thromboembolism in pregnancy, 363
- Anticonvulsants
 - for eclamptic seizures, 308
 - prophylactic, 308
 - and recurrent seizures, 308
 - for headache, in pregnancy, 136
 - for peripartum seizures, 125
 - teratogenicity of, 6, 136
 - therapy with, in pregnancy, 136
- Antidepressants
 - for headache, in pregnancy, 136
 - for interstitial cystitis, 242, 259
 - teratogenicity of, 6
 - therapy with, in pregnancy, 136
 - toxicity in fetus and/or newborn, 6
 - and women's sexuality, 1089
- Antidiarrheals, over-the-counter, use of, in pregnancy, 89
- Antidiuretic hormone (ADH), secretion of, 449
- Antiemetics
 - for headache, in pregnancy, 136
 - over-the-counter, use of, in pregnancy, 89
- Antiepileptic therapy, effects on fetal activity, 993
- Antihistamines
 - for interstitial cystitis, 242, 259
 - over-the-counter, use of, in pregnancy, 89
 - and women's sexuality, 1089
- Antihypertensives
 - in eclampsia, 308
 - for hypertensive crisis in preeclampsia, 308
 - intravenous, 518
 - perioperative management of, 449
 - postpartum use of, 22
 - for severe hypertension, in pregnancy, 125
 - therapy with, in pregnancy, 22
 - toxicity in fetus and/or newborn, 6
 - and women's sexuality, 1089
- Anti-infectives, teratogenicity of, 6
- Antimetabolite therapy, in pregnancy, 153
- Antineoplastics
 - adverse effects of, in breast-fed infant, 6
 - toxicity in fetus and/or newborn, 6
- Antiphospholipid syndrome
 - management of, in pregnancy, 136
 - and venous thromboembolism in pregnancy, 363
- Antiplatelet therapy, in prevention of thromboembolism, 545
- Antiproliferative factor, as urinary marker for interstitial cystitis, 250
- Antipsychotics
 - use of, in pregnancy, 136
 - and women's sexuality, 1089
- Antiretroviral therapy, in pregnancy, 136
- Antisecretory agents, for gastroesophageal reflux disease, in pregnancy, 136
- Antiseizure medications, for interstitial cystitis, 259
- Antisocial personality, lifetime prevalence of, sex differences in, 1162
- Antithrombin 518 deficiency, and venous thromboembolism in pregnancy, 363
- Antithyroid agents, teratogenicity of, 6
- Antitussives, use of, in pregnancy, 89
- Antivert. *See* Meclizine
- Antiviral therapy, in pregnancy, 136
 - for disseminated herpes simplex infection, 393
 - for varicella pneumonia, 393
- Anxiety
 - and lower urinary tract symptoms, 182
 - pharmacologic therapy for, in pregnancy, 136
- Aorta, descending, fetal, Doppler ultrasound evaluation of, 1015
- Aortic regurgitation/insufficiency, perioperative management of, 449
- Aortic stenosis, perioperative management of, 449
- Aortocaval compression, by gravid uterus. *See also* Supine hypotensive syndrome
 - and trauma care, 414
- APC gene, mutation of, and cancer risk, 711
- Appendectomy, in pregnancy, 405, 553
- Appendiceal perforation, in pregnancy, 405
- Appendicitis
 - conditions mimicking, 405
 - in pregnancy, 405, 553
 - diagnosis of, 405
 - fetal mortality and morbidity in, 405
 - imaging in, 405
 - maternal mortality in, 405
- ARDS. *See* Acute respiratory distress syndrome
- Arginine, and immune enhancement, 537
- Aromatic amines, and bladder cancer, 844
- Arrhythmia(s)
 - atrial, perioperative, 518
 - with pulmonary embolism, 545
 - ventricular, perioperative management of, 518
- Arterial blood gases, 518
 - measurement of, in diagnosis of pulmonary embolism, 545
- Arterial embolization, for postpartum hemorrhage, 330, 553
- Arterial oxygen tension, 518
- Artificial sweeteners, and bladder cancer, 844
- Ascites, and abdominal wound breakdown, 507
- Asphyxia
 - fetal, 975
 - prenatal adaptation to, and adverse long-term outcome, 975
 - perinatal, 975
- Aspiration
 - prevention of, in pregnant trauma victim, 414
 - risk of, in pregnancy, 414
 - during CPR, 377, 414
- Aspirin
 - adverse effects of, in breast-fed infant, 6
 - and colorectal cancer prevention, 812
 - for headache, in pregnancy, 136
 - use of, in pregnancy, 89
- Aspirin therapy
 - in myocardial infarction, 518
 - in prevention of thromboembolism, 545
- Assault, in pregnancy, 414
- Asthma
 - exacerbations, in pregnancy, pharmacologic management of, 125, 136
 - perioperative management of, 449, 518
 - pharmacologic therapy for, in pregnancy, 125, 136
 - in pregnancy

- cardiac complications of, 377
 - effect of pregnancy on, 369
 - effects on pregnancy, 369
 - epidemiology of, 369
 - management of, 369
 - severity of, determination of, 369
 - Astrocytoma
 - biologic behavior of, 904
 - clinical presentation of, 904
 - epidemiology of, 904
 - treatment of, 904
 - Atarax. *See* Hydroxyzine
 - Ataxia-telangiectasia (AT), leukemia in, 855
 - Atelectasis
 - postoperative, 518, 562
 - in pregnancy, 414
 - Atenolol
 - adverse effects of, in breast-fed infant, 6
 - for hypertension, 518
 - toxicity in fetus and/or newborn, 6
 - ATM gene, mutation of, and cancer risk, 711
 - Atosiban, as tocolytic agent
 - contraindications to, 99
 - dosage and administration of, 99
 - efficacy of, 99
 - fetal/neonatal effects of, 99
 - maternal side effects of, 99
 - mechanism of action of, 99
 - pharmacology of, 99
 - Atracurium, contraindications to, 518
 - Atrial fibrillation
 - perioperative management of, 449, 518
 - with pulmonary embolism, 545
 - Atrial flutter
 - perioperative management of, 518
 - with pulmonary embolism, 545
 - Atrial tachyarrhythmias, perioperative, 518
 - Atrioventricular (AV) block
 - classification of, 518
 - perioperative management of, 518
 - Atrioventricular (AV) bypass tachycardia, perioperative management of, 518
 - Atrioventricular (AV) re-entry tachycardia, perioperative management of, 518
 - Atypical squamous cells of undetermined significance (ASCUS), interpretation of, 605
 - Augmentation mammoplasty, 1129
 - benefits of, 1129
 - implants for, 1129
 - outcomes of, 1129
 - patient education about, 1129
 - procedure for, 1129
 - risks of, 1129
 - Augmentin. *See* Amoxicillin-clavulanate
 - Autoimmune disease, environmental exposures and, 1119
 - Autoimmunity, and interstitial cystitis, 259
 - Autosomal disorder(s), 593
 - Autosomal trisomy, 622
 - Autosomes
 - disorders of, 622
 - isochoresomes for, 622
 - Autotransfusion
 - contraindications to, 330
 - for postpartum hemorrhage, 330
 - Axid. *See* Nizatidine
 - Axillary lymph node dissection, in breast cancer, 1140
 - Azathioprine
 - adverse effects of, in breast-fed infant, 6
 - for inflammatory bowel disease, in pregnancy, 136
 - toxicity in fetus and/or newborn, 6
 - Azithromycin
 - cost of, 59
 - obstetric applications of, 59
 - pharmacology of, 59
 - pregnancy category of, 59
 - spectrum of activity of, 59
 - Aztreonam
 - cost of, 59
 - mechanism of action of, 59
 - obstetric applications of, 59
 - for perioperative pneumonia, in pelvic surgery patient, 518
 - pregnancy category of, 59
 - spectrum of activity of, 59
 - Azulfidine. *See* Sulfasalazine
- B**
- Bacille Calmette-Guérin (BCG)
 - for bladder cancer, 844
 - intravesical, for interstitial cystitis, 259
 - Bacitracin
 - for antibiotic-associated colitis, 492
 - use of, in pregnancy, 89
 - Baclofen, for bladder overactivity, 205
 - BACs, 622
 - Bacteremia
 - definition of, 393, 562
 - in pregnancy, epidemiology of, 393
 - Bacteria
 - active immunization against, 42
 - detection of, polymerase chain reaction method for, 605
 - pneumonia caused by, perioperative, in pelvic surgery patient, 518
 - in postoperative (operative site) infection, 562
 - in postoperative sepsis, 562
 - in postoperative urinary tract infection, 562
 - in septic shock, in pregnancy, 393
 - vaginal, 562
 - Bacterial infections, perinatal management of, antibiotics for, 59
 - Bacterial vaginosis, 233
 - and infectious morbidity, 562
 - microbiology of, 562
 - preoperative treatment of, 562
 - prevalence of, 562
 - screening for, 562
 - treatment of, in pregnancy, 59
 - Bacteriuria, asymptomatic, treatment of, in pregnancy, 59
 - Bactrim. *See* Trimethoprim-sulfamethoxazole
 - Balanced translocation, 622
 - Bardet-Biedl syndrome, 593
 - Barium enema, in colorectal cancer screening, 812
 - Barr body, 622
 - Bartholin's gland, malignancy of, unexpected, diagnosed at gynecologic surgery, 439
 - Basal energy expenditure, estimation of, 537

- Basic life support
 - modification of, for pregnant patient, 377
 - techniques for, 377
- BCR-ABL* gene, 855
- Becker muscular dystrophy, 605
- Beckwith-Wiedemann syndrome, 593
 - mosaicism for paternal uniparental disomy of chromosome 11p in, 593
 - uniparental disomy and, 593
- Beclomethasone, for asthma, in pregnancy, 136, 369
- Behavioral therapy
 - for interstitial cystitis, 273
 - for overactive bladder, 273
- Behavior modification, in obesity treatment, 1080
- Benadryl. *See* Diphenhydramine
- Bence Jones protein, 928
- Bendectin. *See* Dicyclomine
- Bentyl. *See* Dicyclomine
- Benzocaine, use of, in pregnancy, 89
- Benzodiazepines
 - for anxiety, in pregnancy, 136
 - for eclamptic seizures, 308
 - fetal effects of, 308
 - perinatal exposure to, fetal/neonatal effects of, 73
 - for peripartum seizures, 125
 - teratogenicity of, 136
- Benzoyl peroxide, use of, in pregnancy, 89
- Beta-adrenergic receptor agonists
 - for asthma, 518
 - in pregnancy, 136, 369
 - for excessive uterine tone, 125
 - as tocolytic agents
 - contraindications to, 99
 - efficacy of, 99
 - fetal/neonatal effects of, 99
 - maternal side effects of, 99
 - mechanism of action of, 99
- Beta-adrenergic receptor blockers
 - adverse effects and side effects of, 22
 - in breast-fed infant, 6
 - antihypertensive therapy with, in pregnancy, 22
 - for congestive heart failure, in pulmonary edema in preeclampsia, 308
 - for headache, in pregnancy, 136
 - for heart rate control, in atrial fibrillation, 518
 - for hypertension, 518
 - perioperative management of, 449
 - toxicity in fetus and/or newborn, 6
- Betamethasone
 - antenatal, dosage and administration of, 35
 - effects on fetal activity, 993
 - toxicity in fetus and/or newborn, 6
- Betel quid, and oral cancer, 952
- Bethesda system, 605
- Bexxar, for lymphoma, 820
- Biliary colic
 - in pregnancy, 553
 - prepregnancy cholecystectomy for, 405
- Biofeedback
 - in high-tone pelvic floor dysfunction, 273
 - in overactive bladder syndrome, 273
- Biophysical profile, 975, 1063
 - and contraction stress test, comparison of, 1005
 - in high-risk pregnancy, 1063
 - medications and, 993
 - and nonstress test, comparison of, 986
 - score
 - and adverse long-term outcome, 975
 - and cerebral palsy, 975
 - management based on, Bundle branch block, 1063
 - parameters measured directly by, 975
 - parameters measured indirectly by, 975
 - perinatal morbidity and, 975, 1063
 - perinatal mortality and, 975, 1063
- Biotherapy, for lymphoma, 820
- Biotinidase deficiency
 - newborn screening for, 697
 - treatment of, 697
- Bipolar disorder, lifetime prevalence of, sex differences in, 1162
- Birth defects
 - antenatal detection of, 993
 - causes of, 6
 - definition of, 6
 - drug-induced
 - diagnosis of, 6
 - maternal drug abuse and, 73
 - genetic and genomic factors associated with, 711
 - incidence of, 6
 - and infant mortality, 136
 - major, definition of, 6
 - maternal smoking and, 784
 - minor, definition of, 6
 - prevalence of, 136
 - studies of, limitations of, 1, 6
- Birth rates, trends in, in United States, 1073
- Birthweight, and shoulder dystocia, 345
- Bismuth subsalicylate, use of, in pregnancy, 89
- Bisphosphonates, in multiple myeloma treatment, 928
- Bitolterol mesylate, for asthma, in pregnancy, 136
- B-K mole syndrome, 830
- Black widow spider bite
 - immunizing agent for, adverse effects and side effects of, 42
 - in pregnancy, 42
- Bladder
 - atony, shoulder dystocia and, 345
 - carcinoma in situ in, 844
 - dysfunction of, in neurological disease, 173
 - dysplasia in, 844
 - epithelial dysfunction, and interstitial cystitis, 242, 259
 - hydrodistention of
 - in diagnosis of interstitial cystitis, 250
 - in treatment of interstitial cystitis, 250, 259
 - injury to, in pelvic surgery
 - incidence of, 428
 - intraoperative detection of, 428
 - prevention of, 428
 - repair of, 428
 - sites of, 428
 - innervation of, 218, 233
 - outflow obstruction, and overactive bladder syndrome, 182
 - overactive. *See* Overactive bladder syndrome
 - painful. *See* Interstitial cystitis; Painful bladder syndrome
 - unstable, definition of, 173
 - urothelial neoplasms of. *See also* Bladder cancer
 - WHO/ISUP consensus classification of, 844
- Bladder cancer, 844

- age distribution of, 844
- deep muscle-invasive, 844
- diagnosis of, 844
- epidemiology of, 844
- etiology of, 844
- histopathology of, 844
- metastases of, 844
- pathobiology of, 844
- pathophysiology of, 844
- in pregnancy, 844
- racial distribution of, 844
- risk factors for, 844
- sex distribution of, 844
- signs and symptoms of, 844
- staging of, 844
- superficial, 844
- treatment of, 844
- Bladder emptying, impaired. *See also* Voiding dysfunction evaluation for, 193
- Bladder retraining
 - in interstitial cystitis, 259, 273
 - in overactive bladder syndrome, 273
- Bladder wall
 - innervation of, alteration, and overactive bladder, 182
 - resection of, in interstitial cystitis treatment, 259
 - unifying theories of overactive bladder and, 182
- Bleeding. *See also* Hemorrhage
 - acute intraoperative, 481
 - arterial, management of, 481
 - hemostatic techniques for, 481
 - management of, 481
 - peg hole defects and, 481
 - potential sites of, 481
 - prevention of, 481
 - venous, management of, 481
 - vulnerable adjacent structures in, 481
 - presacral, biologic tamponade for, 481
 - vaginal
 - irregular, premenopausal, 439
 - postmenopausal, 439
- Blenoxane. *See* Bleomycin
- Bleomycin
 - chemotherapy using, in pregnancy, 153
 - toxicity in fetus and/or newborn, 6
- Blood glucose monitoring
 - with antenatal corticosteroid therapy, 35
 - in diabetes, 165
- Blood loss
 - anemia caused by, perioperative management of, 449
 - in delivery, 330
 - in postpartum hemorrhage, 330
 - in trauma, 414
- Blood pressure
 - perioperative management of, 449
 - in pregnancy, 414, 553
- Blood volume, in pregnancy, effect on CPR, 377
- Bloom syndrome
 - leukemia in, 855
 - and prenatal cellular genetic therapy, 684
- B-Lynch compression suture, for postpartum hemorrhage, 330
- Body image, 1162
 - distortions of, adverse effects of, 1129
 - in obesity and overweight, 1080
 - in pregnancy, 1089
- Body mass index (BMI), 1080
 - classification of overweight and obesity by, 1080
- Bone
 - environmental exposures and, 1119
 - mineral metabolism in, and environmental toxins, 1119
- Bone marrow transplantation (BMT)
 - in acute leukemia, 855
 - in chronic leukemia, 855
 - in lymphoma, 820
- Bone mineral density
 - environmental exposures and, 1119
 - factors affecting, 1099
- Botanicals, medicinal, over-the-counter, use of, in pregnancy, 89
- Botulinum toxin, urologic applications of, 205
- Botulism
 - immunizing agent for, 42
 - in pregnancy, 42
- Bowel. *See also* Gastrointestinal tract
 - function of, in pregnancy, 553
 - injury to, in laparoscopy, 469
 - obstruction of, in pregnancy, 405, 553
 - causes of, 405
 - diagnosis of, 405
 - incidence of, 405
 - management of, 405
 - morbidity and mortality with, 405
 - signs and symptoms of, 405
 - surgery, in ovarian cancer, 439
- Bowel preparation, 481, 492
- Brachial plexus injury
 - laparoscopy-related, 469
 - in shoulder dystocia, 345
- Bradycardia, perioperative management of, 518
- Bradykinin, and bladder overactivity, 182
- Brain death, maternal, and fetal survival, 377
- Brain injury, shoulder dystocia and, 345
- Brain tumor(s), 904
 - benign, 904
 - epidemiology of, 904
 - frontal lobe, signs and symptoms of, 904
 - incidence of, 904
 - malignant, 904
 - metastatic, 904
 - signs and symptoms of, 904
 - in women, classification of, 904
- Branched DNA amplification, 605
- BRCA1* gene, mutation of, and cancer risk, 671, 711, 738, 1140
- BRCA2* gene, mutation of, and cancer risk, 671, 711, 738, 1140
- Breast(s)
 - anatomy of, 1129, 1140
 - atypical ductal hyperplasia in, 774
 - augmentation of. *See* Augmentation mammoplasty
 - development of, 1129, 1140
 - diseases of
 - ANDI classification of, 1129, 1140
 - diagnostic procedures for, 1140
 - in early reproductive period (ages 15–25), 1140
 - in involution (ages 35–55), 1140
 - in mature reproductive period (ages 25–40), 1140
 - in menopause (age 55+), 1140
 - in pregnancy and lactation, 1140

- signs and symptoms of, by reproductive period, 1140
- enhancement
 - alternative/complementary options for, 1129
 - patient education about, 1129. *See also* Augmentation mammoplasty
- hormonal factors affecting, 1129
- metastatic disease in, 758
- microcalcifications in, detection and analysis of, 774
- physiology of, 1129, 1140
- reconstruction of, after mastectomy, 1129, 1140
- reduction. *See* Reduction mammoplasty
- skin changes on, work-up for, 1140
- Breast cancer. *See also* Hereditary breast and ovarian cancer (HBOC)
 - absolute risk of, 738
 - adjuvant therapy for, 738, 767
 - axillary lymph node dissection in, 738
 - biologic behavior of, 738
 - biopsy techniques for, 738, 750, 774. *See also* Fine-needle aspiration biopsy
 - breast-conserving therapy in, 767, 774
 - carcinoma in situ
 - ductal, 774, 1140. *See also* Ductal carcinoma in situ (DCIS)
 - lobular, 774, 1140. *See also* Lobular carcinoma in situ (LCIS)
 - specimen mammography of, 774
 - chemotherapy for, 767, 1140
 - in pregnancy, 770
 - in childhood and adolescence, epidemiology of, 758
 - clinical course of, estrogen replacement therapy and, 738
 - deaths from, 735, 738, 1129, 1140, 1169
 - diagnosis of, 738
 - median age at, 750
 - in pregnancy and lactation, 770
 - ductal carcinoma in situ (DCIS), treatment of, 738
 - epidemiology of, 1073, 1129, 1140
 - etiology of, 1140
 - follow-up for, 1140
 - genetics of, 738, 1140
 - hereditary risk of, 671
 - diagnosis of, 671
 - management of, 671
 - HER-2/neu gene in, 605
 - in Hodgkin's disease survivors, 758
 - hormonal therapy for, 767
 - hormone receptor status of, 767
 - hormone replacement therapy and, 778
 - incidence of, 735, 1129, 1140
 - estrogen replacement therapy and, 738
 - intracystic, 750
 - invasive
 - adjuvant therapy for, 767
 - diagnosis of, in pregnancy and lactation, 770
 - incidence of, 738
 - local treatment of, 1140
 - systemic treatment of, 1140
 - treatment of, 767
 - in pregnancy and lactation, 770
 - and malpractice lawsuits, 738
 - management of, historical perspective on, 738
 - metastases of
 - to brain, 904
 - treatment of, 1140
 - microbiologic therapy for, 738
 - natural history of, 1140
 - neoadjuvant therapy for, 738, 767
 - oral contraceptive use and, 778
 - pregnancy-associated, definition of, 770
 - prevention of
 - primary, 1140
 - raloxifene and, 778
 - tamoxifen and, 778
 - radiation therapy for, 738, 1140
 - in pregnancy, 770
 - risk, calculation of, Gail model for, 1140
 - risk factors for, 750, 1140
 - lifestyle, 778
 - reproductive, 778
 - screening for, 735, 738, 778, 1129, 1140
 - cost-benefit analysis of, 1129
 - in high-risk patient, 1140
 - secretory, in childhood and adolescence, 758
 - in situ, incidence of, 738
 - staging of, 1140
 - surgical therapy for, 738
 - surveillance for, 778, 1129
 - treatment of, 767, 1140
 - local, 1140
 - pregnancy after, 770
 - in pregnancy and lactation, 770
 - systemic, 1140
 - vacuum-assisted core-needle biopsy of, 774
 - and women's sexuality, 1089
 - in women 22 years old and younger, 758
- Breast care, 746
 - practice guidelines for, 738
- Breast-conserving therapy, in breast cancer, 767, 774
- Breast cyst
 - carcinoma in, 750
 - diagnosis of, 750
 - epidemiology of, 750, 758
 - fine-needle aspiration of, 750
 - as normal physiologic process, 1129
- Breast examination
 - clinical, 750
 - anatomical considerations in, 1140
 - in cancer screening, 1140
 - cost-benefit analysis of, 1129
 - self, in cancer screening, 1140
- Breast-feeding
 - augmentation mammoplasty and, 1129
 - chemotherapy and, 153
 - drug exposure from, 1, 6
 - drugs and, patient counseling about, 6
 - drugs contraindicated in, 6
 - reduction mammoplasty and, 1129
- Breast imaging reporting and data system (BI-RADS), 746
- Breast implants, types of, 1129
- Breast mass
 - biopsy of, 750
 - fine-needle aspiration technique, in office practice, 761
 - diagnosis of
 - cytologic, 750
 - histologic, 750
 - diagnostic triad for, 750

- evaluation of, 750
 - history-taking in, 750
 - in lactating patient, 770
 - in pregnancy, 770
- nonpalpable, 750
- palpable, 750
- presentation of, 750
- in women 22 years old and younger, 750, 758
- work-up for, 1140
- Breast milk
 - drugs in
 - adverse effects in infant, 6
 - factors determining, 6
 - environmental toxins in, 1119
- Breast pain, work-up for, 1140
- Breathing
 - assessment of, in CPR, 377
 - mouth-to-mouth, in CPR, 377
- Bristol Female Lower Urinary Tract Symptoms, 173, 193
- Bromocriptine
 - adverse effects of, in breast-fed infant, 6
 - for bladder overactivity, 205
- Brompheniramine
 - adverse effects of, in breast-fed infant, 6
 - use of, in pregnancy, 89
- Bronchitis
 - chronic, perioperative management of, 449
 - treatment of, in pregnancy, 59
- Bronchodilator therapy
 - for asthma, 518
 - perioperative management of, 449
- Bronchoscopy, in lung cancer, 784
- Bronchospasm, perioperative, 518
- Brushfield spots, 622
- Budesonide, for asthma, in pregnancy, 136
- Bulbocavernosus reflex, 193
- Bulimia, lifetime prevalence of, sex differences in, 1162
- Bupivacaine, cardiac toxicity of, peripartum management of, 125
- Bupropion
 - adverse effects of, in breast-fed infant, 6
 - antidepressant therapy with, in pregnancy, 136
 - in smoking cessation, 1169
 - and weight loss, 1080
- Burch retropubic urethropexy
 - intraoperative cystoscopy and, 428
 - urinary tract injury in, 428
- Burkitt's lymphoma (BL), epidemiology of, 820
- Burst abdomen. *See* Wound, abdominal incision, dehiscence
- Buspirone, adverse effects of, in breast-fed infant, 6
- Busulfan therapy, in pregnancy, 153
- Busulfex. *See* Busulfan
- C
 - C₂₂₅, anticancer therapy with, in pregnancy, 153
- Caffeine
 - and bladder cancer, 844
 - use of, in pregnancy, 89
- Calcium, supplementation, in heparin therapy in pregnancy, 363
- Calcium carbonate, use of, in pregnancy, 89
- Calcium-channel blockers
 - for heart rate control, in atrial fibrillation, 518
 - for hypertension, 518
 - for hypertensive crisis in preeclampsia, 308
 - for severe hypertension, in pregnancy, 125
- as tocolytic agents
 - dosage and administration of, 99
 - efficacy of, 99
 - fetal/neonatal effects of, 99
 - maternal side effects of, 99
 - mechanism of action of, 99
 - pharmacology of, 99
- Calories, in nutritional support for surgical patient, 537
- Calorimetry, 537
- Camptosar. *See* Irinotecan
- Cancer. *See also* Malignancy; *specific cancer*
 - cytogenetic changes in, 622
 - gynecologic, hereditary, 671
 - hereditary, risk of
 - diagnosis of, 671
 - family history and, 671
 - gene mutations and, 671
 - and health insurance, 671
 - laboratory testing for, 671
 - management of, 671
 - metastases of
 - to brain, 904
 - unexpected, diagnosed at gynecologic surgery
 - abdominal, 439
 - pelvic, 439
 - vaginal, 439
 - mortality rates for, 1073
 - non-gynecologic, in women. *See also specific cancer*
 - most common types of, 735
 - oral. *See* Mouth cancer
 - in pregnancy
 - chemotherapy for, 153
 - and pregnancy termination, 153
 - prevalence of, 153
 - screening for, 1181
 - unexpected
 - diagnosed at cesarean delivery, 439
 - diagnosed at gynecologic surgery, 439
 - cervical, 439
 - colorectal, 439
 - economic considerations with, 439
 - endometrial, 439
 - ethical considerations with, 439
 - extragenital, 439
 - of fallopian tube, 439
 - legal considerations with, 439
 - ovarian, 439
 - psychological considerations with, 439
 - vaginal, 439
 - vulvar, 439
 - in women
 - death rates for, 735
 - incidence of, 735
 - mortality rates for, 784
 - smoking and, 784
- Cancer-risk syndromes, 671
- Candidiasis
 - recurrent vaginal, 233
 - vulvitis caused by, 233
- Capsaicin
 - for bladder overactivity, 182, 205
 - intravesical therapy with, 205

- for interstitial cystitis, 259
- mechanism of action of, 205
- Captopril, toxicity in fetus and/or newborn, 6
- Carafate. *See* Sucralfate
- Carbamazepine
 - for interstitial cystitis, 259
 - teratogenicity of, 136
 - therapy with, in pregnancy, 136
- Carbapenems
 - adverse effects and side effects of, 59
 - costs of, 59
 - mechanism of action of, 59
 - obstetric applications of, 59
 - precautions with, 59
 - spectrum of activity of, 59
- Carbetocin, for postpartum uterine atony, 125
- Carbimazole, teratogenicity of, 6
- Carboplatin therapy, in pregnancy, 153
- Carboprost tromethamine (Hemabate)
 - midtrimester labor induction with, for pregnancy termination, 114
 - for postpartum hemorrhage, 330
- Carcinoembryonic antigen
 - colorectal cancer and, 812
 - in hepatocellular carcinoma, 939
 - in pancreatic cancer, 855
- Carcinoid tumor, of lung, 784
- Carcinoma in situ, tubal, unexpected, diagnosed at gynecologic surgery, 439
- Cardiac arrest, maternal, in pregnancy, 377, 414
 - advanced cardiac life support techniques for, 377
 - basic life support techniques for, 377
 - causes of, 377
 - nonobstetric, 377
 - obstetric, 377
 - in preeclampsia, 377
 - trauma-related, 414
- Cardiac devices, perioperative management of, 449, 518
- Cardiac emergencies, perioperative, 518
- Cardiac enzymes, in myocardial infarction, 518
- Cardiac output
 - fetal, hypoxemia and, 975
 - management of
 - in heart failure, 518
 - in sepsis, 562
 - in pregnancy, 414, 553
 - effect on CPR, 377
- Cardiac tamponade, postpartum, 377
- Cardinal ligament, anatomy of, 428
- Cardiomyopathy, peripartum, 377
- Cardiopulmonary resuscitation
 - ABCD survey in, 377
 - maternal physiologic changes in pregnancy and, 377
 - in pregnancy, 377, 414
 - aorticaval compression in, management of, 414
 - techniques for, 377
- Cardiorespiratory emergencies, in pelvic surgery patient, 518
- Cardiotocography, in pregnant trauma victim, 414
- Cardiovascular disease
 - complicating pregnancy, 377
 - epidemiology of, 1073
- Cardiovascular physiology, in pregnancy, and trauma, 414
- Care crisis, 1189
- Caregiving gap, 1189
- Care penalty, 1189
- Carisoprodol, adverse effects of, in breast-fed infant, 6
- Cat-eye syndrome, 622
- Catheter(s)
 - for cervical ripening, 114
 - ureteral, preoperative placement of, 428
- CDKN2A* gene, and melanoma, 830
- cDNA arrays, 605
- Cefazolin
 - obstetric applications of, 59
 - spectrum of activity of, 59
- Cefepime
 - cost of, 59
 - for perioperative pneumonia, in pelvic surgery patient, 518
 - spectrum of activity of, 59
- Cefixime
 - obstetric applications of, 59
 - spectrum of activity of, 59
- Cefonicid, spectrum of activity of, 59
- Cefoperazone, spectrum of activity of, 59
- Ceforanide, spectrum of activity of, 59
- Cefotaxime
 - cost of, 59
 - spectrum of activity of, 59
- Cefotetan
 - cost of, 59
 - for operative site infection, 562
 - spectrum of activity of, 59
- Cefoxitin
 - cost of, 59
 - for operative site infection, 562
 - spectrum of activity of, 59
- Ceftazidime, spectrum of activity of, 59
- Ceftizoxime
 - cost of, 59
 - spectrum of activity of, 59
- Ceftriaxone
 - obstetric applications of, 59
 - spectrum of activity of, 59
- Cellular genetic therapy, prenatal. *See also* Stem cell transplantation
 - potential for, 684
 - rationale for, 684
- Cellulitis, cuff, 562
- Centers for Disease Control, guidelines for prevention of surgical site infection, 562
- Central nervous system (CNS)
 - and bladder function, 182
 - fetal, maternal drug abuse and, 73
- Centromere, position of, 622
- Cephalexin
 - obstetric applications of, 59
 - spectrum of activity of, 59
- Cephalosporins
 - adverse effects and side effects of, 59
 - cost of, 59
 - obstetric applications of, 59
 - for operative site infection, 562
 - pregnancy category of, 59
 - prophylactic, in gynecologic surgery, 562
 - for sepsis, in pregnancy, 393
 - spectrum of activity of, 59

- Cerebral arteries, fetal, Doppler ultrasound evaluation of, 1015
- Cerebral palsy
biophysical profile score and, 975
prevention of, 975
- Cerebrovascular accident, in eclampsia, 308
- Cerubidine. *See* Daunorubicin
- Cervical cancer
epidemiology of, 1073
HPV and, 605
management of, by stage, 439
molecular diagnostics and, 605
unexpected, diagnosed at gynecologic surgery, 439
- Cervical intraepithelial neoplasia
HPV and, 605
in hysterectomy specimen, 439
- Cervical ripening, agents for, 114
- Cervidil, for cervical ripening and labor induction, 114
- Cervix, shoulder dystocia and, 345
- Cesarean delivery
in HELLP syndrome, 308
infection control guidelines for, 562
perimortem, 377, 414, 553
previous
and placenta accreta, 330
and placenta previa, 330
in shoulder dystocia, 345
unexpected cancer diagnosed at, 439
- Cetirizine, use of, in pregnancy, 89
- C-fibers, and bladder function, 182, 205, 218
- Charcot-Marie-Tooth 1A disease, 622
- Charcot-Marie-Tooth disease, 622
- Chemoradiation, for pancreatic cancer, 855
- Chemotherapy
adverse effects and side effects of, 855
for bladder cancer, 844
for breast cancer, 738, 1140
in pregnancy, 770
and breast-feeding, 153
combination
efficacy of, 153
mechanism of action of, 153
in pregnancy, 153
rationale for, 153
fetal effects of, 153
for hepatocellular carcinoma, 939
intraperitoneal, for gastric cancer, 892
for leukemia, 855
for lung cancer, 784
for lymphoma, 820
for mouth cancer, 952
for multiple myeloma, 928
neoadjuvant, for gastric cancer, 892
postoperative, for gastric cancer, 892
and pregnancy, 153
regimens for, in pregnancy, 153
secondary leukemia after, 855
teratogenicity of, 153, 855
- Chest compressions
in airway obstruction, in pregnancy, 377
in cardiopulmonary resuscitation, 377, 414
- Chest radiography
in diagnosis of pulmonary embolism, 545
in lymphoma, 820
in pregnancy, 393, 553
in varicella pneumonia, 393
- Childbirth, and women's sexuality, 1089
- Chimerism, mixed hematopoietic
postnatal enhancement of, 684
prenatal stem cell transplantation and, 684
- Chlamydia* infection, treatment of, in pregnancy, 59
- Chlorambucil therapy, in pregnancy, 153
- Chloramphenicol, adverse effects of, in breast-fed infant, 6
- Chlordiazepoxide, adverse effects of, in breast-fed infant, 6
- Chlormethiazole, for prevention of recurrent eclamptic seizures, 308
- Chlorpheniramine, use of, in pregnancy, 89
- Chlorphentermine, 89
- Chlorpromazine
adverse effects of, in breast-fed infant, 6
for nausea, vomiting, and hyperemesis gravidarum, 136
starting dosage for, in pregnancy, 136
- Chlorpropamide
adverse effects of, in breast-fed infant, 6
toxicity in fetus and/or newborn, 6
- Cholangiocarcinoma, intrahepatic, 939
clinical presentation of, 939
pathology of, 939
risk factors for, 939
treatment of, 939
- Cholecystectomy
for biliary colic, prepregnancy, 405
in pregnancy, 405, 553
- Cholecystitis, in pregnancy, 405, 553
diagnosis of, 405
differential diagnosis of, 405
management of, 405
signs and symptoms of, 405
- Cholecystosonography, in pregnancy, 405
- Cholelithiasis
and pancreatitis in pregnancy, 405
in pregnancy, 553
- Cholera
immunizing agent for, 42
in pregnancy, 42
- Cholestasis of pregnancy
pharmacologic treatment of, 136
signs and symptoms of, 136
- Cholestyramine
for antibiotic-associated colitis, 492
for cholestasis of pregnancy, 136
- Chorioamnionitis, treatment of, 59
- Choriocarcinoma, 622
vaginal metastases, 439
- Chorionic villus sampling, 1039
and limb reduction defects, 1039
in multifetal pregnancy, 1039
Rh prophylaxis with, 1039
safety of, 1039
transabdominal, 1039
transcervical, 1039
and transabdominal, comparison of, 1039
- Chromium picolinate, 89
- Chromosome(s) 4
short arm deletion of, 622
short arm duplication of, 622
22, subtelomere deletion, 622, 711

- abnormalities of
 - clinical conditions with, 622
 - frequency of, 622
 - incidence of
 - in first-trimester abortion, 622
 - in liveborns, 622
 - in stillbirths, 622
 - maternal age and, 622, 657, 661
 - in multiple myeloma, 928
 - numerical, 622
 - fluorescence in situ hybridization for, 640, 649
 - preimplantation genetic diagnosis of, 640
 - screening for, 622
 - by fetal nuchal translucency at 11–14 weeks, 661
 - and spontaneous abortion, 661
 - structural (morphologic), 622
 - fluorescence in situ hybridization for, 640
 - interchromosomal, 622
 - intrachromosomal, 622
 - preimplantation genetic diagnosis of, 640
 - types of, 622
 - and umbilical artery velocity waveforms, 1015
- acrocentric, 622
- analysis of
 - cell culture for, 622
 - indications for, 622
- balanced rearrangements of, 622
- description of, abbreviations used for, 622
- fragile sites on, 622
- high-resolution banding of, 622
- marker, 622
- metacentric, 622
- prometaphase, 622
- 1pter deletions, 622
- 1qter deletions, 622
- ring, 622
- staining of, 622
- structural rearrangements of
 - balanced, 622
 - stable vs unstable, 622
 - unbalanced, 622
- submetacentric, 622
- supernumerary, 622
- Chronic lymphocytic leukemia (CLL), 855
- Chronic myelogenous leukemia, 855
- Chronic obstructive pulmonary disease (COPD)
 - perioperative management of, 449, 518
 - in pregnancy, cardiac complications of, 377
- Chronic progressive external ophthalmoplegia. *See* Kearns-Sayre syndrome
- Cimetidine
 - for gastroesophageal reflux disease, in pregnancy, 136
 - for interstitial cystitis, 259
 - use of, in pregnancy, 89
- Ciprofloxacin. *See also* Fluoroquinolones
 - adverse effects of, in breast-fed infant, 6
 - for operative site infection, 562
- Cirrhosis, hepatic, and liver cancer, 939
- Cisapride, for gastroesophageal reflux disease, in pregnancy, 136
- Cisplatin therapy, in pregnancy, 153
- Clark's classification, of melanoma, 830
- Claudin-4, in pancreatic cancer, 855
- Clavicular fracture, shoulder dystocia and, 345
- Clear cell carcinoma, hereditary renal, 884
- Cleft lip/palate, inheritance of, 593
- Clemastine, adverse effects of, in breast-fed infant, 6
- Clindamycin
 - adverse effects and side effects of, 59
 - in breast-fed infant, 6
 - dosage and administration of, 59
 - mechanism of action of, 59
 - obstetric applications of, 59
 - for operative site infection, 562
 - for perioperative pneumonia, in pelvic surgery patient, 518
 - pregnancy category of, 59
 - for sepsis, in pregnancy, 393
 - spectrum of activity of, 59
- Clofazimine, adverse effects of, in breast-fed infant, 6
- Clomipramine, toxicity in fetus and/or newborn, 6
- Clonazepam
 - adverse effects of, in breast-fed infant, 6
 - therapy with, in pregnancy, 136
 - toxicity in fetus and/or newborn, 6
- Clonidine, antihypertensive therapy with, in pregnancy, 22
- Cloning, positional, 711
- Clorapactin WCS-90, intravesical, for interstitial cystitis, 259
- Clostridium difficile*
 - asymptomatic carrier state, 492
 - infection
 - clinical manifestations of, 492
 - diagnosis of, 492
 - imaging in, 492
 - management of, 492
 - medical therapy for, 492
 - onset of, 492
 - relapse of, 492
 - surgical management of, 492
 - toxins of, 492
- Clotting abnormalities. *See* Coagulopathy
- Clozapine, adverse effects of, in breast-fed infant, 6
- Coagulation factors
 - in pregnancy, 414, 553
 - replacement of, in disseminated intravascular coagulation, 308
- Coagulation tests, preoperative, 449
- Coagulopathy. *See also* Disseminated intravascular coagulation (DIC)
 - perioperative management of, 449
 - and venous thromboembolism in pregnancy, 363
- Cocaine
 - abuse
 - health consequences of, 73
 - and pregnancy outcome, 73
 - adverse effects of, in breast-fed infant, 6
 - perinatal exposure to, fetal/neonatal effects of, 73
- Coccygeus-levator spasm, 273
- Cold medications, over-the-counter, use of, in pregnancy, 89
- Colitis
 - antibiotic-associated, 492
 - pseudomembranous, 492
- Colloid osmotic pressure, decreased, 518
- Colon. *See also* Gastrointestinal tract
 - cancer of, unexpected, diagnosed at gynecologic surgery, 439
 - injury to
 - intraoperative, minimization of morbidity in, 492

- in laparoscopy, 469
- microbial replacement therapy in, for antibiotic-associated colitis, 492
- Colonoscopy, in colorectal cancer screening, 812
- Colorectal cancer
 - adenomas and, 812
 - deaths from, reduction of, 812
 - differential diagnosis of, 812
 - epidemiology of, 812
 - high-risk factors for, 812
 - protocols for patients with, 812
 - metastases of, to brain, 904
 - precursor lesion to, 812
 - prevention of, 812
 - risk of, reduction of, 812
 - screening for, 812
 - abnormal results in, protocols for, 812
 - signs and symptoms of, 812
 - staging of, 812
 - treatment of, 812
 - in women
 - deaths from, 735
 - detection of, 735
 - incidence of, 735
 - screening for, 735
- Colorectal surgery, infection control guidelines for, 562
- Color flow Doppler, and amniotic fluid evaluation, 1026
- Colostomy
 - after intraoperative colonic injury, 492
 - in ovarian cancer, 439
- Colposcopy, indications for, 439
- Comparative genomic hybridization (CGH), 622
- Comparative genomics, 711
- Compazine. *See* Prochlorperazine
- Complementary and alternative medicine
 - and breast enhancement, 1129
 - and breast reduction, 1129
 - and reproductive health, 1181
- Compression stockings, in prevention of thromboembolism, 545
- Computed tomography (CT)
 - in appendicitis, in pregnancy, 405
 - in endometrial assessment, 439
 - in gastric cancer staging, 892
 - of gastrointestinal surgical complications, 492
 - of hepatocellular carcinoma, 939
 - in lymphoma, 820
 - of pancreatic cancer, 855
 - in pregnant trauma victim, 414
 - in pseudomembranous colitis, 492
 - of pulmonary embolism, 363
 - in renal cell carcinoma, 884
 - of thyroid, 879
- Condyloma acuminata, 233
- Congenital adrenal hyperplasia
 - newborn screening for, 697
 - strategy for, 697
 - treatment of, 730
- Congenital malformations. *See* Birth defects
- Congestive heart failure
 - perioperative management of, 518
 - in pulmonary edema in preeclampsia, 308
- Conotruncal defects, genetic and genomic factors associated with, 711
- Constipation
 - in pregnancy, 553
 - treatment of, in pregnancy, 89
- Contamination, definition of, 562
- Contiguous gene syndromes, 622
- Continuous positive airway pressure, for perioperative upper airway obstruction, 518
- Contraction stress test, 1054, 1063
 - and biophysical profile, comparison of, 1005
 - equivocal, management of, 1005
 - frequency of, 1005
 - in high-risk pregnancy, 1063
 - interpretation of, 1005
 - method for, 1005
 - negative, 1005
 - and nonstress test, comparison of, 986, 1005, 1063
 - positive, management of, 1005
 - suspicious, management of, 1005
 - timing of, 1005
 - unsatisfactory, management of, 1005
 - utility of, 1005
- Contrast venography, in diagnosis of deep venous thrombosis, 545
- Cortical blindness, in preeclampsia, 308
- Cortical neuropathy, and overactive bladder, 182
- Corticosteroids
 - antenatal
 - dosage and administration of, 35
 - and fetal lung maturation, 35
 - with preterm premature rupture of membranes, 35
 - repetitive courses of, concerns about, 35
 - risks of, 35
 - for asthma, in pregnancy, 125, 136
 - effects on fetal activity, 993
 - postnatal/neonatal, 35
 - systemic, teratogenicity of, 6
 - topical, use of, in pregnancy, 89
 - toxicity in fetus and/or newborn, 6
- Corticosteroid therapy
 - antepartum, in HELLP syndrome, 308
 - for asthma, in pregnancy, 369
 - perioperative management of, 449
 - postpartum, in HELLP syndrome, 308
- Corticotropin-releasing hormone (CRH) test, 904
- Cortisol, serum levels, antenatal corticosteroid therapy and, 35
- Cosmegen. *See* Dactinomycin
- Coumadin, for deep venous thrombosis, 545
- Count to 10 fetal kick chart, 993
- COX-2 inhibitors, and colorectal cancer prevention, 812
- CpG islands, 593
- Craniopharyngioma, 904
- Creatinine clearance, in pregnancy, 414
- Creatinine height index, in surgical patient, 537
- Cri-du-chat syndrome, 622
- Critical period, for drug toxicity in pregnancy, 6
- Crohn's disease (CD)
 - and colorectal cancer risk, 812
 - treatment of, in pregnancy, 136
- Cromakalin, for bladder overactivity, 205
- Cromolyn
 - for asthma, in pregnancy, 136
 - use of, in pregnancy, 89

- Cryoprecipitate, transfusion of, in disseminated intravascular coagulation, 308
- Cryosurgery, for hepatocellular carcinoma, 939
- Cuff cellulitis, 562
- Curare, contraindications to, 518
- Cushing syndrome
 paraneoplastic, in lung cancer, 784
 tumors producing, 904
- Cutaneous lymphatic mapping, in melanoma, 830
- Cyclophosphamide
 and bladder cancer, 844
 doxorubicin, Oncovin, and prednisone (CHOP) regimen, for lymphoma, 820
 therapy with, in pregnancy, 153
- Cyclosporin, adverse effects of, in breast-fed infant, 6
- Cystadenoma
 mucinous, of pancreas, 855
 serous, of pancreas, 855
- Cystectomy
 for bladder cancer, 844
 for interstitial cystitis, 259
- Cystic fibrosis
 clinical features of, 605
 genomics and genetics of, 711
 management of, 697
 molecular diagnosis of, 605
 newborn screening for, strategy for, 697
 point mutations in, 605
 screening for, 697
- Cystic fibrosis transmembrane conductance regulator (CFTR) gene, 605
- Cystistat. *See* Hyaluronic acid
- Cystitis, treatment of, in pregnancy, 59
- Cystometrograph, in detrusor instability, 173
- Cystoscopy
 in bladder cancer diagnosis, 844
 in diagnosis of interstitial cystitis, 250
 intraoperative
 in Burch retropubic urethropexy, 428
 equipment for, 428
 technique for, 428
 urinary tract injuries detected by, 428
 transurethral, of ureteral patency, 428
- Cystourethroscopy, 193
- Cytarabine, chemotherapy using, in pregnancy, 153
- Cytochrome C oxidase deficiency, 593
- Cytogenetics, 622
- Cytogenetic testing, indications for, 622
- Cytokeratin, 605
- Cytokines
 in postoperative sepsis, 562
 in response to surgery, 537
 in sepsis, 393
- Cytosar-U. *See* Cytarabine
- Cytotec. *See* Misoprostol (Cytotec)
- Cytoxan. *See* Cyclophosphamide
- D
- Dacarbazine therapy, in pregnancy, 153
- Dactinomycin, chemotherapy using, in pregnancy, 153
- Dalfopristin. *See* Quinupristin-dalfopristin
- Dapsone, adverse effects of, in breast-fed infant, 6
- Daunomycin. *See* Daunorubicin
- Daunorubicin, chemotherapy using, in pregnancy, 153
- DDAVP. *See* Desmopressin
- Death
 fetal. *See also* Fetal loss
 risk of, assessment of, 975, 993, 1063
 shoulder dystocia and, 345
 perinatal, risk of, assessment of, 975, 1063
- Decongestants, use of, in pregnancy, 89
- Deep venous thrombosis
 anticoagulation for, in pregnancy, 136
 incidence of, by risk group, 545
 postpartum
 incidence of, 363
 risk factors for, 363
 in pregnancy, 363
 diagnosis of, 363
 in surgical patient
 diagnosis of, 545
 prevention of, 545
 signs and symptoms of, 545
 treatment of, 545
- Defibrillation, in cardiopulmonary resuscitation, 377
- Defibrillator, intracardiac, perioperative management of, 449, 518
- Deformation, definition of, 6
- Deletions
 chromosomal, 622
 analysis for, 605
 causes of, 622
 clinical consequences of, 622
 diseases caused by, 605
 identification of, 622
 interstitial, 622, 711
 telomeric, 711
 terminal, 622
 subtelomeric
 clinical features of, 622
 screening for, 622
- Delivery
 in acute respiratory distress syndrome, 369
 blood loss in, 330
 in eclamptic patient, evaluation for, 308
 in HELLP syndrome, 308
 in hypertensive crisis in preeclampsia, 308
 midpelvic, and shoulder dystocia, 345
 in pregnant trauma victim, 414
 in shoulder dystocia, documentation of, 345
- Dementia, and overactive bladder, 182
- Dentatorubral-pallidoluysian atrophy, 593
- Depakote. *See* Valproic acid
- Depression
 in adolescents, 1181
 detection of, 1181
 epidemiology of, 1181
 and hypothyroidism, 1162
 lifetime prevalence of, sex differences in, 1162
 pharmacologic therapy for, in pregnancy, 136
 premenstrual, 1162
 stress and, 1099
- Dermoscopy, 830
- Desipramine
 adverse effects of, in breast-fed infant, 6
 starting dosage for, in pregnancy, 136
- Desmopressin
 for bladder overactivity, 205
 mechanism of action of, 205

- Detrol. *See* Tolterodine
- Detrusor hyperactivity with impaired contractility
- epidemiology of, 173
 - pathophysiology of, 173
 - prevalence of, age-related differences in, 173
 - signs and symptoms of, 173
- Detrusor hyperreflexia, 173
- neurogenic causes of, 182
 - in Parkinson's disease, 173
- Detrusor instability. *See also* Overactive bladder syndrome
- definition of, 173
 - diagnosis of, 193
 - diagnostic criteria for, 173
 - idiopathic, 182
 - prevalence of, age-related differences in, 173
 - and stress incontinence, 182
 - triggers of, 182
- Detrusor sphincter dyssynergia
- in overactive bladder syndrome, 193
 - treatment of, 205
- Development, pediatric, prenatal drug exposure and, 73
- Developmental defects, genetic and genomic factors associated with, 711
- Dexamethasone
- antenatal, dosage and administration of, 35
 - effects on fetal activity, 993
 - sulfiting agents in, neurotoxicity of, 35
- Dexfenfluramine, adverse effects of, in breast-fed infant, 6
- Dextran 70, in prevention of thromboembolism, 545
- Dextromethorphan, use of, in pregnancy, 89
- Diabetes mellitus
- antenatal corticosteroid therapy and, 35
 - gestational, and shoulder dystocia, 345
 - management of, in pregnancy, 165
 - advances in (future directions for), 165
 - perioperative management of, 449
- Diabetic cystopathy, treatment of, advances in (future directions for), 205
- Dialysis, in HELLP syndrome, 308
- Diarrhea
- antibiotic-associated, 492
 - treatment of, in pregnancy, 89
- Diazepam
- adverse effects of, in breast-fed infant, 6
 - for eclamptic seizures, 308
 - for prevention of recurrence, 308
 - for high-tone pelvic floor dysfunction, 273
 - for peripartum seizures, 125
 - toxicity in fetus and/or newborn, 6
- Diazoxide
- contraindications to, in pregnancy, 125
 - toxicity in fetus and/or newborn, 6
- Dicyclomine, for nausea, vomiting, and hyperemesis gravidarum, 136
- Diet
- and colorectal cancer prevention, 812
 - in diabetes, 165
 - and gastric cancer, 892
 - high-protein, 1080
 - in interstitial cystitis treatment, 259
 - low-calorie, 1080
 - low-fat, 1080
 - for overactive bladder treatment, 273
 - recommended, 1080
 - very low-calorie, 1080
 - weight-reduction, 1080
- Diethylstilbestrol (DES)
- intrauterine exposure to, 1119
 - teratogenicity of, 6
- Diet pills, over-the-counter, use of, in pregnancy, 89
- Digitalis therapy, perioperative management of, 449
- Digoxin
- for heart failure, perioperative management of, 518
 - for heart rate control, in atrial fibrillation, 518
- Dilantin. *See* Phenytoin
- Diltiazem, for heart rate control, in atrial fibrillation, 518
- Dimenhydrinate
- for nausea, vomiting, and hyperemesis gravidarum, 136
 - use of, in pregnancy, 89
- Dimethylsulfoxide (DMSO), intravesical, for interstitial cystitis, 259
- D-immunoglobulin, for pregnant trauma victim, 414, 553
- Dinoprostone (Prostin E2)
- for cervical ripening and labor induction
 - cervical gel, 114
 - vaginal gel, 114
 - midtrimester labor induction with, for pregnancy termination, 114
 - for postpartum hemorrhage, 330
- Diphenhydramine
- for nausea, vomiting, and hyperemesis gravidarum, 136
 - toxicity in fetus and/or newborn, 6
 - use of, in pregnancy, 89
- Diphtheria
- immunizing agent for, adverse effects and side effects of, 42
 - in pregnancy, 42
- Disability
- and reproductive health, 1181
 - and women's sexuality, 1089
- Dispermy, 622
- Disseminated intravascular coagulation (DIC)
- in acute promyelocytic leukemia, 855
 - causes of, 449
 - management of, 308, 449
 - postoperative, 562
 - in preeclampsia, 308
 - diagnosis of, 308
 - management of, 308
- Ditropan XL. *See* Oxybutynin
- Diuretics
- for pulmonary edema, in pregnancy, 125
 - therapy with, in pregnancy, 22
- Diuretic therapy
- indications for, 449
 - intravenous, for heart failure, perioperative management of, 518
 - perioperative management of, 449
 - for pulmonary edema
 - in preeclampsia, 308
 - in pregnancy, 369
- Divorce
- demographics of, 1099
 - economic effects of, 1099
 - and vulnerability to stress, 1099
 - and women's health, 1099

- DNA (deoxyribonucleic acid)
 amplification of. *See also* Branched DNA amplification
 by ligase chain reaction, 605
 by polymerase chain reaction, 605. *See also* Polymerase chain reaction (PCR)
 cell-free fetal, in maternal blood, prenatal diagnosis using, 649
 denaturation of, for polymerase chain reaction, 605
 extraction from dried blood, in newborn screening, 697
 fetal, prenatal diagnosis using, 649, 711
 in situ hybridization of, 605
 mitochondrial. *See* Mitochondrial DNA
 sequencing of, 711
 synthesis of, in polymerase chain reaction, 605
 variants of
 allele frequency in, 711
 clinical consequences of, 711
- DNA polymerase, thermostable, in polymerase chain reaction, 605
- Dobutamine therapy
 perioperative
 for heart failure, 518
 in sepsis, 562
 in sepsis, in pregnancy, 393
- Docusate, use of, in pregnancy, 89
- Dopamine-1 agonist, for hypertension, 518
- Dopamine therapy
 perioperative
 in heart failure, 518
 in sepsis, 562
 in sepsis, in pregnancy, 393
- Doppler velocimetry. *See* Ultrasound, Doppler
- Down syndrome
 chromosomal translocations and, 622
 clinical features of, 622
 double/triple screening and, 657
 fetal nuchal translucency in, 661
- α -fetoprotein screening for, test performance in, 657
- leukemia in, 855
- mosaic, 622
- screening for, 661
- spontaneous abortion rate for, 622
- Doxepin
 adverse effects of, in breast-fed infant, 6
 toxicity in fetus and/or newborn, 6
- Doxorubicin, chemotherapy using, in pregnancy, 153
- Doxylamine
 for headache, in pregnancy, 136
 for nausea, vomiting, and hyperemesis gravidarum, 136
- Drains
 abdominal, indications for, 492
 in abdominal wounds, 507
 in cesarean delivery, in HELLP syndrome, 308
- Dramamine. *See* Dimenhydrinate
- Dressings, for superficial separation of abdominal incision wound, 507
- Droperidol, for nausea, vomiting, and hyperemesis gravidarum, 136
- Drug(s). *See also* Medications; Over-the-counter drugs
 absorption of, in pregnancy, 136
 contraindicated in pregnancy and breast-feeding, 6
 distribution of, in pregnancy, 136
 dosage and administration of, in pregnancy, 1
- effects of
 on breast-fed infant, 1, 6
 on embryo, 1, 6
 on fetus, 1, 6
 on newborn, 1, 6
- excretion of
 in breast milk, factors determining, 6
 in pregnancy, 136
- exposure to, in pregnancy
 patient counseling about, 1, 6
 studies of, limitations of, 1, 6
 types commonly used, 1
 for woman who requires therapy, 6
- and length of gestation, 1
- metabolism of
 intestinal epithelium and, 205
 in pregnancy, 136
- for nonpregnant woman who requires therapy and may become pregnant, 6
- nonprescription, exposure to, during pregnancy, 1
- pharmacokinetics and pharmacodynamics of, in pregnancy, 377
- pharmacokinetics of, in pregnancy, 1, 136
- preconception management of, 1, 6
- pregnancy risk categories of, 1, 136
- teratogenicity of
 patient counseling about, 1, 6
 studies of, limitations of, 1, 6
 topical, use of, in pregnancy, 89
 toxic to fetus and/or newborn, 6
 tracheal administration of, in CPR, in pregnancy, 377
 transplacental transport of, 1, 6
- Drug abuse, in pregnancy, 73
- fetal effects of, 73
- and neonatal abstinence syndrome, 73
- and neurobehavioral characteristics of offspring, 73
- patient characteristics in, 73
- and pediatric development, 73
- prevalence of, assessment of, 73
- teratogenicity of, 73
- treatment of
 assessment for, 73
 comprehensive perinatal care in, 73
 engagement procedures for, 73
 intake for, 73
 models for, 73
 obstetric care in, 73
 pediatric care in, 73
 program components for, 73
- Drug abuse without dependence, lifetime prevalence of, sex differences in, 1162
- Drug dependence, lifetime prevalence of, sex differences in, 1162
- Drug development, genomics and, 711
- Dry mouth, with anticholinergic therapy, 205
- Duchenne muscular dystrophy
 germline mosaicism in, 593
 molecular diagnosis of, 605
- Ductal carcinoma in situ (DCIS), of breast
 axillary lymph node dissection or biopsy in, 774
 breast-conserving therapy for, 774
 classification of, 774
 diagnosis of, 774
 mortality rate for, 774
 radiation therapy for, 774

- recurrence of
 - risk factors for, 774
 - treatment of, 774
- tamoxifen therapy for, 774
- treatment of, 774, 1140
- Ductus venosus. Doppler ultrasound evaluation of, 1015
- Duloxetine
 - for bladder overactivity, 205
 - mechanism of action of, 205
- Duplication, chromosomal, 622
- clinical consequences of, 622
- origins of, 622
- phenotypic effects of, 622
- Durie-Salmon staging system, for multiple myeloma, 928
- Dyspareunia, 233, 1089
 - deep, 233
 - gynecologic causes of, 233
 - of interstitial cystitis, 233, 250
 - introital, 233
 - with pentosan polysulfate therapy, 259
- Dyspepsia, treatment of, in pregnancy, 89
- Dysplastic nevus syndrome, 830
- Dysthymia, lifetime prevalence of, sex differences in, 1162
- Dystocia. *See* Shoulder dystocia
- Dystrophin gene, 605
- E
- Ear pain, in head and neck cancer, 952
- Ebstein anomaly, 622
- Echinacea, use of, in pregnancy, 89
- Echocardiography, 449
 - in myocardial infarction, 518
- Eclampsia. *See also* Preeclampsia/eclampsia
 - clinical manifestations of, 308
 - diagnosis of, 308
 - differential diagnosis of, 308
 - epidemiology of, 308
 - evaluation for delivery in, 308
 - hypertension in, treatment of, 308
 - incidence of, 308
 - management of, 308
 - maternal mortality rate for, 308
 - perinatal mortality rate for, 308
 - prediction of, 308
 - prognosis for, 308
 - recurrence of, in subsequent pregnancy, 308
 - seizures in, 308
 - control of, 308
 - pharmacologic therapy for, 125
 - prevention of, 308
 - repeat, prevention of, 308
- Ectopic pregnancy, ultrasound diagnosis of, 553
- Educational status, and women's health, 1073
- Edwards syndrome, clinical features of, 622
- Effexor. *See* Venlafaxine
- Efudex. *See* 5-Fluorouracil
- Egg protein, in vaccines, 42
- Elavil. *See* Amitriptyline
- Electrical stimulation, in overactive bladder syndrome, 273
- Electrocardiography
 - in diagnosis of pulmonary embolism, 545
 - in myocardial infarction, 518
 - in pregnancy, 553
- Electrocautery, and abdominal wound breakdown, 507
- Electrogalvanic stimulation, in high-tone pelvic floor dysfunction, 273
- Electromagnetic fields, leukemia caused by, 855
- Electromyography (EMG)
 - in overactive bladder syndrome, 193
 - for pelvic floor muscle evaluation, 273
- Electrophysiology, of bladder overactivity, 182
- Elmiron. *See* Pentosan polysulfate
- Embolotherapy, for postpartum hemorrhage, 330, 553
- Embryo
 - androgenetic, 593
 - android, 593
 - biopsy of, 640
 - drug exposure and, 1
 - critical period for, 6
 - gynogenetic, 593
 - gynoid, 593
 - preimplantation, chromosome analysis of, 640
- Emeprium bromide, intravesical therapy with, 205
- Emergencies
 - acute abdominal, in pregnancy, 553
 - cardiorespiratory, in pelvic surgery patient, 518
 - gastrointestinal, postoperative, 492
 - gynecologic, 427. *See also specific emergency*
 - hypertensive, in preeclampsia, 308
 - obstetric, 307. *See also specific emergency*
 - infectious disease and, 393
 - peripartum, pharmacologic therapy for, 125
 - uterine, in pregnancy, 553
- Emphysema
 - perioperative management of, 449
 - subcutaneous, laparoscopy-related, 469
- EMX2 gene, mutation of
 - and cancer risk, 711
 - and schizencephaly, 711
- Enalapril
 - for heart failure, perioperative management of, 518
 - for hypertension, 518
- En bloc secondary closure, for superficial separation of
 - abdominal incision wound, 507
- Encephalopathy, hypertensive, in preeclampsia, 308
- Endocrine disease, perioperative management of, 449
- Endometrial cancer
 - epidemiology of, 1073
 - genetic and genomic factors associated with, 711
 - hereditary risk of, 671
 - diagnosis of, 671
 - management of, 671
 - risk of, tamoxifen and, 778
- Endometriosis, 233
 - genetic and genomic factors associated with, 711
- Endometritis
 - chronic, 233
 - postoperative, treatment of, 59
 - puerperal, treatment of, 59
- Endometrium
 - cancer of, unexpected, diagnosed at gynecologic surgery, 439
 - imaging of, 439
- Endoscopy
 - in pseudomembranous colitis, 492
 - upper gastrointestinal, in gastric cancer diagnosis, 892
- Endotoxin A, 393

- Enoxacin. *See* Fluoroquinolones
- Enteral nutrition, for surgical patient
immune-enhancing formulas for, 537
and parenteral nutrition, comparison of, 537
postoperative, 492, 537
- Enterococcal infection, treatment of, in pregnancy, 59
- Enterococcus faecium* infection, vancomycin-resistant, treatment of, 59
- Enuresis
age and, 193
nocturnal, 193
prevalence of, 193
- Environmental endocrine disrupters, 1119
- Environmental exposures
definition of, 1119
internal, in men vs women, physiological factors affecting, 1119
levels of, in men vs women, 1119
outcomes of
with greater severity or prevalence in women, 1119
specific to women, 1119
pathways of, for women, 1119
and women's health, 1119
- Ependymoma
diagnosis of, 904
epidemiology of, 904
treatment of, 904
- Epigenetics, 593
- Epilepsy. *See also* Seizures
pharmacotherapy for, in pregnancy, 136
and pregnancy outcome, 136
- Epiluminescence microscopy, 830
- Epinephrine, toxicity in fetus and/or newborn, 6
- Episiotomy, shoulder dystocia and, 345
- Epithelium, bladder, and interstitial cystitis, 242, 259
- Erb's palsy, shoulder dystocia and, 345
- Ergot alkaloids, for postpartum hemorrhage, 330
- Ergotamine
adverse effects of, in breast-fed infant, 6
contraindications to, in pregnancy, 136
toxicity in fetus and/or newborn, 6
- Eros therapy, for female sexual dysfunction, 1089
- Erythromycin
adverse effects and side effects of, 59
pharmacology of, 59
pregnancy category of, 59
spectrum of activity of, 59
- Erythroplasia, oral, 952
- Erythropoietin (EPO), in multiple myeloma treatment, 928
- ESHRE PGD Consortium, 640
- Esmolol
for heart rate control, in atrial fibrillation, 518
for hypertension, 518
- Estrogen receptors, in breast cancer, 767
- Estrogens
adverse effects of, in breast-fed infant, 6
synthetic, teratogenicity of, 6
- Estrogen therapy, and breast cancer, 738, 778
- Ethanol. *See* Alcohol
- Ethosuximide therapy, in pregnancy, 136
- Etoposide, chemotherapy using, in pregnancy, 153
- Etretinate, teratogenicity of, 6
- Euploidy, 622
- Evisceration. *See* Wound, abdominal incision, dehiscence
- Exercise
maternal, effects on fetal behavior, 993
and weight loss, 1080
- Expectorants, toxicity in fetus and/or newborn, 6
- Extracorporeal membrane oxygenation (ECMO), for varicella pneumonia in pregnancy, 393
- Extrafascial dehiscence. *See* Wound, abdominal incision, superficial separation of
- F
- Factor V Leiden, 711
detection of, 605
and venous thromboembolism in pregnancy, 363
- Fallopian tube, cancer of, unexpected, diagnosed at gynecologic surgery, 439
- Famciclovir, 136
- Familial adenomatous polyposis (FAP)
and colorectal cancer, 812
and colorectal cancer risk, 812
- Familial atypical mole and melanoma syndrome, 830
- Family, and women's sexuality, 1089
- Family history
and breast cancer risk, 1140
and colorectal cancer risk, 812
and hereditary cancer risk, 671
- Famotidine
for gastroesophageal reflux disease, in pregnancy, 136
use of, in pregnancy, 89
- Fanconi anemia
leukemia in, 855
and prenatal cellular genetic therapy, 684
- Fascial dehiscence. *See* Wound, abdominal incision, dehiscence
- Fat, dietary, in nutritional support for surgical patient, 537
- Fatty acid oxidation disorders, newborn screening for, 697
- Febrile morbidity, definition of, 562
- Fecal occult blood testing (FOBT)
in colorectal cancer screening, 812
plus sigmoidoscopy, in colorectal cancer screening, 812
- Fecundity, genetic and genomic factors associated with, 711
- Felbamate, adverse effects of, in breast-fed infant, 6
- Felodipine, antihypertensive therapy with, during pregnancy, 22
- Fenfluramine, adverse effects of, in breast-fed infant, 6
- Fenoldopam, for hypertension, 518
- Fertility, after leukemia treatment, 855
- Fetal alcohol syndrome, 73
- Fetal anomalies, genetic and genomic factors associated with, 711
- Fetal asphyxia, 975
- Fetal breathing, hypoxemia and, 975
- Fetal breathing movements, 993, 1063
- Fetal cells
from maternal blood
culture of, 649
enrichment of, 649
prenatal diagnosis using, 649
prenatal diagnosis using, 649, 711

- Fetal growth
 abnormalities of, and umbilical artery velocity waveforms, 1015
 assessment of, 993
 maternal drug abuse and, 73
 restriction of
 versus constitutionally small fetus, 1015
 Doppler ultrasound evaluation of, 1015
- Fetal heart rate
 accelerations, 1054, 1063
 control of, 1005
 intrapartum, abnormal patterns of, 1054
 late decelerations, in hypoxemia, 1005
 nonreactive pattern of, 1054
 variability, 1005
- Fetal heart rate monitoring. *See also* Contraction stress test; Nonstress test
 in contraction stress test, 1005
 in fetal movement monitoring, 993
 indications for, 1005
 in nonstress test, 986
 perioperative, 553
- Fetal hydatin syndrome, 136
- Fetal kick counts, charting, 993
- Fetal loss
 amniocentesis and, 1039
 chorionic villus sampling and, 1039
- Fetal malformations. *See* Birth defects
- Fetal movement(s)
 characterization of, 993
 clonic, 993
 general body, 993
 isolated arm or leg, 993
 maternal (subjective) perception of, 993, 1063
 monitoring, 1063
 cost of, 993
 by Doppler ultrasound, 993
 fetal heart rate monitoring in, 993
 in fetal surveillance, 993
 limitations of, 993
 by maternal perception, 993
 medications and, 993
 in multifetal pregnancy, 993
 patient inconvenience caused by, 993
 by real-time ultrasound, 993
 techniques for, 993
- Fetal nuchal translucency
 and chromosomal defects, 661
 in Down syndrome, 661
 increased
 morbidity associated with, 661
 pathophysiology of, 661
 and maternal serum biochemistry, 661
 measurement of, 661
 in screening for chromosomal defects, implementation of, 661
 and second-trimester maternal serum biochemistry, 661
 and second-trimester ultrasound, 661
- Fetal scalp blood sampling
 applications of, 1054
 elimination of, 1054
- Fetal stress, in labor, management of, 125
- Fetal surveillance
 fetal movement charting in, 993
 invasive procedures for, 1039
 techniques for, 993
- Fetal testing, antenatal. *See also* Biophysical profile; Fetal movement(s), monitoring
 external stimulation in, 1054, 1063
 indications for, 1005
 invasive procedures for, 1039
- Fetus
 assessment of. *See also* Biophysical profile; Fetal heart rate; Fetal movement(s), monitoring; Vibroacoustic stimulation
 antepartum, external stimulation in, 1054, 1063
 digital scalp stimulation in, 1054
 intrapartum, external stimulation in, 1054, 1063
 invasive procedures for, 1039
 manual manipulation in, 1054
 in trauma, 414
 chemotherapy and, 153
 death of
 prediction of, 993
 risk of, assessment of, 975, 993
 shoulder dystocia and, 345
 development of, 553
 drug exposure and, 1, 6, 73
 critical period for, 6
 genetic therapies for, 684
 rationale for, 684
 immune function of, 684
 immune tolerance of, 684
 and prenatal stem cell transplantation, 684
 injury to, shoulder dystocia and, 345
 maternal CPR and, 377, 414
 maternal leukemia and, 855
 physiology of, 553
 radiation dose to, in maternal radiography, 414, 553
 sleep-wake cycles of, 993
 urine production by, 975
 well-being of, perioperative assessment of, 553
- Fever, postoperative, 562
- Feverfew
 adverse effects and side effects of, 89
 contraindications to, in pregnancy, 89
 Fexofenadine, use of, in pregnancy, 89
 Fibroadenoma, of breast, 750, 758
 Fibrocystic disease, of breast, 750, 758
 Fibroma, uterine, malignant transformation of, signs and symptoms of, 439
- Fine-needle aspiration biopsy
 of breast lesions, 738, 750, 1140
 in childhood and adolescence, 758
 in office practice, 761
 materials and methods for, 761
 results with, 761
 in pregnancy and lactation, 770
 of thyroid, 879
- First trimester
 chemotherapy in, 153
 pregnancy termination in, 114
- Fistula
 ureterovaginal, 428
 vesicovaginal, 428
- Flovent Rotadisk, for asthma, in pregnancy, 136
- Fluconazole, teratogenicity of, 6
- Fluid and electrolyte disorders, perioperative management of, 449

- Fluid compartments, 449
 - Fluid management. *See also* Volume replacement
 - in acute respiratory distress syndrome, in pregnancy, 369
 - Flunisolide, for asthma, in pregnancy, 136
 - Fluorescein sodium, adverse effects of, in breast-fed infant, 6
 - Fluorescence-activated cell sorting (FACS), fetal cell enrichment using, 649
 - Fluorescence in situ hybridization (FISH), 605
 - for aneuploidy screening in IVF patients, 640
 - applications of, 622
 - in diagnosis of chromosomal disorders, 622
 - interphase multicolor, 649
 - in single cell analysis, 640
 - for numerical chromosome aberrations, 640
 - in preimplantation genetic diagnosis, 640
 - for sex determination, 640
 - technique for, 622
 - Fluoroquinolones
 - adverse effects and side effects of, 59
 - in breast-fed infant, 6
 - cost of, 59
 - mechanism of action of, 59
 - obstetric applications of, 59
 - for perioperative pneumonia, in pelvic surgery patient, 518
 - pregnancy category of, 59
 - spectrum of activity of, 59
 - teratogenicity of, 553
 - 5-Fluorouracil
 - chemotherapy with, in pregnancy, 153
 - for pancreatic cancer, 855
 - Fluoxetine
 - adverse effects of, in breast-fed infant, 6
 - starting dosage for, in pregnancy, 136
 - Fluticasone, for asthma, in pregnancy, 136
 - Fluvoxamine, adverse effects of, in breast-fed infant, 6
 - FMRI* gene, 593, 605
 - Food(s), and interstitial cystitis symptoms, 259
 - Food and Drug Administration (FDA), drug classification system of, 136
 - Forceps, hemostatic, 481
 - Founder effect, 671
 - Fracture(s)
 - clavicular, shoulder dystocia and, 345
 - pelvic, trauma-induced, in pregnancy, 414
 - Fragile X syndrome, 622
 - clinical features of, 593, 605
 - molecular diagnosis of, 605
 - premutation carriers of, 593
 - trinucleotide repeat expansion in, 593, 605
 - French-American-British (FAB) classification, of acute leukemias, 855
 - Frequency, urinary. *See also* Interstitial cystitis, signs and symptoms of
 - clinical evaluation of, 233
 - definition of, 173, 193
 - prevalence of, 193
 - FRET system, 605
 - Functional residual capacity (FRC), in pregnancy, effect on CPR, 377
 - Fundal pressure, for shoulder dystocia, 345
 - Furosemide (Lasix)
 - for pulmonary edema
 - in preeclampsia, 308
 - in pregnancy, 125
 - therapy with, in pregnancy, 22
 - G
 - Gabapentin
 - for interstitial cystitis, 259
 - therapy with, in pregnancy, 136
 - Gail model, for breast cancer risk calculation, 1140
 - Galactosemia
 - newborn screening for, 697
 - treatment of, 697
 - Gallium scan
 - in hepatocellular carcinoma, 939
 - in lymphoma, 820
 - Garlic, contraindications to, in pregnancy, 89
 - Gas embolism, laparoscopy-related, 469
 - Gastrectomy
 - complications of, 892
 - curative, for gastric cancer, 892
 - Gastric bypass
 - adverse effects and side effects of, 1080
 - for weight reduction, 1080
 - Gastric cancer
 - advanced, treatment of, 892
 - clinical features of, 892
 - diagnosis of, 892
 - early, 892
 - treatment of, 892
 - epidemiology of, 892
 - genetics of, 892
 - pathology of, 892
 - physical findings in, 892
 - in pregnancy, 892
 - risk factors for, 892
 - signs and symptoms of, 892
 - staging of, 892
 - surgical resection of, for cure, 892
 - survival in, 892
 - treatment of, 892
 - in young women, 892
- Gastrinoma, 855
- Gastroesophageal reflux disease (GERD), in pregnancy, 553
 - pharmacologic treatment of, 136
- Gastrointestinal disorders, in pregnancy, pharmacologic treatment of, 136
- Gastrointestinal emergencies, postoperative, 492
- Gastrointestinal tract. *See also* Bowel; Colon
 - abscess in, management of, 492
 - intraoperative injury to, 492
 - evaluation for, 492
 - minimization of morbidity in, 492
 - prevalence of, 492
 - prevention of, 492
 - repair of, 492
 - risk factors for, 492
 - normal function of, postoperative return of, 492
 - perforation of
 - in *Clostridium difficile* infection, 492
 - intraoperative, 492
 - in pregnancy, 414, 553
 - effect on CPR, 377
- Gastroplasty, vertical banded, for weight reduction, 1080
- Gitifloxacin. *See* Fluoroquinolones

- Gelatin sponge (Gelfoam), thrombact loaded with, for hemostasis, 481
- Gemcitabine
chemotherapy using, in pregnancy, 153
for pancreatic cancer, 855
- Gemzar. *See* Gemcitabine
- Generalized anxiety disorder, lifetime prevalence of, sex differences in, 1162
- Gene therapy
prenatal
advances in (future directions for), 730
ethical issues in, 684
experience with, 684
potential for, 684
potential of, 684
rationale for, 684
safety issues in, 684
vectors for, 684
urologic applications of, 205
for voiding dysfunctions, 205
- Genetic anticipation, 593
- Genetic discrimination, and health insurance, 671
- Genetics
advances in (future directions for), 730
for clinical practice, 591
core competencies in, 711
Internet resources on, 711
principles of, 593
- Genetic therapy. *See* Gene therapy
- Genomics, 711
and clinical practice, 711
and genetics, interface between, 711
- Gentamicin. *See also* Aminoglycosides
cost of, 59
dosage and administration of, 59
teratogenicity of, 553
- Geophagy, 1119
- Germ cell tumors, of central nervous system, 904
- Gestation, length of, drugs and, 1
- Gestational diabetes, and shoulder dystocia, 345
- Gigantism, 904
- Giggle incontinence, 193
- Ginger
for gastrointestinal disorders in pregnancy, 136
precautions with, in pregnancy, 89
- Glioblastoma multiforme
epidemiology of, 904
signs and symptoms of, 904
treatment of, 904
- Glioma, epidemiology of, 904
- Glucocorticoid(s), for multiple myeloma, 928
- Glucosamine, 89
- Glucose, in nutritional support for surgical patient, 537
- Glucose intolerance, management of, in pregnancy, 165
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency
newborn screening for, 697
treatment of, 697
- Glutamine, and immune enhancement, 537
- Glycoprotein-51, as urinary marker for interstitial cystitis, 250
- Gold sodium thiomalate, adverse effects of, in breast-fed infant, 6
- Gonorrhea, treatment of, in pregnancy, 59
- Grepafloxacin. *See* Fluoroquinolones
- Growth factor pathway blocking agents, chemotherapy using, in pregnancy, 153
- Growth hormone (GH), excess, tumors producing, 904
- Guafenesin, use of, in pregnancy, 89
- Gunshot wound. *See* Trauma, penetrating
- H
- Haemophilus influenzae*
infection, antibiotic treatment of, 59
type B
immunizing agent for, adverse effects and side effects of, 42
in pregnancy, 42
- Haldol. *See* Haloperidol
- Haloperidol
adverse effects of, in breast-fed infant, 6
for nausea, vomiting, and hyperemesis gravidarum, 136
starting dosage for, in pregnancy, 136
- Halothane, for excessive uterine tone, 125
- Haploinsufficiency, 622
- Hart's line, 233
- Headache
with brain tumor, 904
chronic daily, diagnostic criteria for, 136
cluster, diagnostic criteria for, 136
pharmacotherapy for, in pregnancy, 136
tension-type, diagnostic criteria for, 136
- Head lice, treatment of, in pregnancy, 89
- Head tilt-chin lift maneuver, in cardiopulmonary resuscitation, 377
- Health
social model of, 1189
WHO definition of, 1073, 1189
- Health care, reform of, 1189
- Health insurance
hereditary cancer risk and, 671
women's coverage by, 1189
- Health records, 1181
- Hearing, newborn screening for, 697
- Heart. *See also* Cardiac
ischemic disease of, perioperative management of, 449
valvular disease of, perioperative management of, 449
- Heartburn. *See* Gastroesophageal reflux disease (GERD)
- Heart disease, stress and, 1099
- Heart murmurs, 449
- Heimlich maneuver, 377
- Helicobacter pylori*
and gastric cancer, 892
and MALT lymphoma, 820
- Helix database, 605
- HELLP syndrome
clinical manifestations of, 308
delivery in, 308
diagnosis of, 308
etiology of, 308
incidence of, 308
management of, 22, 308, 377
maternal death in, 377
pathophysiology of, 308
recurrence of, in subsequent pregnancy, 308
- Hemabate. *See* Carboprost tromethamine (Hemabate)
- Hematocrit, in pregnancy, 414, 553
- Hematologic disease, perioperative management of, 449

- Hematoma, postoperative, 492
- Hematopoiesis, in pregnancy, 855
- Hematopoietic stem/progenitor cells. *See* Stem cell transplantation
- Hematuria
in bladder cancer, 844
evaluation of, 844
- Hemochromatosis, hereditary
clinical features of, 605
molecular diagnosis of, 605
point mutations in, 605
treatment of, 605
- Hemoclips, 481
- Hemodynamics
and abdominal wound breakdown, 507
in pregnancy, and response to trauma, 414
- Hemoglobin, blood levels of
in anemia, 449
and surgery, 449
- Hemorrhage. *See also* Bleeding
after gastrectomy, 892
fetomaternal, trauma-related, 414
obstetric, 377
postpartum
adjunct therapies for, 330
arterial embolization for, 330, 553
autotransfusion for, 330
blood loss in, 330
cardiac arrest in, 377
etiology of, 330
management of, 330, 553
maternal mortality rate for, 330
pelvic pressure pack for, 330
with placenta accreta/increta/percreta, 330
shoulder dystocia and, 345
surgical therapy for, 330
suture techniques for, 330
uterine atony and, 330, 553
uterine packing for, 330
uterotonic agents for, 330
in pregnant trauma victim, 414
retroperitoneal, in pregnancy, 414, 553
- Hemorrhoids, and colonic neoplasia, 812
- Hemostasis
abnormalities of, and venous thromboembolism in pregnancy, 363
for acute intraoperative bleeding, 481
biologic tamponade for, 481
forceps for, 481
thumbtack loaded with gelatin sponge for, 481
vascular clips for, 481
- Heparin
adverse effects and side effects of, 363
for deep venous thrombosis, 545
intravesical, for interstitial cystitis, 242, 259
low-molecular-weight
for deep venous thrombosis, 545
in prevention of thromboembolism, 545
use of, in pregnancy, 136
for venous thromboembolism in pregnancy, 363
unfractionated
in prevention of thromboembolism, 545
use of, in pregnancy, 136
for venous thromboembolism in pregnancy, 363
for venous thromboembolism in pregnancy, 363
- Hepatectomy, in hepatocellular carcinoma, 939
- Hepatitis
herpes, in pregnancy, 393
viral, treatment of, in pregnancy, 136
- Hepatitis A
immunization against, in pregnancy, 136
immunizing agent for, adverse effects and side effects of, 42
in pregnancy, 42
- Hepatitis B
high-risk groups for, 42
immunization against, in pregnancy, 136
immunizing agent for, adverse effects and side effects of, 42
and liver cancer, 939
in pregnancy, 42
- Hepatitis C
and liver cancer, 939
management of, 136
- Hepatocellular carcinoma (HCC)
clinical presentation of, 939
diagnosis of, definitive, 939
diagnostic imaging in, 939
epidemiology of, 939
etiology of, 939
incidence of, 939
metastases of, to brain, 904
paraneoplastic syndromes with, 939
physical findings in, 939
risk factors for, 939
screening for, 939
signs and symptoms of, 939
staging of, 939
treatment of
curative, 939
palliative, 939
work-up for, 939
- Herbal therapy, 1181
contraindicated in pregnancy, 89
in pregnancy, 89
- Hereceptin, 605
anticancer therapy with, in pregnancy, 153
for breast cancer, 738
- Hereditary breast and ovarian cancer (HBOC)
genetic and genomic factors associated with, 711
risk of
family history and, 671
laboratory testing for, 671
susceptibility to, 671
- Hereditary cancer syndromes, 671
- Hereditary nonpolyposis colorectal cancer (HNPCC), 711, 812
and colorectal cancer risk, 812
risk of
family history and, 671
laboratory testing for, 671
susceptibility to, 671
- HER-2/neu gene, expression of, prognostic and predictive value of, 605
- Heroin
abuse
health consequences of, 73
and pregnancy outcome, 73
adverse effects of, in breast-fed infant, 6
perinatal exposure to, fetal/neonatal effects of, 73

- Herpes simplex
 disseminated, in pregnancy, 393
 clinical presentation of, 393
 diagnosis of, 393
 management of, 393
 mortality rate for, 393
 treatment of, in pregnancy, 136, 393
 vulvovaginitis caused by, 233
- Heterodisomy, 593
- Heteroplasmy, 593
- HFE C282Y, assays for, 605
- Hiccups, fetal, 993
- Histamine, and bladder overactivity, 182
- Histamine (H_2) antagonists
 for gastroesophageal reflux disease, in pregnancy, 136
 use of, in pregnancy, 89
- HIV-infected (AIDS) patients. *See also* Human immunodeficiency virus (HIV) infection
 amniocentesis in, 1039
 immunization of, 42
 lymphoma in, 820
 oral cavity cancers in, 952
 pharmacotherapy for, in pregnancy, 136
- Homans' sign, 545
- Home-brew assays, real-time PCR for, 605
- Homocystinuria
 newborn screening for, 697
 vitamin B_{12} -nonresponsive, treatment of, 697
 vitamin B_{12} -responsive, treatment of, 697
- Homoplasmy, 593
- Hormone replacement therapy (HRT)
 and breast cancer, 778
 and breast physiology, 1129
 and colorectal cancer prevention, 812
- Hormones
 and breast cancer, 1140
 and women's sexuality, 1089
- Human chorionic gonadotropin (HCG), beta-, maternal serum, and Down syndrome, 661
- Human genome
 applications of, to obstetrics and gynecology, 711
 number of transcribed and translated genes in, 711
 sequencing of, 711
 and understanding biologic processes, 711
- Human Genome Project, implications of, 730
- Human immunodeficiency virus (HIV) infection. *See also* HIV-infected (AIDS) patients
 and bladder cancer, 844
 genetic and genomic factors associated with, 711
 newborn screening for, 697
 testing for, in high- versus low-risk populations, test performance in, 657
- Human papillomavirus (HPV)
 and bladder cancer, 844
 detection of, polymerase chain reaction method for, 605
 and oral cancer, 952
- Huntington disease
 clinical features of, 593, 605
 molecular diagnosis of, 605
 trinucleotide repeat expansion in, 593, 605
- Hyaluronic acid, intravesical, for interstitial cystitis, 259
- Hycamtin. *See* Topotecan
- Hydatid cyst, 622
- Hydatidiform mole, 622
 complete, 622
 partial, 622
- Hydralazine, antihypertensive therapy with, 518
 for acute severe hypertension, 22
 in eclampsia, 308
 for hypertensive crisis in preeclampsia, 308
 during pregnancy, 22, 125
 for severe hypertension, in pregnancy, 125
- Hydration. *See also* Volume replacement
 perioperative management of, 545
- Hydrochlorothiazide therapy, in pregnancy, 22
- Hydrocortisone cream, use of, in pregnancy, 89
- Hydronephrosis, physiologic, of pregnancy, 414
- Hydroureter, in pregnancy, 553
- Hydroxydaunorubicin. *See* Doxorubicin
- Hydroxyzine
 for interstitial cystitis, 242, 259
 for nausea, vomiting, and hyperemesis gravidarum, 136
- Hyperadrenocorticism, tumors producing, 904
- Hyperalimentation, and abdominal wound breakdown, 507
- Hypercalcemia, in lung cancer, 784
- Hypercapnia, 518. *See also* Respiratory failure, hypercapnic
- Hypercarbia, laparoscopy-related, 469
- Hyperemesis gravidarum, pharmacologic treatment of, 136
- Hyperglycemia, antenatal corticosteroid therapy and, 35
- Hyperkalemia
 in leukemia treatment, 855
 perioperative management of, 449
- Hypersensitivity reactions, and immunization, 42
- Hypertension
 and abdominal wound breakdown, 507
 acute severe, drug therapy for, 22
 in pregnancy, 125
 causes of, 449
 chronic
 diagnostic criteria for, 22
 postpartum management of, 22
 preeclampsia superimposed on, 22
 in pregnancy, 22
 pre-pregnancy management of, 22
 treatment of, 22
 definition of, 449
 eclamptic, treatment of, 308
 essential, 22, 449
 gestational, 22
 postpartum management of, 22
 perioperative management of, 449, 518
 pharmacotherapy for, 22, 125, 449
 postpartum management of, 22
 in pregnancy
 classification of, 22
 definition of, 22
 prevalence of, 22
 treatment of, 22
 rationale for, 22
 secondary, 22, 449
- Hypertensive crisis, 449
- Hypertensive emergencies, in preeclampsia, 308
- Differential diagnosis of, 308
 management of, 308
 pathophysiology of, 308

- Hypertensive encephalopathy, in preeclampsia, 308
 management of, 308
 pathophysiology of, 308
- Hypoactive sexual desire disorder, 1089
- Hypoalbuminemia, in surgical patient, 537
- Hypocapnia, 518
- Hypogastric artery, ligation of, for postpartum hemorrhage, 330, 553
- Hypoglycemics
 oral, therapy with, in pregnancy, 165
 toxicity in fetus and/or newborn, 6
- Hypokalemia, perioperative management of, 449
- Hypomelanosis of Ito, chromosomal mosaicism in, 593
- Hyponatremia
 in lung cancer, 784
 perioperative management of, 449
- Hypopituitarism, tumors producing, 904
- Hypoproteinemia, and abdominal wound breakdown, 507
- Hypotension. *See also* Supine hypotensive syndrome
 anesthetic-induced
 peripartum pharmacologic management of, 125
 in pregnancy, 553
 drugs causing, 518
 in sepsis, 393
 in total spinal anesthesia, peripartum management of, 125
- Hypothalamic-pituitary-adrenocortical axis, in stress response, 1099
- Hypothalamic-pituitary-thyroid axis, in stress response, 1099
- Hypothermia, and abdominal wound breakdown, 507
- Hypothyroidism
 congenital
 management of, 697
 newborn screening for, 697
 strategy for, 697
 depression and, 1162
- Hypovolemia
 in pregnancy, 553
 in sepsis, management of, 562
- Hypoxemia, fetal
 biophysical effects of, 975
 and fetal heart rate, 986
 late decelerations of heart rate in, 1005
 regulatory center, biophysical effects of, 975
- Hypoxia
 in acute respiratory distress syndrome, 518
 cause of, determination of, 518
 in pregnancy, 414
- Hysterectomy
 abdominal, antibiotic prophylaxis with, 562
 emergency, indications for, 330
 gastrointestinal complications of
 prevalence of, 492
 risk factors for, 492
 for postpartum hemorrhage, 330
 preoperative assessment for, 439
 specimen from
 cervical intraepithelial neoplasia in, 439
 malignancy detected in, 439
 tubal cancer and, 439
 urinary tract injury in
 incidence of, 428
 prevention of, 428
 in uterine atony, 553
 in uterine rupture, 553
 vaginal
 antibiotic prophylaxis with, 562
 ureteral protection during, 428
- Hysteroscopy, gastrointestinal complications of, 492
- Hysterotomy, for shoulder dystocia, 345
- I**
- Ibuprofen, use of, in pregnancy, 89
- IC System Index, 250
- Ileus, postoperative
 clinical manifestations of, 492
 incidence of, 492
 management of, 492
- Illness
 chronic, aging and, 1099
 stress model of, 1099
 and women's sexuality, 1089
- Imaging
 in bladder cancer diagnosis, 844
 in hepatocellular carcinoma, 939
 in lymphoma, 820
 in renal cell carcinoma diagnosis, 884
 of urinary tract, 193
- Imipenem-cilastatin
 cost of, 59
 dosage and administration of, 59
 mechanism of action of, 59
 obstetric applications of, 59
 spectrum of activity of, 59
- Imipramine
 adverse effects and side effects of, 205
 in breast-fed infant, 6
 for bladder overactivity, 205
 starting dosage for, in pregnancy, 136
- Immun-Aid, and immune enhancement, 537
- Immune competence, in surgical patient, 537
 nutritional formulas for enhancement of, 537
- Immune tolerance, fetal, 684
- Immunization
 active, 42
 advances in (future directions for), 42
 adverse effects and side effects of, 42
 agents for, 42
 administration of, 42
 advances in (future directions for), 42
 egg proteins in, 42
 hypersensitivity to, 42
 residual antibiotics in, 42
 storage of, 42
 blood transfusion and, 42
 fetal effects of, 42
 of HIV-infected (AIDS) patients, 42
 maternal, and immune response in offspring, 42
 of neonate/infant, 42
 passive, 42
 postpartum, 42
 in pregnancy, 42, 136
 anticipatory, 42
 inadvertent, 42
 prophylactic, after significant exposure, 42
 for travel, 42
 serologic response to, assessment of, 42

- Immunosuppressants, toxicity in fetus and/or newborn, 6
- Immunosuppression
and cutaneous malignancy, 830
in HELLP syndrome, 308
- Immunotherapy, for pancreatic cancer, 855
- Impact (enteral nutrition formula), and immune enhancement, 537
- Impedance plethysmography, in diagnosis of deep venous thrombosis, 545
- Implantable defibrillator. *See* Defibrillator, intracardiac
- Imprinting, genomic, 593, 622
parent-of-origin effect of, 593
- Inapsine. *See* Droperidol
- Incision, abdominal, wound breakdown. *See* Wound
- Incontinence, urinary. *See also* Stress incontinence; Urge incontinence
costs of, 173
epidemiology of, 173
history-taking in, 193
mixed, prevalence of, gender differences in, 173
pharmacotherapy for, 205
prevalence of, 173
gender differences in, 173
- Incontinence Impact Questionnaire, 173, 193
- Incontinence QOL, 173
- Indomethacin
for bladder overactivity, 205
as tocolytic agent, efficacy of, 99
toxicity in fetus and/or newborn, 6
- Infection(s)
after gastrectomy, 892
bacterial, perinatal management of, antibiotics for, 59
and bladder cancer, 844
definition of, 562
in myeloma patient, 928
obstetric emergencies caused by, 393
occult, and interstitial cystitis, 259
postoperative, treatment of, 59
postoperative (nonoperative site), 562
postoperative (operative site), 562
antibiotic prophylaxis for, 562
antibiotic therapy for, 562
microbiology of, 562
pathogenesis of, 562
pelvic, 562
prevention of, 562
risk factors for, 562
suspected, evaluation of patient with, 562
respiratory tract, postoperative, 562
skin, treatment of, in pregnancy, 59
upper respiratory tract, viral, perioperative management of, 449
urinary tract. *See* Urinary tract infection(s) (UTI)
viral, pharmacotherapy for, in pregnancy, 136
- Infectious disease
molecular diagnosis of, 605
newborn screening for, 697
- Infective endocarditis, prophylaxis, perioperative, 449
- Inferior vena cava, fetal, Doppler ultrasound evaluation of, 1015
- Inflammation, definition of, 562
- Inflammatory bowel disease (IBD)
and colorectal cancer risk, 812
treatment of, in pregnancy, 136
- Influenza
immunization against, in pregnancy, 136
immunizing agent for, adverse effects and side effects of, 42
in pregnancy, 42
- Inheritance
dominant, 593
mitochondrial, 593
multifactorial, 593
liability factors in, 593
recurrence risk for, 593
nonmendelian, 593
recessive, 593
triallelic, 593
- Inherited disease, genetic assays for, 605
- Insertion, chromosomal, 622
- In situ hybridization (ISH), 605
probes
for hematologic malignancy, 605
for soft tissue tumors, 605
- Insulin
formulations of, 165
therapy with
perioperative management of, 449
in pregnancy, 165
intravenous, 165
maintenance, 165
- Insulinoma, 855
- Insulin resistance, antenatal corticosteroid therapy and, 35
- Interferon(s) (IFN)
alfa-2b, for melanoma, 830
for renal cell carcinoma, 884
therapy with, in pregnancy, 136
- Interleukin(s) (IL)
in response to surgery, 537
in sepsis, 393
- Intermittent pneumatic compression, in prevention of thromboembolism, 545
- Internal iliac artery. *See* Hypogastric artery
- Interstim Sacral Nerve Stimulation System
central sacral nerve stimulation using, 218
for interstitial cystitis treatment, 259
- Interstitial cystitis. *See also* Painful bladder syndrome; Pelvic floor dysfunction, high-tone
allergy and, 242
autoimmunity and, 259
bladder wall resection for, 259
clinical presentation of, 250
variability of, 242
continuum of, 242
cystectomy for, 259
cystitis and, 259
definition of, 242
diagnosis of, 250
cysto hydrodistention in, 250
exclusion criteria for, 250
inclusion criteria for, 250
Potassium Sensitivity Test in, 242, 250
urinary markers in, 250
differential diagnosis of, 233, 242, 250
disorders mimicking, 233, 242, 250
dyspareunia of, 233, 250
epithelial dysfunction and, 242, 259
in gynecologic patients, 233, 242

- incidence of, 242
- intravesical therapy for, 205
- laser therapy for, 259
- mast cells in, 242, 259
- in men, 242
- multiple pathologies in, interaction of, 259
- neurogenic inflammation in, 259
- neurologic upregulation and, 242, 259
- neuromodulation for, 259
- occult infection and, 259
- pathogenesis of, 242, 259
- pelvic pain with, 233, 242, 250
- prevalence of, 242
- severe, treatment of, special considerations in, 242
- signs and symptoms of, 233, 242, 250
 - flares of, 242
 - premenstrual flare of, 233
 - substance P in, 259
- symptom scores for, 250
- treatment of, 205, 242, 259
 - advances in (future directions for), 205
 - behavioral approach to, 273
 - bladder retraining protocols in, 259
 - dietary changes in, 259
 - hydrodistention in, 250, 259
 - intravesical, 259
 - multimodal and multifaceted strategy for, 259
 - oral, 242, 259
 - pelvic floor muscle re-education in, 273
 - principles of, 259
 - self-care in, 259
 - surgical, 259
- urinary diversion for, 259
- urinary toxins and, 259
- urodynamic evaluation in, 250
- in urologic patients, 242
- Interventional radiology, for deep venous thrombosis, 545
- Intestine. *See* Bowel; Colon; Gastrointestinal tract
- Intracranial pressure, increased, with brain tumor, 904
- Intrauterine growth restriction, uniparental disomy and, 593
- Intrauterine growth retardation (IUGR), biophysical profile score and, 975
- Intravascular volume, in pregnancy, 553
- Intravenous pyelography (IVP), 844
 - postoperative, in detection of urinary tract injury, 428
 - preoperative, 428
- Intraventricular hemorrhage, decreased incidence of, antenatal corticosteroids and, 35
- Intravesical drug delivery, 205
- Inversions, chromosomal, 622
 - origins of, 622
 - paracentric, 622
 - pericentric, 622
- In vitro fertilization (IVF), embryos from, preimplantation genetic diagnosis in, 640
- Iodides, toxicity in fetus and/or newborn, 6
- Iodine
 - adverse effects of, in breast-fed infant, 6
 - teratogenicity of, 6
- Iressa, anticancer therapy with, in pregnancy, 153
- Irinotecan, chemotherapy using, in pregnancy, 153
- Iron deficiency anemia, perioperative management of, 449
- Irritable bowel syndrome (IBS), 233
 - and overactive bladder syndrome, 193
- Ischemic heart disease
 - perioperative management of, 449
 - risk factors for, 449
- Isochromosomes, 622
- Isodisomy, 593, 622
- Isotretinoin, teratogenicity of, 6
- Isoxsuprine, toxicity in fetus and/or newborn, 6
- Itraconazole, adverse effects of, in breast-fed infant, 6
- J
 - JAG1* gene, 711
 - Japanese encephalitis virus
 - immunizing agent for, adverse effects and side effects of, 42
 - in pregnancy, 42
 - Jaw-thrust maneuver, in cardiopulmonary resuscitation, 377
- K
 - Kanamycin, teratogenicity of, 6
 - Kaposi's sarcoma, 820
 - oral, 952
 - Karnofsky Performance Status Scale, 784
 - Karyotype
 - description of, abbreviations used for, 622
 - preparation of, 622
 - Kava-kava, contraindications to, in pregnancy, 89
 - Kearns-Sayre syndrome, 593
 - Ketamine, toxicity in fetus and/or newborn, 6
 - Ketanserin, contraindications to, in pregnancy, 125
 - Kil 769, effects on urinary tract, 205
 - Kidney
 - cancer of. *See also* Renal cell carcinoma
 - epidemiology of, 884
 - etiology of, 884
 - in myeloma, 928
 - Kidney failure. *See* Renal failure
 - King's Health Questionnaire, 173, 193
 - Kleihauer-Betke test, in pregnant trauma patient, 414, 553
 - Klinefelter syndrome, 622
 - Klonopin. *See* Clonazepam
 - K-ras, and pancreatic cancer, 855
 - KRN2391, effects on urinary tract, 205
 - L
 - Labetalol
 - adverse effects and side effects of, 22
 - antihypertensive therapy with, 518
 - for acute severe hypertension, 22
 - for hypertensive crisis in preeclampsia, 308
 - in pregnancy, 22, 125
 - in eclampsia, 308
 - Labor
 - arrest disorder of, and shoulder dystocia, 345
 - augmentation of, agents for, 114
 - fetal stress in, management of, 125
 - induction of
 - agents for, 114
 - midtrimester, for pregnancy termination, 114
 - preterm. *See* Preterm labor
 - prolonged second stage of, and shoulder dystocia, 345

- Laboratory testing
 in hepatocellular carcinoma, 939
 for hereditary cancer risk, 671
 in thyroid cancer, 879
- Labor force
 sex segregation in, 1099
 women in, 1099
- Lacerations, shoulder dystocia and, 345
- Lactation
 breast cancer in
 diagnosis of, 770
 treatment of, 770
 breast symptoms in, 1140
 and women's sexuality, 1089
- Lactic acidosis, postoperative, 562
- Lactobacillus acidophilus*, in vagina, 562
- Lamictal. *See* Lamotrigine
- Laminaria, for cervical ripening, 114
- Lamotrigine therapy, in pregnancy, 136
- Lansoprazole, for gastroesophageal reflux disease, in pregnancy, 136
- Laparoscopy
 for appendectomy, in pregnancy, 405, 553
 for cholecystectomy, in pregnancy, 405
 complications of
 prevalence of, 492
 types of, 492
 gastrointestinal injury in
 minimization of morbidity in, 492
 prevention of, 492
 gynecologic
 closed or blind entry technique for, complications of, 469
 complications of, 469
 anesthesia-related, 469
 entry technique and, 469
 frequency of, 469
 operative procedure and, 469
 pneumoperitoneum and, 469
 requiring laparotomy, 469
 types of, 469
 contraindications to, 439
 and hernia at site of abdominal wall trocar, 469
 hospital readmission after, 469
 intestinal injury in, 469
 mortality related to
 causes of, 469
 rate of, 469
 open entry technique for, complications of, 469
 patient positioning for, complications of, 469
 ureteral injury in, 428
 urinary tract injury in, 469
 vascular injury in
 abdominal wall, 469
 causes of, 469
 major, 469
 in pregnancy, 405, 553
- Laparotomy
 laparoscopic complications requiring, 469
 in ovarian cancer, 439
 in pregnancy, 405
 in pregnant trauma victim, 414
- Laryngoscopy, in thyroid cancer, 879
- Laser capture microdissection (LCM), 649
- Laser catapult method, for isolation of fetal cells, 649
- Laser therapy, for interstitial cystitis, 259
- Lasix. *See* Furosemide (Lasix)
- Laxatives, over-the-counter, use of, in pregnancy, 89
- Leber hereditary optic neuropathy, 593
- Legionnaire's disease, pneumonia caused by, perioperative, in pelvic surgery patient, 518
- Leigh syndrome, 593
- Lemierre's syndrome, 377
- Lentigo maligna melanoma, 830
- Leukemia(s), 855
 acute, 855
 classification of, 855
 clinical presentation of, 855
 cytogenetics of, 855
 immunophenotyping of, 855
 molecular genetics of, 855
 in pregnancy, 855
 treatment of, 855
 chronic, 855
 in pregnancy, 855
 classification of, 855
 in pregnancy
 diagnosis of, 855
 effect on labor and delivery, 855
 pretreatment preparations in, 855
 secondary, 855
- Leukeran. *See* Chlorambucil
- Leukocytosis. *See also* White blood cell count
 in pregnancy, 855
- Leukoplakia, 952
- Leukotriene pathway moderators, for asthma, in pregnancy, 369
- Leukotriene receptor antagonists, for asthma, in pregnancy, 136
- Levator ani muscle myalgia, 233
- Levator syndrome, 273
- Levromakalin, for bladder overactivity, 205
- Levofloxacin. *See* Fluoroquinolones
- Lichen planus, 233
- Lichen sclerosis, 233
- Lidocaine
 intravesical therapy with, 205
 toxicity in fetus and/or newborn, 6
- Life expectancy, of women, trends in, 1073
- Lifestyle
 assessment of, 1181
 and women's health, 1181
- Li-Fraumeni syndrome, 904
- Ligase chain reaction (LCR), 605
- Limb reduction defects, chorionic villus sampling and, 1039
- Linear array technology, advances in (future directions for), 730
- Linezolid
 adverse effects and side effects of, 59
 cost of, 59
 mechanism of action of, 59
 obstetric applications of, 59
 spectrum of activity of, 59
- Lipids, serum levels of, exercise and, 1080
- 5-Lipoxygenase inhibitors, for asthma, in pregnancy, 136
- Lithium
 adverse effects of, in breast-fed infant, 6
 starting dosage for, in pregnancy, 136
 teratogenicity of, 6, 136

- toxicity in fetus and/or newborn, 6
- Liver
 - biopsy of, in herpes hepatitis, 393
 - cancer of, 939. *See also* Hepatocellular carcinoma (HCC)
 - in disseminated herpes simplex infection, 393
 - rupture of, in preeclampsia, 308
 - clinical manifestations of, 308
 - diagnosis of, 308
 - management of, 308
 - transplantation of, for hepatocellular carcinoma, 939
- Lobular carcinoma in situ (LCIS), of breast
 - diagnosis of, 774
 - treatment of, 1140
- Local anesthetics
 - cardiac toxicity of, peripartum management of, 125
 - total spinal anesthesia with, peripartum management of, 125
- Lomefloxacin. *See* Fluoroquinolones
- Long-chain fatty acid acyl-CoA dehydrogenase deficiency, newborn screening for, 697
- Long QT syndrome, 377
- Loop diuretics, therapy with, in pregnancy, 22
- Loperamide, use of, in pregnancy, 89
- Loratadine, use of, in pregnancy, 89
- Lorazepam
 - adverse effects of, in breast-fed infant, 6
 - for peripartum seizures, 125
- Lower urinary tract symptoms (LUTS), in men, and interstitial cystitis, 242
- L-PAM. *See* Melphalan
- Lumbar puncture, in lymphoma, 820
- Lumpectomy, in breast cancer, 738, 1140
- Lung(s)
 - fetal, maturation of, corticosteroids and, 35
 - injury to, in acute respiratory distress syndrome, 369, 518
 - metastatic disease in, 784
- Lung cancer
 - biopsy of, 784
 - classification of, 784
 - histologic, 784
 - TNM system for, 784
 - clinical presentation of, 784
 - deaths from, 784, 1169
 - sex differences in, 784
 - diagnosis of, 784
 - early detection of, 784
 - histopathology of, 784
 - sex differences in, 784
 - incidence of, sex differences in, 784
 - lobar distribution of, 784
 - metastases of
 - to brain, 904
 - signs and symptoms of, 784
 - paraneoplastic syndromes in, 784
 - performance status in, 784
 - residual disease after treatment of, classification of, 784
 - risk factors for, 784
 - risk of
 - factors affecting, 784
 - sex differences in, 784
 - years since smoking cessation and, 784
 - screening for, 784
 - smoking and, 784
 - staging of, 784
 - clinical, 784
 - pathologic, 784
 - survival with
 - disease dissemination and, 784
 - nodal status and, 784
 - treatment of
 - radiologic, 784
 - surgical, 784
 - systemic, 784
 - in women, 784
 - deaths from, 735
 - mortality rate for, 784
 - smoking and, 735, 784
- Lyme disease
 - immunizing agent for, adverse effects and side effects of, 42
 - in pregnancy, 42
- Lymphocytic hypophysitis, 904
- Lymphoma(s)
 - central nervous system, 820
 - diagnostic work-up for, 820
 - epidemiology of, 820, 904
 - risk factors for, 904
 - signs and symptoms of, 904
 - treatment of, 904
 - lymphoblastic, 820
 - mantle cell, 820
 - metastases of, to brain, 904
 - mucosa-associated lymphoid tissue (MALT), 820
 - non-Hodgkin's, 820
 - bone marrow involvement in, 820
 - classification of, 820
 - clinical presentation of, 820
 - diagnostic work-up for, 820
 - epidemiology of, 820
 - extranodal, epidemiology of, 820
 - high-grade, treatment of, 820
 - histologic types of, geographic distribution of, 820
 - in HIV-infected (AIDS) patients, 820, 952
 - imaging studies in, 820
 - indolent (low-grade), treatment of, 820
 - intermediate-grade, treatment of, 820
 - laboratory evaluation of, 820
 - nodal, epidemiology of, 820
 - oral, in HIV-infected (AIDS) patients, 952
 - pathology of, 820
 - refractory, treatment of, 820
 - relapsed, treatment of, 820
 - staging of, 820
 - treatment of, 820
 - Waldeyer's ring involvement in, 820
 - testicular, 820
 - of thyroid, characteristics of, 879
 - Lymphoscintigraphy, in melanoma, 830
 - Lysosomal storage disorder(s), prenatal treatment of, potential for, 684
 - M
 - Macrobid. *See* Nitrofurantoin
 - Macroclantin. *See* Nitrofurantoin
 - Macrolide antibiotics
 - obstetric applications of, 59

- pregnancy category of, 59
- Macromastia
 - alternative/complementary therapy for, 1129
 - definition of, 1129
 - management of, 1129
 - psychological effects of, 1129
 - reduction mammoplasty for, 1129
- Macrosomia
 - detection of, 345
 - and shoulder dystocia, 345
 - ultrasound in, 345
- Magnesium hydroxide, use of, in pregnancy, 89
- Magnesium sulfate
 - for eclamptic seizures, 308
 - for peripartum seizures, 125
 - prophylaxis with, in HELLP syndrome, 308, 377
 - for seizure prophylaxis
 - in eclamptic women, 125, 308
 - in hypertension, 22
 - as tocolytic agent
 - contraindications to, 99
 - dosage and administration of, 99
 - efficacy of, 99
 - fetal/neonatal effects of, 99
 - maternal side effects of, 99
 - mechanism of action of, 99
 - pharmacology of, 99
 - toxicity in fetus and/or newborn, 6
- Magnetic cell sorting (MACS), for fetal cell isolation
 - from maternal blood, 649
- Magnetic resonance imaging (MRI)
 - in endometrial assessment, 439
 - in hepatocellular carcinoma, 939
 - in lymphoma, 820
 - of placenta percreta, 330
 - of thyroid, 879
- Malignancy. *See also* Cancer
 - and abdominal wound breakdown, 507
 - Bartholin's gland, unexpected, diagnosed at gynecologic surgery, 439
- Malignant melanoma. *See* Melanoma
- Malnutrition, in surgical patient, 537
- Malpractice litigation, breast cancer and, 738
- Mammography
 - abnormalities on, management of, 738, 1140
 - density
 - age and, 746
 - hormonal changes and, 746
 - and mass margin visibility, 746
 - diagnostic, 738, 746, 750, 1140
 - digital, 746
 - interpretation of, 1140
 - mass margin visibility on, 746
 - in pregnancy, 770
 - radiation exposure in, 1140
 - screening, 735, 738, 746, 1129, 1140
 - specimen, of in situ breast carcinoma, 774
- Maple syrup urine disease
 - genetic variations of, 697
 - newborn screening for, 697
 - treatment of, 697
- Marijuana
 - abuse, health consequences of, 73
 - adverse effects of, in breast-fed infant, 6
 - perinatal exposure to, fetal/neonatal effects of, 73
- Marker chromosomes, 622
- Marlex. *See* Polypropylene (Marlex) mesh
- Mass spectrometry, tandem, in newborn screening, 697
 - applications of, 697
- Mast cells, in interstitial cystitis, 242, 259
- Mastectomy
 - modified radical, 1140
 - prophylactic, 778
 - indications for, 671
 - radical, 1140
 - simple (total), 1140
- Mastitis, puerperal, treatment of, 59
- Maternal age
 - and chromosomal abnormalities, 622, 657, 661
 - and Down syndrome, 622, 657, 661
- McRoberts' maneuver, for shoulder dystocia
 - mechanism of action of, 345
 - success rates for, 345
- Measles
 - immunizing agent for, adverse effects and side effects of, 42
 - in pregnancy, 42
- Mechanical ventilation
 - in acute respiratory distress syndrome, 518
 - in pregnancy, 369
 - in chronic obstructive pulmonary disease, 518
 - in pulmonary edema, in pregnancy, 369
- Meclozine
 - for nausea, vomiting, and hyperemesis gravidarum, 136
 - teratogenicity of, 89
 - use of, in pregnancy, 89
- MECP2 gene, mutations of, 593
- Media, and women's sexuality, 1089
- Medical disorders. *See also* specific disorder
 - pharmacologic therapy for, in pregnancy, 136
- Medically at-risk patient, preoperative management of, 449
- Medications. *See also* Drug(s)
 - effects on fetal behavior, 993
 - in obesity treatment, 1080
 - weight gain caused by, 1080
 - and women's sexuality, 1089
- Medium-chain fatty acid acyl-CoA dehydrogenase (MCAD) deficiency
 - epidemiology of, 697
 - newborn screening for, 697
- Medulloblastoma
 - diagnosis of, 904
 - epidemiology of, 904
 - genetics of, 904
 - treatment of, 904
- Melanoma
 - acral lentiginous, 830
 - cutaneous, 830
 - Clark's classification of, 830
 - clinical characteristics of, 830
 - diagnosis of, 830
 - advances in (future directions for), 830
 - differential diagnosis of, 830
 - epidemiology of, 830
 - etiology of, 830
 - follow-up for, 830
 - genetics of, 830
 - growth patterns of, 830

- historical perspective on, 830
- incidence of, 830
- in situ, 830
- nodal dissection in, 830
- pathogenesis of, 830
- prognosis for, 830
- recurrence of, 830
- risk factors for, 830
- screening for, 830
- signs and symptoms of, 830
- staging of, 830
- TMN staging of, 830
- treatment of, 830
 - advances in (future directions for), 830
 - types of, 830
- lentigo maligna, 830
- metastases of, to brain, 904
- nodular, 830
- oral, 952
- prevention of, 1181
- superficial spreading, 830
- vulvar, 830
 - unexpected, diagnosed at gynecologic surgery, 439
- Melphalan
 - for multiple myeloma, 928
 - therapy with, in pregnancy, 153
- Men, and interstitial cystitis, 242
- Menarche, age of, genetic and genomic factors associated with, 711
- Meningioma
 - biologic behavior of, 904
 - epidemiology of, 904
 - signs and symptoms of, 904
 - treatment of, 904
- Meningococcal infection
 - immunizing agent for, adverse effects and side effects of, 42
 - in pregnancy, 42
- Menopause
 - age at, environmental exposures and, 1119
 - age of, genetic and genomic factors associated with, 711
 - psychiatric considerations in, 1162
 - smoking and, 784
 - symptoms of, environmental exposures and, 1119
 - and women's sexuality, 1089
- Menstrual disorders, environmental exposures and, 1119
- Mental health
 - history-taking about, 1162
 - of women, 1162
- Mental illness. *See* Psychiatric disorders
- Mental retardation, telomeric rearrangements and, 622
- Meperidine, adverse effects of, in breast-fed infant, 6
- 6-Mercaptopurine (6-MP), for inflammatory bowel disease, in pregnancy, 136
- Meropenem
 - cost of, 59
 - dosage and administration of, 59
 - mechanism of action of, 59
 - obstetric applications of, 59
 - spectrum of activity of, 59
- Mesalamine
 - adverse effects of, in breast-fed infant, 6
 - for inflammatory bowel disease, in pregnancy, 136
- Mesh, for abdominal wound dehiscence, 507
 - placement of, 507
- Metabolic response, in surgical patient, 537
- Metamucil, use of, in pregnancy, 89
- Metaproterenol, for asthma, in pregnancy, 136
- Metastatic disease, vaginal involvement in, unexpected, diagnosed at gynecologic surgery, 439
- Metformin, and weight loss, 1080
- Methadone, effects on fetal activity, 993
- Methimazole, teratogenicity of, 6
- Methotrexate
 - chemotherapy using, in pregnancy, 153
 - for pregnancy termination, 114
- Methyldopa
 - adverse effects and side effects of, 22
 - antihypertensive therapy with, during pregnancy, 22
- Methylene Blue, intra-amniotic injection of, teratogenicity of, 6
- Methylenetetrahydrofolate reductase (MTHFR) gene, mutations of, and neural tube defects, 593
- Methylergonovine (Methergine)
 - for postpartum hemorrhage, 330, 553
 - for postpartum uterine atony, 125
- Methylprednisolone, for asthma, 518
 - in pregnancy, 136
- Metoclopramide
 - adverse effects of, in breast-fed infant, 6
 - for headache, in pregnancy, 136
 - for nausea, vomiting, and hyperemesis gravidarum, 136
- Metoprolol
 - for heart rate control, in atrial fibrillation, 518
 - for hypertension, 518
- Metronidazole
 - adverse effects and side effects of, 59
 - in breast-fed infant, 6
 - for antibiotic-associated colitis, 492
 - mechanism of action of, 59
 - obstetric applications of, 59
 - for operative site infection, 562
 - pregnancy category of, 59
 - prophylactic, in gynecologic surgery, 562
 - for pseudomembranous colitis, 492
 - for sepsis, in pregnancy, 393
 - spectrum of activity of, 59
- Mezlocillin
 - mechanism of action of, 59
 - obstetric applications of, 59
 - spectrum of activity of, 59
- Miconazole, use of, in pregnancy, 89
- Microarray technology, 605, 622
- Microbial replacement therapy, for antibiotic-associated colitis, 492
- Microdeletion syndromes, 622
- Microorganisms, detection of, polymerase chain reaction method for, 605
- Micturition reflex, control of, 205, 218
- Midazolam, adverse effects of, in breast-fed infant, 6
- Mifepristone
 - for labor induction, 114
 - for pregnancy termination, 114
 - toxicity in fetus and/or newborn, 6
- Migraine
 - with aura, diagnostic criteria for, 136
 - treatment of, in pregnancy, 136
 - without aura, diagnostic criteria for, 136

- Milagro Program, for treatment of perinatal substance abuse, 73
- Miller-Dieker syndrome, 622
- Milrinone, for heart failure, perioperative management of, 518
- Minimal residual disease, tests for, 605
- Minoxidil, toxicity in fetus and/or newborn, 6
- Minute ventilation, in pregnancy, 414, 553
effect on CPR, 377
- Misoprostol (Cytotec)
for cervical ripening and labor induction, 114
midtrimester labor induction with, for pregnancy termination, 114
oral, for cervical ripening and labor induction, 114
for postpartum hemorrhage, 330
for postpartum uterine atony, 125
for pregnancy termination, 114
teratogenicity of, 6
toxicity in fetus and/or newborn, 6
for treatment of early pregnancy failure, 114
vaginal, for cervical ripening and labor induction, 114
- Mitochondrial DNA
characteristics of, 593
deletions of, 593
density of, by organ, 593
maternal transmission of, 593
mutations of, 593
aging and, 593
class 671, 593
class I, 593
class II, 593
class IV, 593
phenotypic expression of, variability of, 593
somatic, 593
oxidative damage to, 593
replication of, 593
- Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), 593
- Mitral regurgitation/insufficiency, perioperative management of, 449
- Mitral stenosis, perioperative management of, 449
- Mitral valve prolapse, perioperative management of, 449
- Mittelschmerz, 233
- MLH1* gene, mutation of, and cancer risk, 671, 711
- Molecular cytogenetics, 622
- Molecular diagnostics, 605
- Monoamine oxidase inhibitors (MAOIs), safety of, in pregnancy, 136
- Monoclonal antibody(ies) (MAb), anti-CD20, for lymphoma treatment, 820
- Monoclonal gammopathy, and multiple myeloma, 928
- Monogenic disease
fetal, analysis of, 649
preimplantation genetic diagnosis for, 640
- Monosomy, 622
partial, 622
- Monosomy X, 622
- Montelukast, for asthma, in pregnancy, 136, 369
- Morbidity, perinatal, risk of, assessment of, 975
- Morning sickness. *See* Hyperemesis gravidarum; Nausea; Vomiting
- Morphine
therapy with, in myocardial infarction, 518
toxicity in fetus and/or newborn, 6
- Morphine sulfate, for pulmonary edema in preeclampsia, 308
- Mosaicism, 593
causes of, 622
confined placental, 622
definition of, 622
germline (gonadal), 593
preimplantation genetic diagnosis of, 640
somatic, 593
- Motion sickness, drugs for, over-the-counter, use of, in pregnancy, 89
- Motor vehicle accidents, trauma in, 414
- Mouth
anatomy of, 952
examination of, 952
suspicious lesions in
clinical characteristics of, 952
evaluation of, 952
- Mouth cancer
anatomic considerations in, 952
clinical evaluation of, 952
epidemiology of, 952
etiology of, 952
management of, 952
pathology of, 952
prevention of, 952
- Mouth-to-mouth breathing, in CPR, 377
- Moxifloxacin. *See* Fluoroquinolones
- M protein, 928
- MSH2* gene, mutation of, and cancer risk, 671, 711
- MTHFR 677TT, and venous thromboembolism in pregnancy, 363
- Mucin, bladder surface, 259
- Mucosa-associated lymphoid tissue (MALT) lymphoma, 820
- Multifetal pregnancy
amniocentesis in, 1039
amniotic fluid volume in, 1026
antenatal corticosteroid therapy and, 35
chorionic villus sampling in, 1039
fetal movement monitoring in, 993
- Multi-FISH, 622
- Multiparity, and shoulder dystocia, 345
- Multiple endocrine neoplasia, type 1, 855, 904
- Multiple myeloma (MM)
age at onset of, 928
course of, 928
diagnosis of, 928
epidemiology of, 928
follow-up for, 928
genetics of, 928
historical perspective on, 928
incidence of, 928
prognostic factors in, 928
risk factors for, 928
screening for, 928
staging of, 928
survival with, 928
treatment of, 928
advances in (future directions for), 928
- Multiple organ failure
definition of, 562
postoperative, 562
- Multiple sclerosis (MS)
bladder dysfunction in, 173

- and overactive bladder, 182
- Mumps
 - immunizing agent for, 42
 - in pregnancy, 42
- Muscular dystrophy, prenatal treatment of, potential for, 684
- Mutation, definition of, 711
- Mycosis fungoides, 820
- Myleran. *See* Busulfan
- Myocardial infarct/infarction
 - non-Q-wave, 518
 - perioperative, 518
 - postoperative, risk factors for, 449
 - in pregnancy, 377
 - previous, and risk of perioperative infarction, 449
 - Q-wave, 518
- Myocardial ischemia
 - in hypertensive surgical patient, 449
 - silent, 449
- Myocardial oxygen delivery, and myocardial oxygen requirement, balance between, 449
- Myocardial perfusion scintigraphy, 449
- Myoclonus epilepsy and ragged red fibers, 593
- Myometrium, contractility of
 - mechanisms of, 99
 - stimulants of, 114
- Myotonic dystrophy
 - clinical features of, 593
 - trinucleotide repeat expansion in, 593
- N
 - Nafcillin/vancomycin, for sepsis, in pregnancy, 393
 - Naproxen, use of, in pregnancy, 89
 - Naratriptan, 136
 - Narcotics
 - for interstitial cystitis, 259
 - toxicity in fetus and/or newborn, 6
 - Nasalcrom, use of, in pregnancy, 89
 - National Human Genome Research Institute, 711
 - National Institute of Child Health and Development Fetal Cell Isolation Study, 649
 - National Institutes of Health (NIH)
 - Consensus Statement on antenatal corticosteroid therapy, 35
 - National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), criteria for interstitial cystitis, 242, 250
 - National Surgical Adjuvant Breast and Bowel Project (NSABP), 738
 - Nausea, in pregnancy, pharmacologic treatment of, 136
 - Navelbine. *See* Vinorelbine
 - Necrotizing enterocolitis, decreased incidence of, antenatal corticosteroids and, 35
 - Necrotizing fasciitis, after vulvar surgery, 562
 - Nefazodone, adverse effects of, in breast-fed infant, 6
 - Negative predictive value, of tests, 657
 - Neonatal abstinence syndrome
 - diagnosis of, 73
 - management of, 73
 - risk factors for, 73
 - Neonatal mortality, decreased, antenatal corticosteroids and, 35
 - Neoplasia, molecular diagnosis of, 605
 - Neosar. *See* Cyclophosphamide
 - Nephrectomy, for renal cell carcinoma, 884
 - Nerve conduction tests, in overactive bladder syndrome, 193
 - Neuralgia, pudendal, 233
 - Neural tube defects
 - homocysteine levels and, 593
 - multifactorial etiology of, 593
 - prevention of, folic acid supplementation in, 593
 - Neurodevelopment, prenatal drug exposure and, 73
 - Neurogenic inflammation, in interstitial cystitis, 259
 - Neurokinin receptor antagonists, for bladder overactivity, 205
 - Neuromodulation
 - advances in (future directions for), 218
 - for interstitial cystitis treatment, 259
 - in overactive bladder syndrome, 193, 218
 - for pelvic pain syndromes, 218
 - principles of, 218
 - Neurontin. *See* Gabapentin
 - Nevi. *See also* Dysplastic nevus syndrome
 - congenital, malignant transformation of, 830
 - Newborn, drug exposure and, 1, 6
 - Newborn screening. *See* Screening, newborn
 - Nicardipine, for hypertension, 518
 - Nicotine, 784
 - replacement products
 - for adolescents, 1169
 - in smoking cessation, 1169
 - in pregnancy, 1169
 - Nifedipine
 - antihypertensive therapy with
 - for acute severe hypertension, 22
 - during pregnancy, 22, 125
 - for hypertensive crisis in preeclampsia, 308
 - for severe hypertension, in pregnancy, 125
 - as tocolytic agent, efficacy of, 99
 - NIFTY Study, 649
 - Nipple
 - bloody discharge from, 770
 - work-up for, 1140
 - changes in, work-up for, 1140
 - discharge, spontaneous, work-up for, 1140
 - Nitrates
 - for heart failure, perioperative management of, 518
 - for pulmonary edema, in pregnancy, 369
 - Nitric oxide, and bladder overactivity, 182
 - Nitric oxide donors, as tocolytic agents
 - dosage and administration of, 99
 - efficacy of, 99
 - fetal/neonatal effects of, 99
 - maternal side effects of, 99
 - mechanism of action of, 99
 - pharmacology of, 99
 - Nitrofurantoin
 - adverse effects and side effects of, 59
 - cost of, 59
 - mechanism of action of, 59
 - obstetric applications of, 59
 - pregnancy category of, 59
 - spectrum of activity of, 59
 - Nitroglycerin. *See also* Nitric oxide donors
 - for excessive uterine tone, 125
 - intravenous, as tocolytic agent, efficacy of, 99
 - therapy with
 - for hypertension, 518

- for hypertensive crisis in preeclampsia, 308
- in myocardial infarction, 518
- Nitroprusside
 - antihypertensive therapy with
 - for acute severe hypertension, 22
 - during pregnancy, 22
 - fetal effects of, 22
 - precautions with, 22
- Nizatidine, for gastroesophageal reflux disease, in pregnancy, 136
- Nocturia
 - definition of, 173, 193
 - prevalence of, 193
- Nocturnal enuresis, 193
- Nondisjunction, 622
- Non-Hodgkin's lymphoma. *See* Lymphoma(s)
- Nonprescription medications. *See* Over-the-counter drugs
- Non-small cell lung cancer
 - clinical behavior of, 784
 - clinical presentation of, 784
 - histopathology of, 784
 - risk of, sex differences in, 784
 - treatment of, 784
- Nonsteroidal anti-inflammatory drugs (NSAIDs)
 - for headache, in pregnancy, 136
 - teratogenicity of, 6
 - toxicity in fetus and/or newborn, 6
 - use of, in pregnancy, 89
- Nonstress test, 1063
 - biologic basis of, 986
 - biophysical profile and, comparison of, 986
 - and contraction stress test, comparison of, 986, 1005, 1063
 - developmental factors affecting, 986
 - evidence-based use in high-risk pregnancy, 986
 - fetal factors affecting, 986
 - follow-up of, 986
 - in high-risk pregnancy, 1063
 - indications for, 986
 - interpretation of, 986
 - maternal factors affecting, 986
 - medications and, 993
 - methods for, 986
 - nonrandomized prospective trials of, 986
 - nonreactive, 986, 993
 - physiologic basis of, 986
 - randomized controlled trials of, 986
 - standard, 986
 - validation of, 986
 - and vibroacoustic stimulation, comparison of, 986
 - vibroacoustic stimulation added to, 1054
 - visual versus computer analysis of, 986
- Norepinephrine, therapy with, in sepsis, 562
- Norfloracin. *See also* Fluoroquinolones
 - for operative site infection, 562
- Nortriptyline, starting dosage for, in pregnancy, 136
- Nuchal cord, and shoulder dystocia, 345
- Nucleic acid-based amplification (NASBA), 605
- Nucleoside analogues, chemotherapy using, in pregnancy, 153
- Nullisomy, 622
- Nutraceuticals, use of, in pregnancy, 89
- Nutritional assessment, of surgical patient, 537
- Nutritional support
 - perioperative, 492
 - for surgical patient, 537
 - fat in, 537
 - glucose in, 537
 - goals of, 537
 - immune-enhancing formulas for, 537
 - indications for, 537
 - monitoring during, 537
 - postoperative, 537
 - preoperative, 537
 - principles of, 537
 - protein in, 537
 - regimen for, design of, 537
 - total calories in, 537
- O
- Obesity
 - and abdominal wound breakdown, 507
 - and body image, 1080
 - complications of, 1080
 - disease risk with, 1080
 - epidemiology of, in United States, 1073
 - evaluation of, 1080
 - and pancreatic cancer, 855
 - prevalence of, 1080
 - trends in, 1073
 - and renal cell carcinoma, 884
 - and shoulder dystocia, 345
 - surgical interventions in, 1080
 - treatment of, 1080
 - behavior modification in, 1080
 - contraindications to, 1080
 - diet in, 1080
 - exercise in, 1080
 - modalities for, 1080
 - pharmacologic, 1080
 - planning, 1080
 - and urinary incontinence, 173
 - waist circumference in, 1080
 - weight loss goals in, 1080
- Obstructive sleep apnea syndrome, and perioperative upper airway obstruction, 518
- Occupational exposure
 - and bladder cancer, 844
 - leukemia caused by, 855
 - and multiple myeloma, 928
- Ofloxacin. *See also* Fluoroquinolones
 - for operative site infection, 562
- Oligodendroglioma
 - anaplastic
 - diagnosis of, 904
 - treatment of, 904
 - diagnosis of, 904
 - epidemiology of, 904
 - treatment of, 904
- Oligohydramnios
 - detection of, 1026
 - pathogenesis of, 975
 - and pregnancy outcome, 1026
 - pregnancy outcome with, 1026
- Oligonucleotide arrays, 605
- Omega-3 fatty acids, and immune enhancement, 537

- Omeprazole, for gastroesophageal reflux disease, in pregnancy, 136
- Oncocytoma, familial renal, 884
- Oncovin. *See* Vincristine
- Ondansetron, for nausea, vomiting, and hyperemesis gravidarum, 136
- Online Mendelian Inheritance in Man, 711
- Oophorectomy, prophylactic, indications for, 671
- Opioids
- abuse, health consequences of, 73
 - perinatal exposure to, fetal/neonatal effects of, 73
- Oral cancer. *See* Mouth cancer
- Oral cavity. *See also* Mouth
- anatomy of, 952
 - examination of, 952
- Oral contraceptives
- and breast cancer, 778
 - in reduction of ovarian cancer risk, 671
- Organic acidemias
- biochemical symptoms of, 697
 - newborn screening for, 697
 - pathophysiology of, 697
- Organ transplantation, recipients, cutaneous malignancy in, 830
- Orgasmic disorder, 1089
- Orlistat
- adverse effects and side effects of, 1080
 - effects on plasma lipids, 1080
 - mechanism of action of, 1080
 - and weight loss, 1080
- Oropharynx, anatomy of, 952
- Oseltamivir, 136
- Osteogenesis imperfecta, germline mosaicism in, 593
- Osteoporosis
- environmental exposures and, 1119
 - smoking and, 784
 - stress and, 1099
- Ostomy, and abdominal wound breakdown, 507
- Otitis media, treatment of, in pregnancy, 59
- Ovarian cancer. *See also* Hereditary breast and ovarian cancer (HBOC)
- diagnosis of, 439
 - epidemiology of, 1073
 - genetic and genomic factors associated with, 711
 - hereditary risk of, 671
 - diagnosis of, 671
 - management of, 671
 - intestinal involvement in, 439
 - proteomic profiling in, 605
 - unexpected, diagnosed at gynecologic surgery, 439
- Ovarian function, stress and, 1099
- Ovary
- involvement in renal cell carcinoma, 884
 - torsion of, in pregnancy, 405
- Overactive bladder syndrome, 172. *See also* Detrusor instability
- behavioral and psychosomatic factors in, 182
 - bladder wall innervation and, 182
 - C-fibers and, 182
 - conditions mimicking, 173
 - definition of, 218
 - enhanced sensitivity and, 182
 - epidemiology of, 173
 - evaluation of patient for, 193
 - history-taking in, 193
 - idiopathic, 182
 - incidence of, 173
 - and irritable bowel syndrome, 193
 - management of, costs of, 205
 - myogenic theories for, 182
 - natural history of, 173
 - neurogenic causes of, 182
 - neuromodulation techniques for, 193, 218
 - neurophysiologic testing in, 193
 - outflow obstruction and, 182
 - pathophysiology of, 182, 193
 - pelvic floor and, 182
 - pharmacotherapy for, 205
 - physical examination in, 193
 - predisposing factors, 193
 - prevalence of, 173, 218
 - age-related differences in, 173
 - and quality of life, 173, 193
 - secondary excitatory pathways and, 182
 - severity of, assessment of, 173
 - signs and symptoms of, 173, 182, 193
 - smooth muscle in, 182
 - spontaneous remission of, 173
 - treatment of, 205
 - algorithm for, 218, 273
 - behavioral approach to, 273
 - combination therapy strategy for, 273
 - pelvic floor muscle re-education in, 273
 - triggers of, 182
 - unifying theories of, 182
 - urethral factors affecting, 182
 - urinalysis in, 193
 - urodynamic evaluation in, 193
- Over-the-counter drugs
- teratogenicity of, 89
 - use of, in pregnancy, 89
 - guidelines for, 89
 - prevalence of, 89
- Overweight
- epidemiology of, in United States, 1073
 - prevalence of, trends in, 1073
 - in women
 - and body image, 1080
 - disease risk with, 1080
 - management of, 1080
 - prevalence of, 1080
 - weight loss goals in, 1080
- Oxidative phosphorylation (OXPHOS), 593
- disorders of, 593
- Oxybutynin
- absorption of, 205
 - adverse effects and side effects of, 205
 - controlled-release formulation (oxybutynin XL), 205
 - and oxybutynin, comparison of, 205
 - dosage and administration of, 205
 - intravesical therapy with, 205
 - mechanism of action of, 205
 - metabolism of, 205
 - for overactive bladder syndrome, 173, 205
 - transcutaneous administration of, 205
- Oxycodone, adverse effects of, in breast-fed infant, 6
- Oxygen
- consumption/delivery, in pregnancy, effect on CPR, 377

- therapy with
 - in acute respiratory distress syndrome, in pregnancy, 369
 - for asthma, in pregnancy, 125
 - in chronic obstructive pulmonary disease, 518
 - for pulmonary edema
 - in preeclampsia, 308
 - in pregnancy, 125
 - for varicella pneumonia in pregnancy, 393
- Oxygen tension, and oxygen saturation, relationship between, 518
- Oxyhemoglobin dissociation curve, 449
- Oxymetazoline, use of, in pregnancy, 89
- Oxytocin
 - in contraction stress test, 1005
 - historical perspective on, 114
 - for labor stimulation, dosage and administration of, 114
 - midtrimester labor induction with, for pregnancy termination, 114
 - for postpartum hemorrhage, 330, 553
 - for postpartum uterine atony, 125
- Oxytocin receptor antagonist, as tocolytic agent. *See also* Atosiban
 - efficacy of, 99
- P
- Pacemaker(s), cardiac
 - asynchronous mode for, perioperative, 518
 - classification of, 449
 - patient with, perioperative management of, 449
 - perioperative management of, 518
- Paclitaxel, chemotherapy using, 1140
- in pregnancy, 153
- Pad test, in overactive bladder syndrome, 193
- Paget's disease, of breast, 1140
- Pain. *See also* Pelvic pain
 - from abdominal wall, 233
 - breast, work-up for, 1140
 - ear, in head and neck cancer, 952
 - in interstitial cystitis, 233, 242, 250
 - in sexual pain disorder, 1089
 - shoulder, after laparoscopy, 469
 - vulvar, 233
- Painful bladder syndrome, 172. *See also* Interstitial cystitis
 - diagnosis of, 250
 - treatment of, pelvic floor muscle re-education in, 273
- Pallister-Killian syndrome, 622
- Pancoast tumors, 784
- Pancreas, neuroendocrine tumors of, 855
- Pancreatic cancer
 - adjuvant/neoadjuvant treatment of, 855
 - diagnosis of, 855
 - epidemiology of, 855
 - etiology of, 855
 - follow-up for, 855
 - genetics of, 855
 - histopathology of, 855
 - locally advanced, treatment of, 855
 - metastases of, to brain, 904
 - metastatic, treatment of, 855
 - pathology of, 855
 - prognosis for, 855
 - resectable, treatment of, 855
 - risk factors for, 855
 - serologic markers for, 855
 - staging of, 855
 - treatment of, 855
 - advances in (future directions for), 855
- Pancreatitis, in pregnancy, 405
 - causes of, 405
 - diagnosis of, 405
 - incidence of, 405
 - management of, 405
 - signs and symptoms of, 405
- Panic disorder, lifetime prevalence of, sex differences in, 1162
- Papillary carcinoma, hereditary renal, 884
- Papillomatosis, vulvar, 233
- Pap test, limitations of, 605
- Paraplatin. *See* Carboplatin
- Pararectal space, development of, 481
- Paravesical space, development of, 481
- Parenting. *See also* Single parenthood
 - strains of, 1099
- Parents, aging, caregiving for, stressors of, 1099
- Parent-support ratio, 1099
- Parkinson's disease
 - bladder dysfunction in, 173
 - and overactive bladder, 182
- Paroxetine
 - adverse effects of, in breast-fed infant, 6
 - for interstitial cystitis, 259
 - toxicity in fetus and/or newborn, 6
- Parturition, physiologic cascade of, 99
- Patau syndrome, clinical features of, 622
- Patient, medically at-risk, preoperative management of, 449
- Paxil. *See* Paroxetine
- Pediculocides, use of, in pregnancy, 89
- Peg hole defects, and acute intraoperative bleeding, 481
- Pelizaeus-Merzbacher disease, 622
- Pelvic abscess, postoperative, 562
- Pelvic floor
 - anatomy of, 273
 - evaluation of, 273
 - innervation of, 218, 233, 273
 - neuromodulation of, 218
 - normal function of
 - in pelvic support, 273
 - in urinary continence, 273
 - prolapse, voiding dysfunction caused by, 233
- Pelvic floor dysfunction
 - high-tone
 - combination therapy for, 273
 - definition of, 273
 - electrogalvanic stimulation in, 273
 - etiology of, 273
 - literature review on, 273
 - pelvic floor muscle exercises for, 273
 - pharmacologic therapy for, 273
 - physical therapy for, 273
 - Thiele massage for, 273
 - treatment of, 273
 - low-tone
 - definition of, 273
 - etiology of, 273
 - rehabilitation for, 273

- Pelvic floor muscles
 anatomy of, 273
 contraction, evaluation of, 273
 denervation
 age-associated, 273
 postpartum, 273
 exercises for
 in high-tone pelvic floor dysfunction, 273
 in overactive bladder syndrome, 273
 normal functions of, 273
 and overactive bladder syndrome, 182, 273
 re-education of, 273
 algorithm for, 273
 strength, evaluation of, 273
 tenderness, evaluation of, 273
- Pelvic fractures, trauma-induced, in pregnancy, 414
- Pelvic pain
 chronic, 218. *See also* Interstitial cystitis
 clinical evaluation of, 233
 cyclic, 233
 gynecologic causes of, 233
 interstitial cystitis and, 233, 242, 250
 neuromodulation for, 218
 pathophysiology of, 218
- Pelvic pressure pack, for postpartum hemorrhage, 330
- Pelvic vein thrombophlebitis, septic, postoperative, 562
- Pelvis. *See also* Surgery, pelvic
 anatomy of, 428, 481
 avascular spaces of, 481
 anatomy of, 428, 481
- Penicillamine, teratogenicity of, 6
- Penicillin
 allergy to, 59
 cost of, 59
 extended-spectrum
 cost of, 59
 dosage and administration of, 59
 obstetric applications of, 59
 pregnancy category of, 59
 spectrum of activity of, 59
 formulations of, 59
 obstetric applications of, 59
 for operative site infection, 562
 pregnancy category of, 59
 for sepsis, in pregnancy, 393
 spectrum of activity of, 59
- Pentosan polysulfate
 adverse effects and side effects of, 259
 for interstitial cystitis, 259
 dosage and administration of, 242
 effectiveness of, 242
 guidelines for, 242
- Pepcid. *See* Famotidine
- Peptic ulcer disease, in pregnancy, pharmacologic treatment of, 136
- Pepto-Bismol. *See* Bismuth subsalicylate
- Percutaneous umbilical blood sampling, 1039
 clinical applications of, 1039
 complications of, 1039
 Rh prophylaxis with, 1039
 risks of, 1039
 technique for, 1039
- Perinatal mortality, shoulder dystocia and, 345
- Perineometry, for pelvic floor muscle evaluation, 273
- Peripartum emergencies, pharmacologic therapy for, 125
- Peritoneal lavage, in pregnancy, 414, 553
- Periventricular leukomalacia, antenatal corticosteroid therapy and, 35
- Perphenazine
 adverse effects of, in breast-fed infant, 6
 for nausea, vomiting, and hyperemesis gravidarum, 136
- Pertussis
 immunizing agent for, 42
 in pregnancy, 42
- Pharmacogenomics, 711
- Pharmacokinetics, in pregnancy, 136
- Pharyngeal cancer, epidemiology of, 952
- Phencyclidine, adverse effects of, in breast-fed infant, 6
- Phenobarbital
 adverse effects of, in breast-fed infant, 6
 therapy with, in pregnancy, 136
- Phenolphthalein, use of, in pregnancy, 89
- Phentermine, 89
 adverse effects of, in breast-fed infant, 6
- Phenylalanine mustard. *See* Melphalan
- Phenylephrine, toxicity in fetus and/or newborn, 6
- Phenylketonuria
 newborn screening for, 697
 strategy for, 697
 treatment of, 697
- Phenylpropanolamine, contraindications to, 89
- Phenytoin
 prophylactic
 for eclamptic seizures, 125, 308
 for recurrent eclamptic seizures, 308
 teratogenicity of, 136
 therapy with, in pregnancy, 136
- Phlebitis, postoperative, 562
- Phosphodiesterase inhibitors, for heart failure, perioperative management of, 518
- Pineal region tumors
 diagnosis of, 904
 epidemiology of, 904
 treatment of, 904
- Piperacillin
 mechanism of action of, 59
 obstetric applications of, 59
 spectrum of activity of, 59
- Piperacillin-tazobactam (Zosyn)
 mechanism of action of, 59
 obstetric applications of, 59
 for operative site infection, 562
 for perioperative pneumonia, in pelvic surgery patient, 518
 spectrum of activity of, 59
- Piperonyl butoxide, use of, in pregnancy, 89
- Pirbuterol, for asthma, in pregnancy, 136
- Pituitary-adrenal axis, suppression of, surgery and, 449
- Pituitary apoplexy, 904
- Pituitary neoplasms
 classification of, 904
 epidemiology of, 904
 null cell, 904
 prolactin-producing, 904
 signs and symptoms of, 904
 transsphenoidal resection of, 904
- PIVKA-2, in hepatocellular carcinoma, 939
- Placenta, abnormalities of, and umbilical artery velocity waveforms, 1015

- Placenta accreta/increta/percreta
 incidence of, 330
 number of previous cesarean deliveries and, 330
 magnetic resonance imaging of, 330
 management of, preoperative, 330
 maternal mortality rate for, 330
 postpartum hemorrhage with, 330
 ultrasound of, 330
- Placental abruption. *See* Abruptio placentae
- Placental transfer, of drugs, 1, 6
- Placenta previa, incidence of, number of previous cesarean deliveries and, 330
- Plague
 immunizing agent for, adverse effects and side effects of, 42
 in pregnancy, 42
- Plasma, fresh-frozen, transfusion of, in disseminated intravascular coagulation, 308
- Plasma cell labeling index (PCLI), in multiple myeloma, 928
- Plasmapheresis, in HELLP syndrome, 308
- Plasma volume
 in preeclampsia, 330
 in pregnancy, 330, 414
 effect on CPR, 377
- Platelet count, in pregnancy, 414, 553
- Platelet transfusion, in disseminated intravascular coagulation, 308
- Platinol. *See* Cisplatin
- PLISSIT acronym, 1089
- Pneumococcal infection
 immunizing agent for, adverse effects and side effects of, 42
 in pregnancy, 42
 treatment of, 59
- Pneumocystis carinii* infection, treatment of, in pregnancy, 59
- Pneumomediastinum, laparoscopy-related, 469
- Pneumonia
 perioperative, in pelvic surgery patient, 518
 treatment of, in pregnancy, 59
 varicella, in pregnancy, 393
- Pneumoperitoneum, laparoscopy-related
 complications of, 469
 persistence of, 469
- Pneumothorax, laparoscopy-related, 469
- Point mutations
 analysis for, 605
 diseases caused by, 605
- Polar body
 biopsy of, 640
 genetic analysis of, 640
- Poliomyelitis
 immunizing agent for, adverse effects and side effects of, 42
 in pregnancy, 42
- Polyglactin (Vicryl) mesh, for abdominal wound dehiscence, 507
- Polymerase chain reaction (PCR), 605
 in cancer diagnosis, 605
 diagnostic use of, in lymphoma, 820
 efficiency of, 605
 fidelity of, 605
 in infectious disease diagnosis, 605
 multiplex fluorescent, 640
 polymerase for, 605
 in preimplantation genetic diagnosis, 640
 contamination and, 640
 primers for, 605
 real-time, 605
 of fetal cell-free DNA from maternal blood, 649
 results of
 false-negative, 605
 false-positive, 605
 reverse transcriptase, in tumor cell detection, 605
 in single cell analysis, 640, 649
 specificity of, 605
 template for, 605
- Polymorphism. *See also* Single nucleotide polymorphisms (SNP)
 definition of, 711
 of drug-metabolizing enzymes, 711
- Polypropylene (Marlex) mesh, for abdominal wound dehiscence, 507
- Polyps, colonic, adenomatous. *See* Adenomas
- Position/positioning, patient
 during CPR, in pregnancy, 414
 for laparoscopy, complications of, 469
 for pulmonary edema in preeclampsia, 308
- Positive predictive value, of tests, 657
- Positron emission tomography (PET)
 in lung cancer, 784
 in lymphoma, 820
 of thyroid, 879
- Post-dates gestation, and shoulder dystocia, 345
- Postpartum hemorrhage. *See* Hemorrhage, postpartum
- Postpartum period, psychiatric considerations in, 1162
- Potassium, urinary, and interstitial cystitis, 242
- Potassium channel openers, for bladder overactivity, 205
- Potassium Sensitivity Test, in interstitial cystitis, 242, 250
- p16 protein, in pancreatic cancer, 855
- Prader-Willi syndrome
 clinical features of, 593, 622
 genomic imprinting and, 593
 uniparental disomy in, 593, 622
- Prealbumin, in surgical patient, 537
- Prednisone, for asthma, 518
- Preeclampsia/eclampsia
 acute complications of, 308, 377
 cardiac arrest in, 377
 cortical blindness in, 308
 definition of, 308
 disseminated intravascular coagulation in, 308
 eclampsia in, 308
 genetic and genomic factors associated with, 711
 HELLP syndrome in, 308
 hypertensive emergencies in, 308
 hypertensive encephalopathy in, 308
 liver rupture in, 308
 management of, 22
 ophthalmological manifestations of, 308
 pathophysiology of, 22, 308
 plasma volume in, 330
 postpartum management of, 22
 prevention of, 22
 pulmonary edema in, 308
 renal failure in, 308
 risk factors for, 711

- seizures caused by, pharmacologic management of, 125
- superimposed on chronic hypertension, 22
- PREG1* gene, 711
- Pregnancy
 - abdominal trauma in, 414, 553
 - acute abdomen in, 405, 553
 - acute abdominal emergencies in, 553
 - alcohol use/abuse and, 1169
 - appendicitis in, 405, 553
 - biliary colic in, 553
 - bladder cancer in, 844
 - bowel obstruction in, 405, 553
 - breast cancer in
 - diagnosis of, 770
 - treatment of, 770
 - in breast cancer survivor, 770
 - breast symptoms in, 1140
 - cardiopulmonary resuscitation in, 377, 414
 - chemotherapy in, 770
 - cholecystitis in, 553
 - cholelithiasis in, 553
 - disseminated herpes simplex infection in, 393
 - drug exposure in
 - patient counseling about, 1, 6
 - studies of, limitations of, 1, 6
 - drugs commonly used during, 1
 - drugs contraindicated in, 6
 - elective termination of, in breast cancer patient, 770
 - failure, early, misoprostol therapy for, 114
 - hematologic function in, 855
 - hypertension treatment during, 22
 - laparoscopy in, 405
 - laparotomy in, 405
 - maternal cardiac arrest in, 377
 - maternal cardiac risks associated with, 377
 - maternal physiology in, 330, 377, 553
 - effect on CPR, 377
 - and response to trauma, 414
 - outcomes, environmental exposures and, 1119
 - pancreatitis in, 405
 - pharmacokinetics in, 1, 855
 - pulmonary complications in, 369
 - pulmonary physiology in, 369
 - radiation therapy in, 770
 - smoking and, 784, 1169
 - smoking cessation in, 1169
 - surgery in
 - abdominal, 553
 - nonobstetric, 553
 - termination of
 - in cancer patient, 153
 - medical, 114
 - trauma in, 414, 553
 - uterine emergencies in, 553
 - varicella pneumonia in, 393
 - and women's sexuality, 1089
- Pregnancy-associated plasma protein-A, in Down syndrome, 661
- Preimplantation genetic diagnosis (PGD), 640
 - advances in (future directions for), 640
 - aneuploidy screening, 640
 - for chromosomal abnormalities, 640
 - limitations of, 640
 - for single gene disorders, 640
 - for social sexing, 640
- Premature ventricular contractions, perioperative management of, 518
- Premenstrual dysphoric disorder, 1162
- Premenstrual syndrome, 1162
- Prenatal diagnosis
 - advances in (future directions for), 730
 - of fetal single gene disorders, 649
 - using cell-free fetal DNA in maternal blood, 649
 - using fetal cells, 649
- Prepidil, for cervical ripening and labor induction, 114
- Preterm labor
 - contemporary understanding of, 99
 - definition of, 99
 - diagnosis of, 99
 - pharmacologic inhibition of, 99. *See also* Tocolytic agents
 - contraindications to, 99
 - criteria for, 99
 - gestational age and, 99
 - goals of, 99
 - recommendations for, 99
 - signs and symptoms of, 99
- Preterm premature rupture of membranes (PPROM), antenatal corticosteroid therapy with, 35
- Prevacid. *See* Lansoprazole
- Preventive medicine, and reproductive health, 1181
- Prilosec. *See* Omeprazole
- Primidone, adverse effects of, in breast-fed infant, 6
- Pringle maneuver, 939
- Problem drinking. *See* Alcohol, abuse
- Prochlorperazine
 - for headache, in pregnancy, 136
 - for nausea, vomiting, and hyperemesis gravidarum, 136
- Progesterone receptors, in breast cancer, 767
- Progesterone therapy, and breast cancer, 778
- Prolactin, excess, tumors producing, 904
- Prolactinoma(s), 904
- Promethazine, for nausea, vomiting, and hyperemesis gravidarum, 136
- Promotility drugs, for gastroesophageal reflux disease, in pregnancy, 136
- Promyelocytic leukemia, 855
- Propantheline
 - adverse effects and side effects of, 205
 - for bladder overactivity, 205
 - dosage and administration of, 205
- Propranolol
 - for headache, in pregnancy, 136
 - for heart rate control, in atrial fibrillation, 518
 - therapy with, in pregnancy, 22
- Propulsid. *See* Cisapride
- Prostaglandin inhibitors, for bladder overactivity, 205
- Prostaglandin(s) (PG)
 - and bronchoconstriction in asthmatic patient, 125
 - cervical effects of, 114
 - for cervical ripening and labor induction
 - advantages and disadvantages of, 114
 - adverse effects and side effects of, 114
 - available products, 114
 - clinical trials of, 114
 - contraindications to, 114
 - dosage and administration of, 114
 - mechanism of action of, 114

- historical perspective on, 114
 - PGE₁, for cervical ripening, clinical trials of, 114
 - PGE₂, for cervical ripening, clinical trials of, 114
 - PGF_{2α}, for postpartum uterine atony, 125
 - for postpartum hemorrhage, 330, 553
 - uterine effects of, 114
 - as uterine stimulants, 114
 - Prostaglandin synthetase inhibitors, as tocolytic agents
 - dosage and administration of, 99
 - efficacy of, 99
 - fetal/neonatal effects of, 99
 - maternal side effects of, 99
 - mechanism of action of, 99
 - pharmacology of, 99
 - Prosthetic heart valves, anticoagulation with, in pregnancy, 136
 - Prostin E2. *See* Dinoprostone (Prostin E2)
 - Protein
 - in nutritional support for surgical patient, 537
 - visceral stores of, markers of, 537
 - Protein C
 - activated
 - recombinant human, therapy with, 562
 - resistance to, and venous thromboembolism in pregnancy, 363
 - deficiency of, and venous thromboembolism in pregnancy, 363
 - Protein S deficiency, and venous thromboembolism in pregnancy, 363
 - Proteome, analysis of, 711
 - Proteomic profiling, 605
 - Proteomics, 711, 730
 - Prothrombin G20210A, assays for, 605
 - Prothrombin G20210A mutation, and venous thromboembolism in pregnancy, 363
 - Proton pump inhibitors, for gastroesophageal reflux disease, in pregnancy, 136
 - Pseudoephedrine, use of, in pregnancy, 89
 - Pseudomembranous colitis, 492
 - antibiotic-related, 59
 - treatment of, 59
 - Pseudomosaicism, 622
 - Pseudotumor cerebri, 904
 - Psychiatric disorders
 - comorbidity in, 1162
 - gender differences in, 1162
 - lifetime prevalence of, sex differences in, 1162
 - pharmacologic therapy for
 - in pregnancy, 136
 - sex differences in, 1162
 - treatment of, sex differences in, 1162
 - and women's sexuality, 1089
 - Psychoneuroimmunology, 1099
 - Psychostimulants, contraindications to, in pregnancy, 136
 - Psychotropic drugs, use of, in pregnancy, 136
 - Psyllium, use of, in pregnancy, 89
 - PTEN* gene, mutation of, and cancer risk, 711
 - p53* tumor suppressor gene
 - mutation of, and cancer risk, 711
 - in pancreatic cancer, 855
 - Puberty, psychiatric considerations in, 1162
 - Pulmonary artery catheter, in pulmonary edema
 - in preeclampsia, 308
 - in pregnancy, 369
 - Pulmonary artery occlusion pressure, 518
 - Pulmonary capillary wedge pressure
 - in acute respiratory distress syndrome, 369
 - in pulmonary edema, 369
 - Pulmonary disease, and abdominal wound breakdown, 507
 - Pulmonary edema
 - perioperative, 518
 - in preeclampsia
 - diagnosis of, 308
 - etiology of, 308
 - incidence of, 308
 - management of, 308
 - pathophysiology of, 308
 - in pregnancy
 - etiology of, 369
 - pharmacologic management of, 125
 - treatment of, 369
 - Pulmonary embolism
 - anticoagulation for, in pregnancy, 136
 - incidence of, by risk group, 545
 - postpartum
 - incidence of, 363
 - risk factors for, 363
 - in pregnancy, 377
 - diagnosis of, 363
 - maternal mortality rate for, 363
 - in surgical patient
 - diagnosis of, 545
 - treatment of, 545
 - work-up for, 363
 - Pyelonephritis, treatment of, 59
 - Pyrethrin, use of, in pregnancy, 89
 - Pyridoxine
 - for gastrointestinal disorders in pregnancy, 136
 - for headache, in pregnancy, 136
 - for nausea, vomiting, and hyperemesis gravidarum, 136
- Q**
- Quality of life, overactive bladder syndrome and, 173, 193
 - Questran. *See* Cholestyramine
 - Quinine, high-dose, teratogenicity of, 6
 - Quinolones, for operative site infection, 562
 - Quinupristin-dalfopristin
 - adverse effects and side effects of, 59
 - cost of, 59
 - mechanism of action of, 59
 - obstetric applications of, 59
 - spectrum of activity of, 59
- R**
- Rabies
 - immunizing agent for, adverse effects and side effects of, 42
 - in pregnancy, 42
 - Race, and bladder cancer, 844
 - Radiation dose, fetal, in maternal radiography, 414, 553
 - Radiation exposure
 - and multiple myeloma, 928
 - secondary leukemia after, 855

- Radiation therapy
 - for breast cancer, in pregnancy, 770
 - for ductal carcinoma in situ (DCIS) of breast, 774
 - for hepatocellular carcinoma, 939
 - for lung cancer, 784
 - for pancreatic cancer, 855
 - pelvic, and bladder cancer, 844
 - postoperative, for gastric cancer, 892
 - for renal cell carcinoma, 884
 - and women's sexuality, 1089
- Radiofrequency ablation, for hepatocellular carcinoma, 939
- Radiography. *See also* Chest radiography
 - fetal irradiation dose in, 553
 - postoperative, in detection of urinary tract injury, 428
 - in pregnant trauma victim, 414
- Radiology, interventional, for deep venous thrombosis, 545
- Radionuclide scan, myocardial, 449
- Radiopharmaceuticals
 - adverse effects of, in breast-fed infant, 6
 - toxicity in fetus and/or newborn, 6
- Raloxifene
 - and breast cancer prevention, 778, 1140
 - in breast cancer treatment, 738
- Ranitidine
 - for gastroesophageal reflux disease, in pregnancy, 136
 - use of, in pregnancy, 89
- Rapacuronium, 518
- Rape, in pregnancy, 414
- Reciprocal translocation, 622
- Record-keeping, 1181
- Rectovaginal space, development of, 481
- Rectus abdominis muscle, for biologic tamponade, 481
- Red blood cells, packed, transfusion of, in disseminated intravascular coagulation, 308
- Reduction mammoplasty
 - alternative/complementary options for, 1129
 - benefits of, 1129
 - complications of, 1129
 - outcomes of, 1129
 - patient education about, 1129
 - procedure for, 1129
- Reglan. *See* Metoclopramide
- Relationships, and women's sexuality, 1089
- Religion, and women's sexuality, 1089
- Renal artery, fetal, Doppler ultrasound evaluation of, 1015
- Renal blood flow, in pregnancy, 414
- Renal cell carcinoma
 - diagnosis of, 884
 - epidemiology of, 884
 - etiology of, 884
 - follow-up for, 884
 - genetics of, 884
 - hereditary, 884
 - as incidental tumor, 884
 - metastases of, 884
 - to brain, 904
 - prognosis for, 884
 - risk factors for, 884
 - screening for, 884
 - signs and symptoms of, 884
 - staging of, 884
 - treatment of, 884
- Renal failure
 - acute
 - etiology of, 449
 - perioperative management of, 449
 - surgical risk factors for, 449
 - chronic
 - clinical manifestations of, 449
 - perioperative management of, 449
 - in preeclampsia, 308
 - etiology of, 308
 - management of, 308
 - pathogenesis of, 308
 - prognosis for, 308
- Reproductive aging in women, stages/nomenclature of, 1181
- Reproductive health, 1181
 - common issues in, 1181
 - complementary and alternative medicine and, 1181
 - consumer information about, 1181
 - patient-provider communication and, 1181
 - preventive care and, 1181
 - self-help movement and, 1181
- Reproductive tract, female
 - diseases of, 1073
 - environmental exposures and, 1119
 - and urinary tract
 - anatomic overlap of, 233
 - common innervation of, 233
 - embryology of, 233
 - hormonal links between, 233
- Residual urine volume, estimation of, 193
- Resiniferatoxin
 - for bladder overactivity, 182, 205
 - intralesional therapy with, 205
 - for interstitial cystitis, 259
 - mechanism of action of, 205
- Respiration
 - assessment of, in cardiopulmonary resuscitation, 377
 - in pregnancy, 553
 - effect on CPR, 377
- Respiratory disease
 - in pelvic surgery patient, 518
 - perioperative management of, 449
- Respiratory distress syndrome, incidence of
 - amniocentesis and, 1039
 - antenatal corticosteroids and, 35
- Respiratory failure
 - acute, perioperative, 518
 - classification of, 518
 - clinical conditions associated with, 518
 - hypercapnic
 - and decreased ventilatory drive, 518
 - and increased ventilatory drive, 518
- Respiratory tract infection, postoperative, 562
- Retinal binding protein, in surgical patient, 537
- Rett syndrome, in males, 593
- Reverse Woods' (Rubin's) maneuver, for shoulder dystocia, 345
- Revised European-American Lymphoma Classification (REAL), 820
- RFC-1 gene, mutation of, and neural tube defects, 593
- RhD, fetal genotype for, determination of, 649
- Rh isoimmunization, amniocentesis and, 1039
- Rh prophylaxis, with invasive procedures for fetal evaluation, 1039

- Ribavirin therapy, in pregnancy, 136
 Richter's syndrome, 820
 Rimantadine, 136
 Ring chromosomes, 622
 Ritodrine
 as tocolytic agent
 contraindications to, 99
 dosage and administration of, 99
 efficacy of, 99
 fetal/neonatal effects of, 99
 maternal side effects of, 99
 mechanism of action of, 99
 pharmacology of, 99
 toxicity in fetus and/or newborn, 6
 Rituximab (Rituxan), for lymphoma, 820
 Rizatriptan, 136
 RNA, amplification of, by self-sustained sequence replication, 605
 Robertsonian translocation, 622
 Role strain, and women's health, 1099
 Rubella
 immunizing agent for, adverse effects and side effects of, 42
 in pregnancy, 42
 Rubex. *See* Doxorubicin
 Rubidomycin. *See* Daunorubicin
- S
- Saccharin, and bladder cancer, 844
 Sacral neuromodulation
 advances in (future directions for), 218
 Interstim Sacral Nerve Stimulation System for, 218
 Stoller Afferent Nerve Stimulator (SANS) for, 218
 Sacral reflex pathways, evaluation of, 193
 St. John's wort
 antidepressant therapy with, efficacy of, 136
 contraindications to, in pregnancy, 89, 136
 Salbutamol, for asthma, 518
 Saline, extraamniotic infusion of, 114
 Salmeterol, for asthma, in pregnancy, 136
 Sarcoma
 metastases of, to brain, 904
 uterine, unexpected, diagnosed at gynecologic surgery, 439
 Satellite, chromosomal, 622
 Scars, surgical, and women's sexuality, 1089
Schistosoma hematobium, and bladder cancer, 844
 Schizencephaly, genetic and genomic factors associated with, 711
 Schizophrenia, lifetime prevalence of, sex differences in, 1162
 Schwannoma, epidemiology of, 904
 Scopalamine, for bladder overactivity, 205
 Screening
 for colorectal cancer, 812
 guidelines for, 711
 for hepatocellular carcinoma, 939
 mammograms in, 735, 738
 for melanoma, 830
 for multiple myeloma, 928
 newborn, 697
 advances in (future directions for), 697, 730
 automated, 697
 cost-effectiveness of, 697
 definition of, 697
 disorders available for, 697. *See also specific disorder*
 follow-up for, 697
 historical perspective on, 697
 obstetrician's role in, 697
 parent education about, 697
 procedures for, 697
 sample collection for, 697
 screeners for, 697
 systems/services for, 697
 obstetrical (first-trimester), 730
 principles of, 657
 tests for
 and diagnostic tests, comparison of, 657
 negative predictive value of, 657
 positive predictive value of, 657
 sensitivity of, 657
 specificity of, 657
 Seasonal affective disorder, lifetime prevalence of, sex differences in, 1162
 Seatbelt, and maternal/fetal outcome in trauma, 414
 Secondhand smoke, 784
 Seizures. *See also* Epilepsy
 with brain tumor, 904
 in bupivacaine toxicity, 125
 eclamptic, 308
 pharmacologic therapy for, 125
 prevention of
 in eclampsia, 308
 in HELLP syndrome, 308
 tonic-clonic, peripartum, pharmacologic therapy for, 125
 Selective estrogen-receptor modulator. *See also* Raloxifene; Tamoxifen
 in breast cancer prevention, 1140
 Selective serotonin reuptake inhibitors (SSRIs)
 for interstitial cystitis, 259
 therapy with, in pregnancy, 136
 and women's sexuality, 1089
 Self-care, in interstitial cystitis treatment, 259
 Self-sustained sequence replication (3SR), 605
 Sensitivity, of tests, 657
 Sentinel node biopsy, in melanoma, 830
 Sepsis
 and abdominal wound breakdown, 507
 definition of, 393, 562
 postoperative, 427, 562
 severe, definition of, 393, 562
 Sepsis syndrome. *See also* Sepsis; severe
 definition of, 562
 Septic abortion, 562
 Septic shock
 definition of, 393, 562
 in pregnancy, 377, 393
 bacteriology of, 393
 diagnostic criteria for, 393
 epidemiology of, 393
 management of, 393
 maternal mortality rate for, 393
 pathogenesis of, 393
 perinatal mortality rate for, 393
 physiologic responses in, 393
 prognosis for, 393
 treatment of, 562

- Septra. *See* Trimethoprim-sulfamethoxazole
- Serotonin receptor agonists, for headache, in pregnancy, 136
- Sertraline, adverse effects of, in breast-fed infant, 6
- Severe combined immunodeficiency (SCID)
adenosine deaminase deficiency in, 684
and prenatal cellular genetic therapy, 684
X-linked
prenatal cellular genetic therapy for, 684
selective advantage for normal cells in, 684
- Sex chromatin body, 622
- Sex chromosomes
abnormalities of, 622
disorders of, 622
- Sex determination
fluorescence in situ hybridization for, 640
using fetal cells from maternal blood, 649
- Sex differences, in bladder cancer incidence, 844
- Sexual abuse, in pregnancy, 414
- Sexual arousal disorder, 1089
- Sexual assessment, 1089
- Sexual aversion, 1089
- Sexual desire, factors affecting, 1089
- Sexual dysfunction, 1089
definition of, 1089
treatment of, 1089
types of, 1089
- Sexual health care for women, 1089
management of, 1089
- Sexuality, 1089
disability and, 1089
factors affecting, 1089
in health and development, 1089
in illness, 1089
- Sexual pain disorder, 1089
- Sexual response cycle, female, 1089
- Shigella* spp., traveler's diarrhea caused by, treatment of, in pregnancy, 59
- Short-chain fatty acid acyl-CoA dehydrogenase deficiency, newborn screening for, 697
- Shoulder dystocia
all-fours maneuver for, 345
cesarean delivery in, 345
complications of
fetal, 345
incidence of, 345
maternal, 345
types of, 345
definition of, 345
documentation of delivery with, 345
duration of, and central neurological injury, 345
forces acting in, 345
fundal pressure for, 345
hysterotomy for, 345
incidence of, 345
management of
evidence-based evaluation of, 345
and perinatal outcome, 345
proctoepisiotomy for, 345
suprapubic pressure for, 345
McRoberts' maneuver for
mechanism of action of, 345
success rates for, 345
nuchal cord and, 345
pathophysiology of, 345
posterior arm extraction in, 345
recurrence risks for, 345
reverse Woods' (Rubin's) maneuver for, 345
risk factors for, 345
rotational maneuvers for, 345
symphysiotomy for, 345
ultrasound predictors for, 345
Woods' corkscrew maneuver for, 345
Zavanelli maneuver for, 345
- Shoulder pain, postoperative, laparoscopy-related, 469
- Shunt, right to left, and ventilation/perfusion mismatch, differentiation of, 518
- Sibutramine
adverse effects and side effects of, 1080
mechanism of action of, 1080
and weight loss, 1080
- Sickle cell anemia
epidemiology of, 697
perioperative management of, 449
screening for, 697
treatment of, 697
- Sickle cell disease
epidemiology of, 697
newborn screening for, strategy for, 697
- Sidestream smoke, 784
- Sigmoidoscopy, in colorectal cancer screening, 812
- Sildenafil, for women, 1089
- Silver nitrate, intravesical, for interstitial cystitis, 259
- Simethicone, use of, in pregnancy, 89
- Single gene disorders
fetal
analysis of, 649
recurrence risk for, 711
preimplantation genetic diagnosis for, 640
- Single nucleotide polymorphisms (SNP), 711
- Single parenthood
demographics of, 1099
economic effects of, 1099
and vulnerability to stress, 1099
and women's health, 1099
- Sinusitis, treatment of, 59
- Sinus tachycardia, with pulmonary embolism, 545
- Skin infection, treatment of, in pregnancy, 59
- Skin lesions. *See also* Melanoma
biopsy of, 830
diagnosis of, 830
- Small bowel
injury to
intraoperative, management of, 492
in laparoscopy, 469
obstruction, postoperative
clinical manifestations of, 492
incidence of, 492
management of, 492
- Small cell lung cancer, 784
histopathology of, 784
risk of, sex differences in, 784
treatment of, 784
- Smoking. *See also* Tobacco
and alcohol problems, concurrent, 1169
and bladder cancer, 844
and cervical cancer, 1073
cessation
for adolescents, 1169
drugs approved for, 1169

- management of, 1169
- OB/GYN's role in, 784
- in pregnancy, 1169
- sex differences in, 784
- and weight gain, 1169
- years since, and cancer risk, 784
- diseases related to, 784
 - trends in, 1073
- dose and duration of, and lung cancer risk, 784
- endocrine effects of, 784
- epidemiology of, 1169
- health consequences of, 73, 1169
- historical perspective on, 784
- initiation of, sex differences in, 784
- leukemia caused by, 855
- and lung cancer, 735, 784
- maternal, fetal/neonatal effects of, 73
- and menopausal symptoms, 1119
- morbidity and mortality caused by, 1169
- and oral cancer, 952
- and pancreatic cancer, 855
- parental, and children's health, 784
- perioperative management of, 449
- in pregnancy, 1169
 - trends in, 1073
- prevalence of, sex differences in, 784
- and renal cell carcinoma, 884
- reproductive effects of, 784
- by women, 784, 1169
- Smooth muscle, in overactive bladder syndrome, 182
- Snakebite
 - immunizing agent for, adverse effects and side effects of, 42
 - in pregnancy, 42
- Social phobia, lifetime prevalence of, sex differences in, 1162
- Social structure, and women's health, 1099
- Sociological stress model, and women's health, 1099
- Sodium
 - depletion, and water depletion, combined, perioperative management of, 449
 - excess, perioperative management of, 449
 - restriction of, for pulmonary edema in preeclampsia, 308
- Sodium bicarbonate, use of, in pregnancy, 89
- Sodium iodide, toxicity in fetus and/or newborn, 6
- Sodium nitroprusside
 - for heart failure, perioperative management of, 518
 - for hypertension, 518
 - for hypertensive crisis in preeclampsia, 308
- Solitary pulmonary nodule
 - clinical presentation of, 784
 - diagnosis of, 784
 - excisional biopsy of, 784
- Southern blot, 605
- Sparfloxacin. *See* Fluoroquinolones
- Specificity, of tests, 657
- Spectral karyotyping (SKY), 622
- Spinal cord, in control of bladder function, 218
- Spinal trauma, and overactive bladder, 182
- Spinocerebellar ataxia, autosomal dominant
 - clinical features of, 593
 - trinucleotide repeat expansion in, 593
- Sputum cytology, in lung cancer, 784
- Squamous cell carcinoma
 - of lung, 784
 - oral, 952
 - vulvar, unexpected, diagnosed at gynecologic surgery, 439
- Stab wound. *See* Trauma, penetrating
- Staphylococcal infection, treatment of, in pregnancy, 59
- Startles, fetal, 993
- Stem cell transplantation, prenatal
 - advances in (future directions for), 684
 - chimerism after, 684
 - clinical experience with, 684
 - diseases that may benefit from, 684
 - in diseases with selective advantage for normal cells, 684
 - engraftment after, 684
 - fetal immune function and, 684
 - potential for, 684
 - rationale for, 684
 - stem cell plasticity and, 684
- Stent, ureteral, indications for, 428
- Steroids. *See also* Corticosteroid therapy and abdominal wound breakdown, 507
 - for asthma, 518
- Stillbirth. *See* Death, fetal
- Stockings, compression, in prevention of thromboembolism, 545
- Stoller Afferent Nerve Stimulator (SANS), peripheral sacral nerve stimulation using, 218
- Stomach, intraoperative injury to, management of, 492
- Streptococci, group B, colonization, treatment of, 59
- Streptomycin, teratogenicity of, 6
- Stress
 - definition of, 1099
 - and depression, 1099
 - experienced by women, types of, 1162
 - and heart disease, 1099
 - and illness, 1099
 - occupational, and women's health, 1099
 - and osteoporosis, 1099
 - and ovarian function, 1099
 - physiological response to, 1099
 - vulnerability to
 - aging and, 1099
 - divorce and, 1099
 - factors affecting, 1099
 - single parenthood and, 1099
 - and women's health, 1099, 1162
 - research on, 1099
- Stress incontinence
 - detrusor instability and, 182
 - diagnosis of, 193
 - prevalence of, 193
 - gender differences in, 173
 - obesity and, 173
- Stress model of illness, 1099
- Stroke, in eclampsia, 308
- Substance abuse. *See also* Drug abuse
 - health care costs of, 1169
- Substance P, in interstitial cystitis, 259
- Subtelomeric deletions, 622
- Sucralfate, for gastroesophageal reflux disease, in pregnancy, 136
- Sudden cardiac death, 377
- Suicide, drug abuse and, 73

- Sulbactam, spectrum of activity of, 59
- Sulfasalazine, for inflammatory bowel disease, in pregnancy, 136
- Sulfonamides
adverse effects of, in breast-fed infant, 6
toxicity in fetus and/or newborn, 6
- Sumatriptan, for headache, in pregnancy, 136
- Sunlight exposure, and melanoma, 830
- Superficial skin closure, for superficial separation of abdominal incision wound, 507
- Supine hypotensive syndrome, 553
in trauma victim, 414
- Supraventricular tachycardia, perioperative management of, 518
- Surface enhanced laser desorption ionization (SELDI), 605
- Surfactant, production of, antenatal corticosteroids and, 35
- Surgery. *See also* Cesarean delivery
abdominal incision for, wound breakdown, 507. *See also* Wound
for bladder cancer, 844
in *Clostridium difficile* infection, 492
colorectal, infection control guidelines for, 562
for colorectal cancer, 812
for gastric cancer, 892
gastrointestinal, preparation for, 492
gynecologic
antibiotic prophylaxis in, 562
emergencies related to, 427. *See also specific emergency*
gastrointestinal complications of, 492
thromboembolic complications of, 545
unexpected cancer diagnosed at, 439
for hepatocellular carcinoma, 939
for lung cancer, 784
for melanoma, 830
metabolic response to, 537
for mouth cancer, 952
for pancreatic cancer, 855
pelvic
anatomical considerations in, 481
bleeding in
hemostatic techniques for, 481
management of, 481
potential sites of, 481
prevention of, 481
cardiorespiratory emergencies with, 518
dissection for, principles of, 481
exposure in, 481
patient positioning for, 481
preparation for, 481
traction-countertraction in, 481
urinary tract injury in, 428
physiologic responses to, 449
in pregnancy, 414, 553
for renal cell carcinoma, 884
for thyroid cancer, 879
vulvar, necrotizing fasciitis after, 562
for weight reduction, 1080
and women's sexuality, 1089
- Suture technique(s), for postpartum hemorrhage, 330
- Sympathetic nervous system, in stress response, 1099
- Sympathomimetics
for asthma, in pregnancy, 136
- toxicity in fetus and/or newborn, 6
use of, in pregnancy, 89
- Symphiotomy, for shoulder dystocia, 345
- Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
in lung cancer, 784
postoperative, 449
- Synercid. *See* Quinupristin-dalfopristin
- Syntocinon. *See* Oxytocin (Syntocinon)
- Syphilis, treatment of, 59
- Systemic inflammatory response syndrome (SIRS)
definition of, 393, 562
postoperative, 562
- Systemic vascular resistance, in pregnancy, 553
- T
- Tachyarrhythmias, atrial, perioperative, 518
- Tagamet. *See* Cimetidine
- Tamoxifen
adverse effects and side effects of, 1140
in breast-fed infant, 6
and breast cancer prevention, 671, 778, 1140
in breast cancer treatment, 738, 1140
for ductal carcinoma in situ (DCIS) of breast, 774, 1140
and endometrial cancer risk, 778
and women's sexuality, 1089
- Tandem repeats, 593
- Taxanes, chemotherapy using, in pregnancy, 153
- Taxol. *See* Paclitaxel
- Tazobactam, spectrum of activity of, 59
- Technology
advances in (future directions for), 730
linear array, advances in (future directions for), 730
- Tegretol. *See* Carbamazepine
- Telomeres
rearrangements of
clinical effects of, 622, 711
screening for, 622
structure of, 622
- Temazepam, adverse effects of, in breast-fed infant, 6
- Tension myalgia of pelvic floor, 273
- Teratogen(s)
chemotherapeutic agents as, 153
databases of, 136
information about, sources of, 1
list of, 6
over-the-counter drugs as, 89
- Teratogenicity
of commonly used drugs
patient counseling about, 1, 6
studies of, limitations of, 1, 6
criteria for, 6
critical period for, 6
- Teratology, 136
- Teratoma, ovarian, 622
- Terbinafine, use of, in pregnancy, 89
- Terbutaline
for asthma, in pregnancy, 136
for excessive uterine tone, 125
as tocolytic agent
contraindications to, 99
fetal/neonatal effects of, 99
maternal side effects of, 99

- mechanism of action of, 99
- Tetanus
 - immunizing agent for, adverse effects and side effects of, 42
 - in pregnancy, 42
- Tetanus toxoid, administration of, in pregnant trauma patient, 553
- Tetracycline
 - prophylactic, in gynecologic surgery, 562
 - teratogenicity of, 6, 553
- Tetralogy of Fallot, genetic and genomic factors associated with, 711
- Tetraploidy, 622
- Thalassemia
 - perioperative management of, 449
 - prenatal diagnosis of, 649
- Thalidomide
 - for multiple myeloma, 928
 - teratogenicity of, 6
- Theophylline
 - adverse effects of, in breast-fed infant, 6
 - for asthma, in pregnancy, 136, 369
- Thiazide diuretics, antihypertensive therapy with, during pregnancy, 22
- Thiele massage, for high-tone pelvic floor dysfunction, 273
- Thioplex. *See* Thiopeta
- Thiopeta therapy, in pregnancy, 153
- Thrombocytopenia, gestational, 855
- Thromboembolism. *See also* Deep venous thrombosis; Pulmonary embolism
 - after gastrectomy, 892
 - anticoagulation for, in pregnancy, 136
 - in pregnancy, 363
 - diagnosis of, 363
 - incidence of, 363
 - risk factors for, 363, 553
 - treatment of, 363
 - risk for, 363, 545, 553
 - in surgical patient, 545
 - prevention of, 545
 - risk factors for, 545
- Thrombolysis, in HELLP syndrome, 308
- Thrombophilia
 - and thromboembolism
 - in pregnancy, 363
 - in surgical patient, 545
 - work-up for, 363
- Thrombophlebitis, pelvic vein, septic, postoperative, 562
- Thrombosis, proximal vein, incidence of, by risk group, 545
- Thyroid
 - imaging of, 879
 - lymphoma of, characteristics of, 879
 - scanning of, 879
- Thyroid cancer
 - anaplastic, characteristics of, 879
 - differential diagnosis of, 879
 - follicular
 - characteristics of, 879
 - staging of, 879
 - incidence of, 879
 - medullary
 - characteristics of, 879
 - staging of, 879
 - metastases of, to brain, 904
 - papillary
 - characteristics of, 879
 - staging of, 879
 - prognosis for, 879
 - signs and symptoms of, 879
 - staging of, 879
 - treatment of, 879
 - types of, 879
 - work-up for, 879
- Thyroid-stimulating hormone (thyrotropin, TSH), tumors producing, 904
- Ticarcillin, spectrum of activity of, 59
- Ticarcillin-clavulanate
 - mechanism of action of, 59
 - obstetric applications of, 59
 - spectrum of activity of, 59
- Ticarcillin-clavulanic acid (Timentin), for operative site infection, 562
- Tidal volume, in pregnancy, 414, 553
 - effect on CPR, 377
- Tigan. *See* Trimethobenzamide hydrochloride
- Timentin. *See* Ticarcillin-clavulanic acid (Timentin)
- Tissue core-needle biopsy, of breast lesions, 738
- Tizanidine hydrochloride, for high-tone pelvic floor dysfunction, 273
- Tobacco. *See also* Smoking
 - smokeless, 784
 - use of
 - diagnosis of, 1169
 - epidemiology of, 1169
 - health hazards in, 784, 1169
 - historical perspective on, 784
 - morbidity and mortality caused by, 1169
 - and oral cancer, 952
 - treatment of, 1169
- Tobramycin. *See also* Aminoglycosides
 - cost of, 59
 - dosage and administration of, 59
- Tocolytic agents. *See also* Preterm labor, pharmacologic inhibition of
 - combination therapy with, 99
 - efficacy of, 99
 - for fetal stress in labor, 125
 - maintenance therapy with, 99
 - mechanism of action of, 99
- Tolbutamide
 - adverse effects of, in breast-fed infant, 6
 - toxicity in fetus and/or newborn, 6
- Tolterodine
 - adverse effects and side effects of, 205
 - dosage and administration of, 205
 - efficacy of, 205
 - long-acting formulation of (Detrol LA), 205
 - for overactive bladder syndrome, 205
 - and oxybutynin XL, comparison of, 205
- Topical drugs, over-the-counter, use of, in pregnancy, 89
- Topiramate, and weight loss, 1080
- Topoisomerase I inhibitors, chemotherapy using, in pregnancy, 153
- Topoisomerase II inhibitors, chemotherapy using, in pregnancy, 153
- Topotecan, chemotherapy using, in pregnancy, 153
- Total body water, 449

- Total parenteral nutrition, for surgical patient
and enteral nutrition, comparison of, 537
perioperative, 492
postoperative, 537
preoperative, 537
- Toxins, urinary, and interstitial cystitis, 259
- Toxoplasmosis, congenital
newborn incidence of, 697
newborn screening for, 697
- Tracheal tube, medication administration through, 377
- Traction-countertraction, in pelvic surgery, 481
- Trait(s)
dominant, 593
recessive, 593
- Tramadol, toxicity in fetus and/or newborn, 6
- Transcription amplification system (TAS), 605
- Transferrin, in surgical patient, 537
- Transfusion medicine, and immunization, 42
- Transfusion therapy. *See also* Autotransfusion
in disseminated intravascular coagulation, 308
for postpartum hemorrhage, 553
- Translocation
balanced, 622
chromosomal, 622
reciprocal, 622
robertsonian, 622
- Trans thoracic needle aspiration, in lung cancer, 784
- Trauma, in pregnancy, 414
abdominal, 553
pathophysiology of, 414
blunt, 553
pathophysiology of, 414
epidemiology of, 414
fetal assessment in, 414
fetomaternal hemorrhage in, 414
initial evaluation and treatment of, 414
management of, 414
principles of, 414
pathophysiology of, 414
penetrating, 553
fetal mortality rate for, 414
pathophysiology of, 414
response to, physiology of, 414
- Traumatic, and immune enhancement, 537
- Travel, international, in pregnancy, immunization for, 42
- Traveler's diarrhea, treatment of, in pregnancy, 59
- Trazodone, adverse effects of, in breast-fed infant, 6
- Trendelenburg position, steep, 481
- Triamcinolone, for asthma, in pregnancy, 136
- Trichomoniasis, 233
treatment of, 59
- Tricyclic antidepressants
for bladder overactivity, 205
therapy with, in pregnancy, 136
- Triethylenethiophosphoramide. *See* Thiotepe
- Trifluoperazine, adverse effects of, in breast-fed infant, 6
- Trilafon. *See* Perphenazine
- Trimethobenzamide hydrochloride, for nausea, vomiting,
and hyperemesis gravidarum, 136
- Trimethoprim-sulfamethoxazole
adverse effects and side effects of, 59
bacterial resistance to, 59
cost of, 59
neonatal effects of, 59
obstetric applications of, 59
pregnancy category of, 59
spectrum of activity of, 59
- Trinucleotide repeat expansion, 593
analysis for, 605
disorders caused by, preimplantation genetic diagnosis
for, 640
- Triploidy, 622
diandric, maternal serum biochemistry in, 661
digynic, maternal serum biochemistry in, 661
fetal findings in, 661
genomic imprinting and, 593
- Trisomic rescue, 593, 622
- Trisomy, 622
autosomal, 622
partial, 622
- Trisomy 13
clinical features of, 622
fetal findings in, 661
maternal serum biochemistry in, 661
spontaneous abortion rate for, 622
- Trisomy 18
clinical features of, 622
fetal findings in, 661
maternal serum biochemistry in, 661
spontaneous abortion rate for, 622
- Trisomy 21. *See* Down syndrome
- Trofloxacin. *See* Fluoroquinolones
- Trovaflaxacin, for operative site infection, 562
- Tuberculosis
drug abuse and, 73
immunizing agent for, 42
in pregnancy, 42
- Tuberous sclerosis, germline mosaicism in, 593
- Tularemia
immunizing agent for, 42
in pregnancy, 42
- Tumors(s)
dyspareunia caused by, 233
pelvic pain caused by, 233
- Tumor lysis syndrome, 855
- Tumor necrosis factor- α (TNF- α), in sepsis, 393
- Tumor suppressor genes, 671
- Turner syndrome
clinical features of, 622
fetal findings in, 661
isochromosome in, 622
mosaic, 622
- Twinning, genetic and genomic factors associated with,
711
- Twitches, fetal, 993
- Typhoid
immunizing agent for, adverse effects and side effects
of, 42
in pregnancy, 42
- U
- Ulcerative colitis (UC)
and colorectal cancer risk, 812
treatment of, in pregnancy, 136
- Ultrasound
of adnexal masses, 439
in appendicitis, 553
in pregnancy, 405
of bladder, 844

- of breast, in pregnancy, 770
- in cholecystitis, in pregnancy, 405
- in diagnosis of deep venous thrombosis, 363
- Doppler
 - of ductus venosus, 1015
 - of fetal cerebral arteries, 1015
 - of fetal descending aorta, 1015
 - fetal evaluation using, 1015, 1063
 - of fetal inferior vena cava, 1015
 - for fetal movement monitoring, 993
 - limitations of, 993
 - of fetal renal artery, 1015
 - of fetal venous circulation, 1015
 - of umbilical artery, 1015, 1063
 - of umbilical vein, 1015
 - of uterine artery, 1015
- duplex Doppler, in diagnosis of deep venous thrombosis, 545
- in ectopic pregnancy, 553
- in endometrial assessment, 439
- endoscopic, in gastric cancer staging, 892
- in hepatocellular carcinoma, 939
- of macrosomia, 345
- of placenta accreta/increta/percreta, 330
- in pregnant trauma victim, 414
- real-time, for fetal movement monitoring, 993
- renal, 193
- in renal cell carcinoma, 884
- second-trimester, fetal nuchal translucency and, 661
- three-dimensional, in evaluation of amniotic fluid volume, 1026
- of thyroid, 879
- Umbilical artery, Doppler ultrasound evaluation of, 1015, 1063
 - chromosomal abnormalities and, 1015
 - fetal growth restriction and, 1015
 - intrapartum, 1015
 - and long-term neurologic outcome, 1015
 - in low-risk pregnancy, 1015
 - and perinatal outcome, 1015
 - placental lesions and, 1015
- Umbilical vein, Doppler ultrasound evaluation of, 1015
- Unasyn. *See* Ampicillin-sulbactam (Unasyn)
- Uniparental disomy, 593, 622
 - clinical syndromes of, 622
- Unisom. *See* Doxylamine
- University of Wisconsin IC Scale (UW-ICS), 250
- Unstable bladder, definition of, 173
- Upper airway obstruction, perioperative, 518
- Upper respiratory tract infection, viral, perioperative management of, 449
- Urea cycle disorders, newborn screening for, 697
- Uremia, and abdominal wound breakdown, 507
- Ureter
 - anatomy of, 428
 - blood supply to, 428
 - burn injury to, in pelvic surgery, 428
 - catheterization, preoperative, 428
 - devascularization of, in pelvic surgery, 428
 - injury to, in pelvic surgery
 - incidence of, 428
 - intraoperative detection of, 428
 - mechanisms of, 428
 - outcome of, 428
 - postoperative recognition of, 428
 - prevention of, 428
 - repair of, 428
 - signs and symptoms of, 428
 - sites of, 428
 - ligation of, in pelvic surgery, 428
 - patency of, intraoperative assessment of, 428
 - retrograde stenting of, 428
- Urethra, and overactive bladder syndrome, 182
- Urethral instability, 173, 193
- Urethrocytography, 193
- Urethrocytometry, in overactive bladder syndrome, 193
- Urge-IIQ, 173
- Urge incontinence
 - definition of, 173
 - incidence of, 173
 - motor, 193
 - definition of, 173
 - prevalence of, 193
 - age-related differences in, 173
 - gender differences in, 173
 - obesity and, 173
 - racial differences in, 173
 - and quality of life, 193
 - sensory, 193
 - definition of, 173
- Urgency, urinary. *See also* Interstitial cystitis, signs and symptoms of
 - clinical evaluation of, 233
 - definition of, 173
- Urge syndrome, 193
- Urge-UDI, 173
- Urinalysis, in overactive bladder syndrome, 193
- Urinary bladder. *See* Bladder
- Urinary diary, 193, 250
- Urinary diversion, for interstitial cystitis, 259
- Urinary incontinence. *See* Incontinence
- Urinary retention
 - etiology of, 218
 - nonobstructive, treatment of, 218
 - prevalence of, 218
 - treatment of, algorithm for, 218
- Urinary stasis, in pregnancy, 553
- Urinary tract
 - anatomy of, 428
 - imaging of, 193
 - injury to
 - in laparoscopy, 469
 - in pelvic surgery, 428
 - incidence of, 428
 - intraoperative detection of, 428
 - occult, 428
 - outcome of, 428
 - postoperative recognition of, 428
 - prevention of, 428
 - repair of, 428
 - surgical management of, 428
 - and reproductive tract
 - anatomic overlap of, 233
 - common innervation of, 233
 - embryology of, 233
 - hormonal links between, 233
- Urinary tract infection(s) (UTI)
 - postoperative, 562
 - in pregnancy, 553
 - signs and symptoms of, 233

- treatment of, 59
- Urine
 - cytologic analysis of, 844
 - toxic substances in, and interstitial cystitis, 259
- Urine leak, postoperative, 492
- Urodynamic evaluation
 - in interstitial cystitis, 250
 - in overactive bladder syndrome, 193
- Urodynamics, ambulatory, 193
- Urogenital atrophy, 233
- Urogenital Distress Inventory, 173
- Urological Distress Inventory, 193
- Ursodeoxycholic acid, for cholestasis of pregnancy, 136
- Ursodiol. *See* Ursodeoxycholic acid
- Uterine artery(ies)
 - Doppler ultrasound evaluation of, 1015
 - ligation of, for postpartum hemorrhage, 330, 553
- Uterine atony
 - diagnosis of, 553
 - management of, 553
 - postpartum, pharmacologic management of, 125
 - postpartum hemorrhage in, 330, 553
 - predisposing factors in, 553
- Uterine cervix. *See* Cervix
- Uterine emergencies, in pregnancy, 553
- Uterine packing, for postpartum hemorrhage, 330
- Uteroplacental insufficiency, detection of, 1005
- Uterotonic agents, for postpartum hemorrhage, 330, 553
- Uterus
 - blood flow to, in pregnancy, 414, 553
 - effect on CPR, 377, 414
 - contractility of, mechanisms of, 99
 - excessive tone, peripartum pharmacologic management of, 125
 - gravid, in trauma, 414
 - aortocaval compression by, 414
 - protective effect of, 414
 - peripartum inversion of, management of, 125
 - rupture of
 - management of, 553
 - shoulder dystocia and, 345
 - signs and symptoms of, 553
 - trauma-related, 414, 553
 - sarcoma of, unexpected, diagnosed at gynecologic surgery, 439
 - stimulants for, 114
- V
- Vaccination. *See* Immunization
- Vaccine, varicella, 393
- Vaccinia
 - immunizing agent for, 42
 - in pregnancy, 42
- Vacuum-assisted core-needle biopsy, of breast cancer, 774
- Vagina
 - bacteria in, 562
 - cancer of, unexpected, diagnosed at gynecologic surgery, 439
 - lacerations of, shoulder dystocia and, 345
 - pH of, measurement of, 562
 - watery discharge from, postoperative, 428
- Vaginal intraepithelial neoplasia (VAIN), 439
- Vaginal strictures, 233
- Vaginismus, 1089
- Vaginitis. *See also* Bacterial vaginosis
 - yeast, 233
- Valacyclovir therapy, in pregnancy, 136
- Valproic acid
 - teratogenicity of, 136
 - therapy with, in pregnancy, 136
- Valsartan, toxicity in fetus and/or newborn, 6
- Valvular heart disease, perioperative management of, 449
- Vanceryl DS, for asthma, in pregnancy, 136
- Vancomycin
 - for antibiotic-associated colitis, 492
 - for pseudomembranous colitis, 492
- Van der Woude syndrome, 593
- Vanilloid therapy. *See* Capsaicin; Resiniferatoxin
- Varicella pneumonia, in pregnancy
 - clinical presentation of, 393
 - epidemiology of, 393
 - management of, 393
 - pathogenesis of, 393
 - postexposure prophylaxis for, 393
 - prevention of, 393
- Varicella vaccine, 393
- Varicella-zoster immune globulin (VZIG), 393
- Varicella-zoster virus (VZV)
 - immunization against, in pregnancy, 136
 - immunizing agent for, adverse effects and side effects of, 42
 - in pregnancy, 42
- Vascular clips, for hemostasis, 481
- Vascular trauma, in pelvic surgery
 - management of, 481
 - prevention of, 481
- Vasculature, in pregnancy, 553
- Vasodilators
 - adverse effects and side effects of, 22
 - antihypertensive therapy with, in pregnancy, 22
 - direct, for hypertension, 518
 - for heart failure, perioperative management of, 518
 - for pulmonary edema, in pregnancy, 369
 - for severe hypertension, in pregnancy, 125
- Velban. *See* Vinblastine
- Velocardiofacial syndrome, 593, 622
- Vena cava, injury to, in laparoscopy, 469
- Venlafaxine, 738
 - for interstitial cystitis, 259
- Venous thromboembolism. *See* Deep venous thrombosis; Pulmonary embolism; Thromboembolism
- Ventilation/perfusion mismatch
 - in chronic obstructive pulmonary disease, 518
 - and right to left shunt, differentiation of, 518
- Ventilation/perfusion scanning, in diagnosis of pulmonary embolism, 363, 545
- Ventricular arrhythmia(s), perioperative management of, 518
- Ventricular fibrillation, perioperative management of, 518
- Ventricular tachycardia, perioperative management of, 518
- VePesid. *See* Etoposide
- Verapamil
 - for heart rate control, in atrial fibrillation, 518
 - intravesical therapy with, 205

- Very long-chain fatty acid acyl-CoA dehydrogenase deficiency, newborn screening for, 697
- Vesicovaginal space, development of, 481
- Vestibulitis, 233
- Viagra. *See* Sildenafil
- Vibroacoustic stimulation, 1063
- in antepartum period, 1054
- effects on hearing, 1054
- fetal, 986
- and nonstress test, comparison of, 986
- and perinatal outcomes, 986
- intrapartum, 1054
- intrauterine sound pressure levels caused by, 1054
- safety of, 1054
- Vieryl. *See* Polyglactin (Vicryl) mesh
- Vidarabine therapy, in pregnancy
- for disseminated herpes simplex infection, 393
- for varicella pneumonia, 393
- Vinblastine, chemotherapy using, in pregnancy, 153
- Vinca alkaloids, chemotherapy using, in pregnancy, 153
- Vincristine, chemotherapy using, in pregnancy, 153
- Vinorelbine, chemotherapy using, in pregnancy, 153
- Vinyl chloride, and liver cancer, 939
- Violence, experience of, and women's sexuality, 1089
- Virtual colonoscopy, in colorectal cancer screening, 812
- Virus(es). *See also specific virus*
- detection of, polymerase chain reaction method for, 605
- immunization against
- active, 42
- passive, 42
- infections by, pharmacotherapy for, in pregnancy, 136
- upper respiratory tract infection, perioperative management of, 449
- Vistaril. *See* Hydroxyzine
- Vitamin A and derivatives, teratogenicity of, 6
- Vitamin B₆. *See* Pyridoxine
- Vitamin supplements, use of, 1181
- Voiding, timed, for overactive bladder treatment, 273
- Voiding diary, 193, 250
- Voiding dysfunction
- interstitial cystitis and, 233
- management of, algorithms for, 218
- pelvic floor prolapse and, 233
- prevalence of, 218
- treatment of, 218
- Volume of distribution, in pregnancy, 136
- Volume replacement
- in disseminated intravascular coagulation, 308
- in HELLP syndrome, 308
- in preeclampsia, 377
- for pregnant trauma victim, 414
- in sepsis, 393, 562
- Volvulus, in pregnancy, 405
- Vomiting. *See also* Hyperemesis gravidarum
- in pregnancy, pharmacologic treatment of, 136
- von Hippel-Lindau disease, 884
- genetics of, 884
- Vulva, cancer of, unexpected, diagnosed at gynecologic surgery, 439
- Vulvar dermatoses, 233
- Vulvar papillomatosis, 233
- Vulvar surgery, necrotizing fasciitis after, 562
- Vulvitis, 233
- Vulvodinia, 233
- essential (dysesthetic), 233
- Vulvovaginitis, 233
- W
- Warfarin
- in prevention of thromboembolism, 545
- teratogenicity of, 6, 136
- Water
- contaminants in, 1119
- depletion
- perioperative management of, 449
- and sodium depletion, combined, perioperative management of, 449
- excess, and sodium excess, perioperative management of, 449
- restriction of, for pulmonary edema in preeclampsia, 308
- Weight gain
- medication-related, 1080
- in pregnancy, and shoulder dystocia, 345
- smoking cessation and, 1169
- Weight loss
- exercise and, 1080
- in overweight and obesity
- goals for, 1080
- health benefits of, 1080
- preoperative
- classification of, 537
- prognostic significance of, 537
- White blood cell count, in pregnancy, 405, 414, 553
- Wickham's striae, 233
- Widowhood
- demographics of, 1099
- stressors of, 1099
- Williams-Beuren syndrome, 622
- Wiskott-Aldrich syndrome, selective advantage for normal cells in, 684
- Wolff-Parkinson-White syndrome, perioperative management of, 518
- Wolf-Hirschhorn syndrome, 622
- Women
- health care visits by, 1162
- life expectancy of, trends in, 1073
- mental health of, 1162
- and paid employment, 1099
- response to physicians, physician's sex and, 1162
- Women's health. *See also* Reproductive health
- educational status and, 1073
- social and political factors affecting, 1073, 1189
- trends in, in United States, 1073
- Women's health movement, 1189
- Woods' corkscrew maneuver, for shoulder dystocia, 345
- Working Formulation, for lymphoma classification, 820
- Wound
- abdominal incision
- breakdown of, 507
- diagnosis of, 507
- electrocautery and, 507
- hypothermia and, 507
- management of, 507
- operating time and, 507
- prevention of, 507
- risk factors for, 507
- surgical technique and, 507

- dehiscence, 507
 - incidence of, 507
 - management of, 507
 - mesh repair for, 507
 - reclosure of, 507
 - tamponade for, 507
 - drains in, 507
 - superficial separation of, 507
 - delayed reclosure of, 507
 - dressings for, 507
 - en bloc secondary closure of, 507
 - incidence of, 507
 - management of, 507
 - superficial skin closure for, 507
 - classification of, 507
 - disruption of. *See* Wound, abdominal incision, superficial separation of
 - extrafascial dehiscence of. *See* Wound, abdominal incision, superficial separation of
 - fascial dehiscence. *See* Wound, abdominal incision, dehiscence
 - infection
 - and abdominal wound breakdown, 507
 - postoperative, treatment of, 59
 - risk of, 507
- X
- X chromosome
 - isochromosome for, 622
 - multples of, 622
 - Xeroderma pigmentosum, 830
 - X-linked disorder(s), 593
 - XXY karyotype, 622
 - YYY karyotype, 622
- Y
- Yellow fever
 - immunizing agent for, adverse effects and side effects of, 42
 - in pregnancy, 42
 - York Incontinence Perception Scale, 173
- Z
- Zafirlukast, for asthma, in pregnancy, 136, 369
 - Zanamivir, 136
 - Zantac. *See* Ranitidine
 - Zarontin. *See* Ethosuximide
 - Zavanelli maneuver, for shoulder dystocia, 345
 - ZD6169, effects on urinary tract, 205
 - Zevalin, for lymphoma, 820
 - Zidovudine therapy, in pregnancy, 136
 - Zileuton, for asthma, in pregnancy, 136
 - Zinc pyrithione, use of, in pregnancy, 89
 - Zofran. *See* Ondansetron
 - Zollinger-Ellison syndrome, 855
 - Zolmitriptan, 136
 - Zosyn. *See* Piperacillin-tazobactam (Zosyn)
 - Zubrod Performance Status Scale, 784
 - Zuclopenthixol, adverse effects of, in breast-fed infant, 6
 - Zyvox. *See* Linezolid

Author *Index*

Aguilar, Vivian C., 233
 Arias, Raquel D., 761
 Aronne, Louis J., 1080
 Aronson, Michael P., 428
 Barbo, Dorothy M., 1181
 Barrilleaux, P. Scott, 22
 Bender, Hans Georg, 439
 Berg, Teresa G., 125
 Bernhard, Linda A., 1089
 Bindra, Renu, 661
 Bobo, Janet Kay, 1169
 Boehm, Frank H., 1063
 Bose, Teresa M., 428
 Briggs, Gerald G., 6
 Broder, Samuel, 711
 Bryant-Greenwood, Peter, 605
 Bui, The-Hung, 640
 Burkle, Christopher M., 518
 Cain, Joanna, 830, 928
 Cannon, Tracy Washington, 205
 Caritis, Steve N., 99
 Chai, Toby C., 250
 Chancellor, Michael B., 205
 Cliby, William A., 481, 507
 Conover, Elizabeth Ann, 89
 Critchfield, Gregory C., 671
 Crookes, Peter F., 892
 Curet, Luis B., 73
 Davila, G. Willy, 173
 Depp, Richard, III, 657
 Devoe, Lawrence D., 986
 Dickstein, Leah, 1162
 Dildy, Gary A., III, 307, 330
 Disaia, Philip John, 784
 Divon, Michael Y., 1015
 Dizon-Townson, Donna, 363
 Druzin, Maurice L., 973
 Duff, Patrick, 59
 Dugoff, Lorraine, 1039
 Dwyer, Peter L., 193
 Evans, Mark I., 591, 657, 730
 Faix, Roger G., 42
 Felix, Juan C., 761
 Ferber, Asaf, 1015
 Flake, Alan W., 684
 Flaws, Jodi A., 1119
 Frank, Thomas S., 671
 Gabbe, Steven G., 1063
 Garite, Thomas J., 35
 Gaylis, Brendan, 952
 Gherman, Robert B., 345

Goldberg, Roger P., 182
 Gonzalez, Jose L., 165
 Gonzalez, Susana, 770
 Gostout, Bobbie S., 481
 Graves, Cornelia R., 369
 Hahn, Sinuhe, 649
 Hansen, Wendy F., 136
 Harper, Joyce C., 640
 Harrison, Barry A., 518
 Heath, Victoria, 661
 Hindle, William H., 735, 738, 746, 750, 758, 761, 767, 770, 774, 778
 Hobbins, John C., 1039
 Holzgreve, Wolfgang, 649
 Hsi, Andrew C., 73
 Hsu, Chaur-Dong, 308
 Huddleston, John F., 1005
 Jackson, Laird, 622
 Jayabalan, Arun, 99
 Jones, Chandra R., 986
 Kasper, Anne S., 1189
 Kent, Karen, 1129
 Kirsch, Wolff, 904
 Klauer, Jana, 1080
 Kohli, Neeraj, 218
 Koonings, Paul P., 952
 Krivchenia, Eric L., 657
 Kurina, Lianne M., 1099
 Larsson, Agne, 697
 Leppert, Phyllis C., 1073
 Leslie, Kimberly K., 153
 Lukban, James Chivian, 273
 Lyons, Cecilia A., 35
 Magrina, Javier F., 469
 Manning, Frank A., 975
 Martin, James N., Jr., 22
 Maupin, Robert T., 393
 Miller, David A., 1054
 Miller, David Scott, 844
 Moldwin, Robert M., 259
 Moore, Thomas R., 1026
 Myers, Deborah L., 233
 Nadelson, Carol C., 1162
 Nehra, Vandana, 537
 Neimark, Minda, 173
 Nicklin, James Lindsay, 545
 Nicolaidis, Kypros H., 661
 Norwitz, Errol R., 308
 O'Meara, Anne T., 855
 Orr-Urtreger, Avi, 593
 Osuch, Janet Rose, 1140

Parsons, C. Lowell, 242
 Pejovic, Tanja, 866
 Pettit, Paul D. M., 492
 Podczaski, Edward, 830, 928
 Podratz, Karl C., 481
 Rayburn, William F., 1, 993
 Repke, John T., 308
 Rosamilia, Anna, 193
 Rosenblatt, Peter L., 218
 Sand, Peter K., 172, 182
 Sant, Grannum R., 172, 259
 Sarkis, Nairy, 758
 Satin, Andrew J., 114
 Schrimmer, David B., 1026
 Schwartz, Peter E., 866
 Schwarzenberger, Paul, 820
 Seltzer, Vicki, 812
 Sevin, Bernd-Uwe, 492
 Sharp, Howard T., 405
 Shoupe, Donna, 1071
 Silbergeld, Ellen K., 1119
 Smith, Carl V., 125
 Smith, Mindy, 1129
 Southorn, Peter A., 449

Stitely, Michael L., 114
 Stone, Keith, 553
 Sueda, Alexandra, 761
 Swensen, Ron, 904
 Tamussino, Karl, 562
 Tewari, Krishnansu Sujata, 784
 Theodossiou, Chris, 820
 Therrell, Bradford L., 697
 Thorneycroft, Ian H., 879
 Valea, Fidel A., 939
 Van Hook, James W., 414
 Velazquez, Maria D., 993
 Venter, J. Craig, 711
 Wai, Clifford Y., 844
 Wapner, Ronald J., 657, 730
 Webb, Maurice J., 427
 Whitmore, Kristene E., 273
 Whitty, Janice E., 377
 Williams, Kristi, 1099
 Woodage, Trevor, 711
 Yankowitz, Jerome, 136
 Yaron, Yuval, 593
 Zweizig, Susan L., 884

STATEMENT OF OWNERSHIP MANAGEMENT AND CIRCULATION (Required by 39 U.S.C. 3685)

1. Publication Title: CLINICAL OBSTETRICS AND GYNECOLOGY
2. Publication no.: 0009-9201. 3. Filing date: 10-01-02. 4. Frequency of issue: Quarterly
5. No. of issues published annually: 4; 6. Annual subscription price: \$196.00
7. Complete mailing address of known office of publication: Lippincott Williams & Wilkins, 16522 Hunters Green Parkway, Hagerstown, MD 21740-2116. 8. Complete mailing address of the headquarters of general business offices of the publisher: 530 Walnut Street, Philadelphia, PA 19106.
9. Full names and complete mailing address of publisher, editor, and managing editor: Publisher: Lippincott Williams & Wilkins, Inc., 530 Walnut Street, Philadelphia, PA 19106; Editor: James R. Scott, MD, Professor, Department of Ob/Gyn, College of Medicine, University of Utah, Salt Lake City, UT 84132; Steven Gabbe, MD, Vanderbilt University, School of Medicine, D-3300 Medical Center North, Nashville, TN 37232; Managing Editor: Marie Chesny, Lippincott Williams & Wilkins, 530 Walnut Street, Philadelphia, PA 19106. 10. Owner: Lippincott Williams & Wilkins, 530 Walnut Street, Philadelphia, PA 19106; 351 West Camden Street, Baltimore MD 21201; Wolters Kluwer, US, 345 Hudson Street, New York, NY 10014; Wolters Kluwer, nv (owns 100% of stock), Stadouderskade 1, 1054 FS Amsterdam, The Netherlands. 11. Known bondholders, mortgagees, and other security holders owning or holding 1% or more of total amount of bonds, mortgages, or other securities: None.
12. Purpose, function, and nonprofit status: Has not changed during preceding 12 months.
13. Publication Name: CLINICAL OBSTETRICS AND GYNECOLOGY
14. Issue Date for circulation data: Volume 45, Issue 2.
15. Extent and nature of circulation: Average number of copies each issue during preceding 12 months: (a) Total No. copies (Net Press Run), 4,925. (b) Paid and/or requested circulation; (1) Paid/requested outside-county mail subscriptions stated on form 3541, (include advertiser's proof and exchange copies), 2,253; (2) Paid in-county subscriptions (include advertiser's proof and exchange copies), N/A; (3) Sales through dealers and carriers, street vendors, counter sales, and other non-USPS paid distribution, 1,570; (4) Other classes mailed through the USPS, N/A. (c) Total paid and/or requested circulation (sum of 15b (1), (2), (3), and (4), 3,823. (d) Free distribution by mail (samples, complimentary, and other free). (1) Outside-county as stated on form 3541, 43; (2) In-county as stated on form 3541, N/A; (3) Other classes mailed through the USPS, N/A. (e) Free distribution outside the mail (carriers or other means), 57. (f) Total free distribution (sum of 15d and 15e), 100. (g) Total distribution (Sum of 15c and 15f), 3,923. (h) Copies not distributed, 1,002. (i) Total (sum of 15g and h), 4,925. (j) Percent paid and/or requested circulation (15c divided by 15g times 100), 97%. No. copies of single issue published nearest to filing date: (a) Total no. copies (Net Press Run), 4,600. (b) Paid and/or requested circulation; (1) Paid/requested outside-county mail subscriptions stated on form 3541, (include advertiser's proof and exchange copies), 2,353; (2) Paid in-county subscriptions (include advertiser's proof and exchange copies), N/A; (3) Sales through dealers and carriers, street vendors, counter sales, and other non-USPS paid distribution, 1,506; (4) Other classes mailed through the USPS, N/A. (c) Total paid and/or requested circulation (sum of 15b (1), (2), (3), and (4), 3,859. (d) Free distribution by mail (samples, complimentary, and other free). (1) Outside-county as stated on form 3541, 237; (2) In-county as stated on form 3541, N/A; (3) Other classes mailed through the USPS, N/A. (e) Free distribution outside the mail (carriers or other means), 265. (f) Total free distribution (sum of 15d and 15e), 502. (g) Total distribution (Sum of 15c and 15f), 4,361. (h) Copies not distributed, 239. (i) Total (sum of 15g and h), 4,600. (j) Percent paid and/or requested circulation (15c divided by 15g x 100), 88%. This Statement of Ownership will be printed in volume 45, issue 4 of this publication.
16. I certify that the statements made by me above are correct and complete.

Jeffrey Brown

Manager, Periodical Operations